ERDC BAA - ARMY

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. Army Corps of Engineers’ Engineer Research and Development Center (ERDC) is issuing a continuously open Broad Agency Announcement to fund basic, applied, and advanced research across a wide range of engineering, environmental, and defense-relevant technology areas. Awards are made on a rolling basis through cooperative agreements, subject to the availability of funds so interested companies should submit as soon as possible.

How much funding would I receive?

ERDC does not specify a standard award size. Individual awards may range from small research efforts to very large, multi-year programs, with an overall program ceiling of $1 billion. Funding levels are determined based on technical scope, relevance, and available funding within the sponsoring ERDC laboratory.

What could I use the funding for?

To be eligible for consideration and possible contract award, the technology or methodology shall be either basic research, applied research, advanced technology development not for a specific system/hardware, or demonstration and validation.

If your technology is novel and fits into one of the following Areas of Interest, you could potentially be funded:

Coastal and Hydraulics Laboratory (CHL)

• Overview

  Research is performed in the areas of hydraulic structures such as locks, dams, outlet works, control gates, stilling basins, spillways, channels, fish handling systems, and pumping stations, flood control channels, navigation channels, riverine and estuarine hydrodynamics and transport processes, groundwater, hydrology; dredgingrelated equipment, and on coastal problems related to coastal storm hazards and risk management, beach erosion, navigation, sedimentation, Regional Sediment Management, inlet stabilization, and construction, operation and maintenance of coastal structures (breakwater, jetties, groins, seawalls, etc.). Major areas of interest include coastal hydrodynamics (wind waves, tides, currents, wind related water levels); coastal sedimentation (longshore transport, inlet sedimentation); coastal geology and geomorphology; design and stability of coastal structures; erosion and storm reduction potential and life-cycle performance of natural and nature-based features; system optimization methods and performance metrics for coastal operations; coastal resiliency; and interaction of structures and coastal processes. Other activities include descriptions of coastal processes; theoretical studies; watershed and regional sediment and water systems studies; numerical and physical model techniques; data collection and analysis techniques; and development of laboratory and prototype instrumentation and equipment. The following sections contain information on these research areas and specific research thrusts.

• A. Physical Processes in Estuaries (CHL-1)

  Research in estuarine physical processes deals with the hydrodynamic and transport characteristics of water bodies located between the sea and the upland limit of tidal effects. Research is directed toward knowledge that will improve field measurements and predictions of these processes. Specific areas of required research include the following physical processes in estuaries and other tidal waters. Specific areas of required research include the following physical processes in estuaries and other tidal waters. a. The propagation of tides. b. Transport of salinity, mixing processes, stratified flows. c. Transport, erosion, and deposition of sediments, including settling velocity, aggregation of sediment, consolidation of sediment. d. Behavior and characteristics of sediment beds, including movement, consolidation, armoring, bonding, physical chemical characteristics, density, erodibility. e. Flow between aquifers and surface waters.

  Specific areas of required research include the following activities with respect to the physical processes listed. a. The effect of human activities, including dredging construction, vessel traffic, flow diversion, training, structures, and protective structures. b. Measurements of parameters that are indicative or descriptive of the processes listed in the 2nd paragraph by in-situ and remote methods in the lab and field. c. Prediction of processes listed in the 2nd paragraph by analytical methods, physical models, numerical models, and other techniques. d. Conceptual and mathematical descriptions of the processes listed in the 2nd paragraph. e. Development of materials, equipment, and methods that potentially lead to applied research that would make human activities listed safer, more economical, or more effective. f. Development of methods, techniques, and procedures that enable the treatment of an estuary as a system.

• B. Inland Hydraulic Structures (CHL-2)

  Research in hydraulic structures is related to the hydraulic performance of locks, dams, outlet works, control gates, stilling basins, spillways, channels, bank protection, riprap stability, pumping plants and other hydraulic structures, and with physical and/or numerical model studies to predict and analyze the physical water quality aspects of water resources projects. Specific areas of required research include the following: a. Conduct physical and numerical hydraulic model investigations of a wide variety of hydraulic structures to verify proposed designs and develop more effective and economical designs. b. Analyze model and prototype data and inspection of field installations to develop design criteria for hydraulic structures. c. Develop methods of correlating theoretical and experimental information with design methods used by the Corps of Engineers to improve existing procedures and provide material for inclusion in appropriate manuals. d. Develop physical and/or numerical models to predict and analyze the water quality aspects of water resources projects and design appropriate hydraulic structures to control water as well as water quantity while satisfying the desired objectives. e. Conduct research and/or develop numerical codes to advance techniques for analyzing physical aspects of water quality in lakes and rivers through a better understanding of the hydrodynamics in density-stratified environments and for improving water quality within and downstream of density-stratified reservoirs and to investigate the ability of existing and proposed water resources projects to satisfy established water quality standards. f. Conduct basic studies for development of hydraulic design and operation guidance for hydraulic structures used in inland waterways for navigation and flood control purposes, including wave forces/loads on gates (tainter, miter, etc.). g. Conduct/analyze tests, both model and prototype, of the performance of hydraulic appurtenances to flood control and navigation dams such as spillways, outlet works, energy dissipaters, and approach and exit channels, to develop design guidance that will provide structures of maximum efficiency and reliability with minimum maintenance. h. Develop innovative methods to prepare and revise engineering manuals for hydraulic design of various hydraulic structures. i. Develop innovative methods to conduct training courses on design of various hydraulic structures. j. Develop innovative methods to prepare technical reports of all work conducted.

• C. Open Channel Flow and Sedimentation (CHL-3)

  Research in open channel flow and sedimentation includes basic studies related to development of hydraulic design guidance for designing modifications to natural stream channels to provide for local flood risk reduction. Emphasis is placed on channel stability as well as channel flow capacity. Specific areas of required research include the following: a. Studies related to the development of effective methods to analyze a natural stream's response to modifications made for flood control purposes. b. Studies applicable to development of stream bank and streambed protection methods where channel instability exists. c. Studies applicable to development of sediment transport, local scour, and stream form relationships for a broad range of stream types, bed and bank materials, and meteorological and hydrological conditions. d. Collection and analysis of data that aid in evaluating existing methods and/or developing new methods to analyze channel stability for the variety of channel flow conditions and stream types existing in natural stream systems.

• D. Dredging Research (CHL-4)

  Protection and enhancement of the environment associated with operation and maintenance of navigable U.S. waterway infrastructure through dredging activities is a national priority. Dredging operations and environmental requirements of navigation projects are inseparable. Research is required to predict the time-dependent movement of non- contaminated sand and sand/silt mixtures of dredged materials placed in the nearshore zone, and all materials placed in the offshore region. The cost of dredging operations attributable to compliance with environmental windows that are determined to be over-restrictive, inconsistent, or technically unjustified can be reduced. More effective contaminated sediment characterization and management will reduce costs and enhance the reliability of methods associated with the assessment, dredging, placement, and control of sediments from navigation projects. Better instrumentation for dredge and site monitoring is required to implement automated dredge inspection and payment methods and accurately monitor placement of contaminated materials. Emerging technologies regarding innovative equipment and processes should be expeditiously introduced into the dredging arena. Enhanced ecological risk management for dredging and disposal projects through technically sound approaches for characterizing, managing, and conducting risk-based evaluations are required for expanding options regarding both contaminated and non-contaminated dredged materials.

• E. Navigation Channel Design (CHL-5)

  Research in navigation channel design involves basic research to develop design guidance for the design of new channels and modifications of existing waterways. It involves identifying maneuvering requirements in restricted waterways that affect the channel dimensions, alignment, and location of appurtenances in the navigation channel under various environmental and vessel traffic conditions. It also involves identifying the stability of the channel, maintenance requirements and designing structures that reduce or eliminate the maintenance requirements. Finally, it involves quantifying the flow and pressure fields generated by a tow or ship passing through a waterway and the related impacts on the sediment resuspension in the channel, channel border, and side channel/backwater areas. Studies involve deep and shallow draft navigation channels and physical and mathematical models. Human factors are included in research and project studies using a ship and tow simulator.

  Specific areas of required research include the following: a. Physical model investigations of a wide variety of navigation channel configurations in many environments with different type vessels to verify proposed designs and to develop more efficient and safe designs and to lower environmental impacts. b. Development and enhancement of mathematical models of vessels, both ships and push-tows, for use on the simulator to add vessel types not available or to increase the accuracy with which the model reproduces the vessels response. c. Development of methods and modeling techniques to predict the currents and sediment transport characteristics of various channel designs and integrate this with the navigation model studies, including those generated by the vessel movement. d. Development of methods and modeling techniques to predict the currents and sediment transport characteristics of various channel designs and integrate this with the navigation model studies. e. Development of methods and techniques to prepare and display visual information for the pilot on the simulator projection system. f. Development of methods and measurement equipment, techniques for measuring scale model performance in physical model navigation studies. g. Development of methods and techniques to improve the ship simulator and increase reliability of design estimates, including data and tools for ship motions, draw down, squat, ship-generated waves, and ship maneuvering. h. Development of methods and techniques for the analysis and evaluation of model results to optimize the channel design and to determine the level of safety, or conversely, risk involved with the various designs and ship transits.

• F. Computer-Aided Hydraulic Engineering (CHL-6)

  Research in this topic area develops computer-aided design tools that can be used by hydraulic engineers in planning, design, construction, operation, and maintenance of navigation and flood control projects. The scope includes open channel and closed conduit flows, equipment, structures, and sediment transport analysis and modeling.

• G. Groundwater (CHL-7)

  Research in groundwater is structured to enhance understanding and prediction of the flow of water and various transported constituents through the environment, including groundwater issues from contaminant remediation to levee erosion as well as surface water problems from flash flooding to nearshore coastal flows. Primary tools are computer models that solve (approximately) conservation equations for mass, momentum, and energy in various physical systems. Work includes developing the numerical methods for solving these equations, writing the computer code to implement the approximations in desktop and high-performance computing environments, and applying the models as part of engineering studies to investigate processes like levee erosion and overtopping, seawater intrusion, and flow through vegetation.

• H. Hydrology (CHL-8)

  Research in this area primarily addresses military applications related to mobility, counter mobility, and water supply. Specific research involves the following areas: a. Large-scale hydrologic modeling. b. Rapid procedures for flood forecasting. c. Groundwater-surface water interaction processes. d. Multi-scale, multi-physics hydrologic modeling. e. Remote sensing and quantification of precipitation. f. Development of spatially varying precipitation hydrology models. g. Visualization of results for hydrology and dam break models. h. Interfacing with existing and new hydrology models. i. Interfacing watershed models with water quality and other environmental models.

• I. H&H GIS/Database Development (CHL-9)

  Research involves the following areas: a. Electronic Navigation Charting. b. Integration of GIS/Database and H&H models. c. Watershed management for erosion control. d. Larger River System management for flood control navigation. e. Visualization Techniques

• J. Coastal Hydrodynamics, Coastal Processes (CHL-10)

  Research in this area includes: shallow water wave estimation; forecasting and hindcasting of wind generated waves for oceanic to local regions; wave theory; statistical distribution of wave parameters; simulation of spectral and phase resolved conditions in wave basins; infragravity (free and bound) waves; nearshore currents; wave breaking; wave/current and wave structure interactions; wave and sediment interactions with natural and nature-based features; long and short waves in ports and harbors; tsunami modeling; wind generated currents; storm surge; tidal circulation; twoand three dimensional numerical simulation models (including finite difference, finite element, finite volume and curvilinear coordinate techniques); coastal meteorology; explosion generated waves; ship response to winds, currents and waves; moored ship response; mooring design and analysis, ribbon bridge hydrodynamics and turbulence.

• K. Coastal Inlets, Navigation Channels (CHL-11)

  Research includes sediment shoaling in coastal inlet channels; stability and performance of inlet channels; scour at structures; sediment transport modeling; influence of structures such as jetties and breakwaters on wave, current, and sedimentation processes. Numerical modeling of inlet hydrodynamics and sedimenttransport processes, including long-term geomorphologic evolution of inlet channels, shoals, and adjacent beaches, and the interaction with navigation structures. Nearshore placement of dredged sediment to foster wave reduction and sediment supply to adjacent beaches. Short- and long-term dune evolution in vicinity of coastal inlets. Shoreline evolution modeling and storm erosion of beaches, particularly concerning over wash and breaching near inlets; wind and wave generated sediment transport; sediment budget analysis; coastal and inlet geomorphology; and PC-, workstation-, and mainframe-based automated coastal engineering software (including relational and GIS data bases)

• L. Coastal Structure and Facility Design (CHL-12)

  Research includes development of functional and stability design criteria for coastal structures and facilities (breakwaters, seawalls, jetties, groins, harbors, marinas, etc.); wave run-up, over-topping, refraction, diffraction, transmission, reflection, etc.; design of floating breakwaters; breakwater stability; application of spectral wave conditions to coastal engineering; stability of riprap to irregular wave attack; stability and functional design of overtopped rubble mound breakwaters; scale modeling of armor unit strength; analysis of structural data for floating breakwaters; investigation of numerical structural models for floating breakwaters; development of wave run-up gage for rough and porous slopes; investigation of attenuation/mooring force models of floating breakwaters; development of materials and techniques to produce high quality breakwater model armor units; analysis of wave run-up overtopping, refraction, diffraction, transmission and/or reflection data on coastal structures and beaches and design of structures for Logistics-Over-The-Shore (LOTS) operations.

• M. Field and Laboratory Measurements, Data Collection, and Analysis (CHL13)

  This topic area includes research in technologies, instrumentation, and monitoring systems in coastal and riverine settings for collecting, analyzing, and disseminating data related to measurements of coastal waves, surface currents, water levels, water quality, sediment, and wind, primarily in the field, but also in a sediment laboratory; advanced data analysis (spectral and non-spectral) techniques; remote sensing techniques; bedload and suspended sediment transport; monitoring and evaluating technical and structural stability of coastal projects; advanced hydrographic survey techniques, field measurement of coastal processes; bathymetric survey systems.

• N. Experimental Coastal Model Equipment, Operation and Analysis (CHL-14)

  Research includes development of equipment and techniques for specialized model construction, experimental wave generation equipment, specialized data acquisition and analysis systems, advanced model operations techniques, and laboratory and scale effects in movable bed model studies.

• O. General Coastal Engineering, Coastal Geology, Dredging Investigations CHL-15)

  This topic area includes topics such as sand bypassing systems and equipment; beach fill design; coastal geology and geomorphology; functional design and evaluation of coastal works and coastal structures; methodologies to assess and track coastal resilience performance; littoral transport; coastal and offshore dredging studies; agitation dredging systems and equipment; physical monitoring of dredged material; physical processes in coastal wetlands; application of Geographic Information Systems; design of nearshore and offshore dredged material placement; evaluation of dredged material disposal sites; analysis of dredging operations management.

• P. Regional and Watershed Sediment Management (CHL-16)

  Regional Sediment Management (RSM) research is intended to provide knowledge and tools that the Corps and the Nation need for effective water resource projects. RSM implies the holistic management of sediment within systems or regions to produce environmentally and economically sustainable projects. Goals include improved project design, operation, and maintenance methods, minimized disruption of natural sediment pathways and processes, and mediation of natural processes that have adverse environmental or economic impact. The approach of the Corps research is to produce targeted R&D serving multiple Corps business areas; to employ ongoing projects’ experience (including Demonstration Projects) to provide data and lessons learned; to use enabling technologies of localscale products and tools, including those generated by other R&D programs within and outside the Corps; to generate technologies that integrate the best available knowledge on sediment behavior and regional morphology into management decision support tools for a) regional and basin scale analyses and b) evaluation of the impacts of projects and management decisions on and by long-term, large-scale sedimentation processes. A key element in ERDC research is full coordination with other organizations with sediment management or monitoring expertise.

• Q. Marine Transportation Technologies (CHL-17)

  Research in this topic area serves one of the USACE’s primary missions, to provide safe, reliable, efficient, effective, and environmentally sustainable waterborne transportation systems for movement of commerce, national security needs, and recreation. To accomplish this mission, the USACE requires R&D to facilitate tracking of vessels on inland waterways (shallow draft) and coastal ports (deep draft). Knowing what vessels are arriving, when, the commodities being carried, etc., will provide lock operators and operations project managers valuable tools to improve safety, efficiency, asset management, and help to make decisions on performance-based funding for navigation project maintenance and improvements. Work in this area focuses on software that uses the United States Coast Guard’s (USCG) Automated Identification Systems (AIS) vessel mounted transmitters which broadcasts a radio signal with the vessels name, position, heading, velocity, and a wide range of other information. Proposals are sought for developing the following: a. Capability that will take the full suite of standard CG AIS messages and provide them in near real time to the Corps facilities in the immediate area of the vessel. b. Capability to allow collection of the full suite of standard AIS messages simultaneously at all pertinent Corps Inland and Deep Draft facilities. c. Capability to customize user interface to allow the Corps operations staff to view vessels in the vicinity of the Corps facilities to make decisions on the order in which to allow commercial tows to pass through lock. d. Provide the capability for Corps facilities to transmit pertinent information to the vessels in the immediate vicinity of the Corps facilities via AIS. e. System optimization methods and performance metrics for vessel operations. Special Considerations: The level of understanding of AIS technology and signal processing, the number of successful installations of similar AIS software processing capabilities; experience with USCG staff, facilities, regulations, and procedures.

• R. Post-Wildfire Hydrologic, Sediment, and Geomorphologic Management (CHL-18)

  Post-Wildfire research is focused on improving understanding of post-fire impacts through exploitation of affordable data acquisition methods and enhancement of numerical modeling capabilities to assist with planning, management, and mitigation in post-wildfire environments. Immediately following a wildfire, vegetation is removed, organic soil horizons are reduced to ash, and hydrophobic soils combine to result in increased water and sediment discharge and debris, mud, and hyper concentrated flows. In the years following a wildfire, ecotone shifts, gully formation, and channel incision alter the hydrologic system response, resulting in dramatic changes in hydraulic and sediment impacts down system. Wildfires represent a significant perturbation to natural systems that dramatically alter the morphologic, hydrologic, and sediment regimes of impacted watersheds. The overall purpose of this area of research and development is to investigate post-wildfire impacts on hydrologic and hydraulic response, geomorphic evolution, and sedimentation, with specific research needed in the following areas: a. Studies related to cost-effective (in situ and remotely sensed) data acquisition and processing methods. b. Studies related to better understanding the longer-term geomorphic impacts and subsequent recovery processes in post-fire environments. c. Studies related to hydrological physical processes, empirical approaches, and numerical modeling. d. Studies related to hydraulics and sediment transport physical processes and numerical modeling.

• S. Nearshore Coastal Research in Support of the U.S. Coastal Research Program (CHL- 19)

  Proposals are invited to address nearshore coastal research needs within three broad research themes as identified by the U.S. Coastal Research Program (USCRP) (see Nearshore Process Community, 2015 for more details). Nearshore systems include the complex interactions of physical, biological, chemical, and human influences within the transition region across the land and the continental shelf, spanning (from onshore to offshore) coastal plains, wetlands, estuaries, coastal cliffs, dunes, beaches, surf zones, and the inner shelf. Worldwide, nearly 1 billion people live at elevations within 10 m of present sea level, an elevation zone in need of engineering solutions that reduce risks to life and property produced by various extreme events. The nearshore is a societally relevant region that requires and improved understanding of the feedbacks and couplings that shape, sustain, and alter coastal landscapes. The three broad research themes include a need to understand, better predict, and respond to (1) Long-term coastal evolution due to natural and anthropogenic processes; (2) Extreme Events including: flooding, erosion, and the subsequent recovery; and (3) The physical biological and chemical processes impacting human and ecosystem health. Each is detailed below a. Long-term coastal evolution due to natural and anthropogenic processes: As storms impact increasingly urbanized coastal communities, an understanding of long-term coastal evolution is critical. Improved knowledge of long-term morphological, ecological, and societal processes and their interactions will result in an improved ability to simulate coastal change and develop proactive solutions for resilient coasts and better guidance for reducing coastal vulnerability. b. Extreme Events including flooding, erosion, and the subsequent recovery: U.S. coastal extreme event related economic losses have increased substantially over the past decades. Addressing this research theme will result in an improved understanding of the physical processes during extreme events, leading to improved models of flooding, erosion, and recovery. Utilization and application of the improved models will produce societal benefit in the form of more resilient coastal communities. c. The physical, biological, and chemical processes impacting human and ecosystem health: Nearshore regions are used for recreation, tourism, human habitation, and provide habitat and valuable ecosystem services. These areas must be sustained for future generations, however overall coastal water quality is declining due to microbial pathogens, fertilizers, pesticides, and heavy metal contamination, threatening ecosystem and human health. To ensure sustainable nearshore regions, predictive real-time water- and sediment-based pollutant modeling capabilities must be developed, which requires expanding our knowledge of the physics, chemistry, and biology of the nearshore. The resulting societal benefits will include better beach safety, healthier ecosystems, and improved mitigation and regulatory policies.

• T. Comprehensive Water Risk Management (CWRM) (CHL- 20)

  Proposals are invited to develop and explore the application of next generation technologies, methods and approaches that lead to the creation of a seamless national hydro-terrestrial capability within the USACE and partner agencies. CWRM includes advanced data collection, prediction and management technologies that can provide water managers the tools required to minimize, mitigate, and better manage water hazards under present and future design requirements. Proposals for research in the following specific areas are needed: a. Inland and Coastal Compound Flooding: Research to support the inclusion of inland and coastal compound flooding in the reduction of comprehensive flood risk from riverine flows, precipitation, coastal storms, groundwater emergence, sea level change, snowmelt, wildfires, subsidence, and other natural as well as anthropogenic events. b. Data Collection: Research to support the collection and analysis of water data through in-situ and standoff measurements including satellite, and various uncrewed systems (UxS). For UxS this includes sensing, perception, control, and data process techniques. Needs include data collection techniques for snowpack analysis, soil-moisture determination, wave environment, estimation of under-water bathymetry, reservoir capacity, etc. c. Probabilistic Modeling – Uncertainty quantification and Data Assimilation: Research to support development of methodology for quantifying numerical uncertainty and forward propagation of that uncertainty into numerical prediction. Additionally, research to develop methods for assimilating observations into probabilistic numerical methods to refine predictions for wave, circulation, and morphologic models. d. Artificial Intelligence and Machine Learning (AI/ML) Technologies: Research to support the use AI/ML technologies to increase the accuracy and efficiency of hydrologic and hydraulic numerical models. Capabilities include advanced data assimilation technologies for error reduction and longer forecasts. e. Flash Flooding: Research to improve the technologies to predict and mitigate water hazards due to flash flooding. Research requirements include downscaling of weather forecasts including precipitation, wind speeds, atmospheric pressure, etc. f. Cold Weather Water Hazards: Research to improve the performance of predictive techniques in cold regions including the arctic. Research requirements include the effects of ice cover on wave and storm mitigation, the effects of the permafrost on hydrologic processes, the effects of flood risk mitigation features on freshwater sources, etc. g. Arid Region Water Hazards: Research to improve the performance of predictive techniques in arid regions. Research requirements include infiltration processes, groundwater and surface water interaction, aquifer recharge, wildfire hydrology, etc. h. Numerical Model Coupling Techniques: Research to improve the performance of numerical model coupling methods. Research requirements include inter and intra-model communication for inter-agency model collaboration.

• U. Innovations in Sediment Management (CHL- 21)

  Proposals are invited to develop leap-ahead innovative and sustainable dredging and sediment management solutions to dramatically reduce costs, increase channel/infrastructure reliability, and add significant economic, environmental, and social value to the Nation. Proposals for research in the following specific areas are requested: a. Coastal/ Hydrodynamic Engineering Nature-Based Solutions (NBS) and Hybrid Solutions: Research to inform the development of tools, techniques and guidance behind designing and engineering nature-based solutions (NBS) and hybrid solutions. This R&D will help in the development of methods and standards which support effective planning, designing, construction, and O&M of NBS/hybrid solutions to support the reduction of coastal and inland flooding risks. This research should focus on exploring the potential for integrating NBS/hybrid solutions within existing hydrodynamic engineering and land use planning practices. b. Innovative Dredging Technologies/ Autonomous Methods: Research to develop technologies and techniques for improved dredging operations. R&D can address evaluating next-generation technologies and dredging operations (e.g., hydrodynamic dredging), real-time dredge position and bottom mapping techniques, autonomous dredging to reduce costs, increase beneficial use of dredged material, sediment transfer and placement equipment to facilitate more beneficial uses (e.g., thin layer placement, strategic placement), reduce channel and reservoir infilling to reduce dredging need, or renewing reservoir capacity through application of technologies developed for navigation channel maintenance. Proposals are invited to develop leap-ahead innovative and sustainable dredging and sediment management solutions to dramatically reduce costs, increase channel/infrastructure reliability, and add significant economic, environmental, and social value to the Nation. Proposals for research in the following specific areas are requested: a. Coastal/ Hydrodynamic Engineering Nature-Based Solutions (NBS) and Hybrid Solutions: Research to inform the development of tools, techniques and guidance behind designing and engineering nature-based solutions (NBS) and hybrid solutions. This R&D will help in the development of methods and standards which support effective planning, designing, construction, and O&M of NBS/hybrid solutions to support the reduction of coastal and inland flooding risks. This research should focus on exploring the potential for integrating NBS/hybrid solutions within existing hydrodynamic engineering and land use planning practices. b. Innovative Dredging Technologies/ Autonomous Methods: Research to develop technologies and techniques for improved dredging operations. R&D can address evaluating next-generation technologies and dredging operations (e.g., hydrodynamic dredging), real-time dredge position and bottom mapping techniques, autonomous dredging to reduce costs, increase beneficial use of dredged material, sediment transfer and placement equipment to facilitate more beneficial uses (e.g., thin layer placement, strategic placement), reduce channel and reservoir infilling to reduce dredging need, or renewing reservoir capacity through application of technologies developed for navigation channel maintenance. c. Hydrodynamic and Geomorphologic Response of Biomaterials: Research into the use of bio-based materials, such as biopolymers, to enhance and increase the resiliency of NBS, including earthen levees, coastal dunes, and dam embankments. This research should focus on the hydrodynamic and geomorphologic response of biomaterials to the impacts of hydrological and meteorological extremes. Considering the performance and sustainability of biobased materials, we seek to understand the potential of bio-based materials to reduce the risk and cost of rehabilitating and maintaining these structures and increase their resiliency against potential threats. We invite research that furthers our understanding and application of bio-based materials for this purpose, as a component of comprehensive water risk management and abilities to adapt to dynamic environmental forcing requirements. The research should be designed to provide evidence and support decision making. It should be based on research available at existing open-source platforms, or data that is proposed to be collected for the research. d. Monitoring of NBS and Beneficial Use of Dredged Sediment Projects: Research to improve the understanding of the performance of NBS and beneficial use of dredged sediment projects through monitoring. Monitoring could include the project’s response to storm events and the post-storm recovery. Monitoring techniques will vary based on the project but may be comprised of satellite data, remote sensing measurements, in-situ measurements, or engaging the public to crowdsource data collection. The monitoring research may also include the development or testing of innovative sensors or monitoring techniques.

• V. Next Generation Water Management (CHL-22)

  Proposals are invited to explore the application of next generation technologies, methods and approaches that are aimed at improving water management practice within the USACE and partner agencies, including efforts that support research, development and implementation of capabilities to support Forecast Informed Reservoir Operations (FIRO). FIRO is a management approach that seeks to improve water supply, enhance flood risk reduction and achieve additional ecosystem benefits through application of advanced weather and watershed forecast capabilities in water management practice.

  FIRO envisions advanced observation and prediction technology that can provide water managers more lead time to selectively retain or release water from reservoirs based on longer- term forecasts. When storms cause moderate-to-high reservoir levels, normal operation is to release water to re-establish flood control space. FIRO pilot studies have demonstrated that some of that water can be retained for future supply as long as no major precipitation is expected and it can be shown that the retained water can be released past downstream flood prone areas prior to the arrival of the next storm. This strategy permits earlier supply capture in some years, improving supply reliability for downstream water users and improving the timing and volume of releases to protect water quality and provide flows needed for ecosystem benefits. Proposals for research in the following specific areas are needed: a. Improvement of forecast skill to support advanced water management, including meteorological phenomena that are major drivers for floods in various regions across the country including atmospheric rivers, tropical storms/hurricanes, clusters of long-lived thunderstorms and Nor’Easters. This can also include improvements in weather observations and numerical weather forecasting models that result in improved forecasting lead times for water management decision-making.

  b. Improvements in data synthesis, decision support systems and data visualization capabilities to enhance water management decision-making.

  c. Hydrologic and reservoir model development and application, including improvements in watershed monitoring to enhance hydrologic and reservoir models.

  d. Application of FIRO screening process tools to regions of the United States where FIRO has not previously been applied or tested.

  e. Application of FIRO viability assessment processes to systems of dams where multiple dams are operated within a watershed to achieve overall system water management objectives.

  f. Research to support updates to USACE Water Control Manuals (WCMs) using FIRO approaches, scenarios and principles. Updates to WCMs require numerous studies in areas of meteorology, hydrology, hydraulics, ecology and economics. Incorporation of next generation approaches such as FIRO require research efforts to identify best management practices on how to safely and effectively incorporate these new approaches into water management practice as defined in WCMs.

Geotechnical & Structures Laboratory (CHL)

• Overview

  Research performed by the Geotechnical and Structures Laboratory’s (GSL) eight branches consists of investigations in the areas of soil mechanics, engineering geology, geophysics and seismology, earthquake engineering, pavements (both expedient and permanent), mobility and traffic ability of military vehicles, structural design and performance of structures under both static and dynamic loadings, earth dynamics, and the uses and performance of concrete, cement, and other construction materials. Research areas also include measurement and analysis of seismic and acoustic signals to locate airborne and ground military targets and buried objects (including unexploded ordnance) and to characterize earth media. Research on concrete and cement is predominantly related to current recognized needs, both civil and military. Military expediency focuses additional attention on ease and speed of concrete placement, development of very high-strength materials, and use of non-traditional, indigenous, and other special materials in concrete construction. Civil works research focuses primarily on the need to improve the performance of both new and old concrete structures. Structures research involves development, testing, and evaluation of a broad class of structures to resist the effects of static and dynamic loads induced by earthquakes and other sources. The Geotechnical and Structures Laboratory also conducts research involving all aspects for improving the survivability of fixed installations.

• A. Earthquake Engineering (GSL-1)

  Research areas of interest include the dynamic behavior of soil and rock; liquefaction of soils, including coarse-grained and fine-grained soils; in-situ testing to evaluate properties related to dynamic behavior; centrifuge scale-model testing using a multi-waveform shake table; in-situ testing to evaluate susceptibility to liquefaction; methods of analysis of dynamic behavior of earth materials; methods of analysis of dynamic soil- structure interaction; risk-based and probability-based methods of analysis; seismic wave propagation in earth materials; seismically induced settlements in soils and remedial treatment of soils potentially susceptible to earthquake-induced instability or strength loss; computer visualization and dynamic simulation; site response analysis; and strong motion instrumentation.

• B. Geophysics (GSL-2)

  ERDC supports research in the development of land, air, or waterborne geophysical methods to be used for characterization of hazardous waste sites, detection and monitoring of seepage, nondestructive investigation of archeological sites, location of groundwater, and detection of buried objects; analytical and data-processing techniques, borehole surveys, cross hole seismic imaging, electromagnetic detection of anomalies, seismic surveys, sub bottom profiling, and acoustic impedance surveys; and uses of microgravity.

• C. Mobility of Vehicles (GSL-3)

  The Mobility Systems Branch addresses engineering research on the performance of vehicles operating cross country and on-road, and/or in negotiating dry and wet obstacles in worldwide terrains. This is a highly specialized technical area involving engineering mechanics, vehicle dynamics, mathematics, statistics, computer specialties, geology, and soil mechanics. Research in this area includes developing fundamental relations between soil and vehicle running gear; improving criteria concerning the effects of vehicle vibration and ride shock on sensors and data streams from rapidly moving sensors over rough terrain; developing algorithms describing weather effects on terrain, multi-vehicle movements along road nets, stochastic processes describing influence of uncertainties of data elements, and developing modeling and simulation capabilities for near real-time assessments of mobility and counter mobility for battlefield operations and operations other than war.

• D. Pavement Technology (GSL-4)

  Research in this area is conducted in support of the Corps mission to design and construct roads and airfields worldwide and other related engineering functions. This research includes the development of engineering criteria for the design, construction, evaluation, maintenance, and rehabilitation of permanent and expedient airfields, pavements, and ports. Research areas of interest include improved design procedures, structural performance modeling, material characterization and evaluation, nondestructive testing, rapid repair of structures, expedient surfacing (to include novel, composite, and metallic systems), aircraft and vehicular ground flotation, access/egress systems, gravel surfaced and non-surfaced areas, the use of geotextiles and geomembranes, grid-confining systems, soil stabilization, dust-control materials and techniques, advanced binder systems, remote assessment, earth anchoring, pavement evaluation, and advanced testing, monitoring, and evaluation equipment, software, and methods to support pavement and pavement related functions.

• E. Soil and Rock Mechanics (GSL-5)

  Research is needed to: (a) improve methods for prediction and control of erosion of unlined spillway channels during uncontrolled releases; (b) develop innovative methods for flood protection and flood fighting, including field evaluations of promising technologies; (c) develop guidance for applications of trenchless technology (e.g., micro tunneling, horizontal directional drilling, pipe ramming, pipe jacking, auger boring, etc.) on Corps structures, including measures to ensure safety and stability of Corps structures when trenchless technology is used to install pipelines, cables, or conduits through or beneath levees and other structures;(d) develop improved methods, including risk-based methods for analyzing earth and rock fill dams and other water control structures for both static- and earthquake-induced stresses; (e) improve the state of knowledge of physical and engineering properties of soil, rock, and clay shales; earth-rock mixtures, granular filters, cohesive and non-cohesive fine- grained soils susceptible to liquefaction; and soils susceptible to drastic volume changes (collapse, consolidation, swell); (f) develop rational analytical procedures and more reliable prediction of behavior of partially saturated soils; (g) determine the response of soils in situ to static and dynamic loading and unloading; (h) determine the susceptibility of earth dams to cracking, hydraulic fracturing, and internal erosion; (i) evaluate improved defensive design measures in use of materials, particularly in filter and transition zones and impervious barriers; (j) improve procedures for monitoring and analysis of the performance of new and existing structures, particularly the use and interpretation of observations and data from specialized instrumentation, and expedient systems for rapid inspection and evaluation of the integrity of dams; (k) improve the understanding of the aging processes in dams and the influence of aging (particularly deterioration of safety-related features) on long-term maintenance and/or rehabilitation requirements for dams; (l) develop a better understanding of failure mechanisms to improve design of defensive measures, to provide information for remedial repairs, to assess potential damages resulting from failure, and to provide a basis for emergency actions; (m) develop expedient remedial measures when hazardous conditions are identified and, thus, reduce the damages and catastrophic potential of dam failures; (n) develop methodology to evaluate forces exerted on structural elements by adjacent soil masses that result from long- term variation in soil properties; (o) develop improved methodology for design and construction procedures for shallow and deep foundations, including mats, footings, piers, and piles for buildings, hydraulic structures and waterfront structures; (p) large-scale physical and numerical modeling of deep underground structures (tunnels, shafts, chambers, and intersections); (q) predictions of rock mass dredgability; (r) acoustic emission (micro-seismic) applications in geotechnical engineering; (s) geotechnical aspects of hazardous and low-level radioactive waste disposal; (t) evaluation of rock for use as riprap; (u) grouting of soil and rock masses; (v) sliding stability of gravity structures, and (w) centrifuge modeling of structures founded on or in rock.

• F. Dam Research (GSL-6)

  Research is conducted in support of the Army’s Dams and Transportation Infrastructure Program, specifically the Dam Safety subcomponents. Research covers design, construction, maintenance, repair, and inspection procedures of Army dams as well as other engineering functions as they relate to transportation structures. This involves the formulation of engineering criteria for the design, construction, evaluation, maintenance, and rehabilitation of dams. Research areas of interest include improved inspection procedures, material characterization and evaluation, nondestructive testing, rapid repair, scour, unknown material properties, unknown foundations, and underwater inspection.

• G. Engineering Geology (GSL-7)

  The GSL conducts a broad range of research in the field of engineering geology in support of federal or other Government technical missions. Specific areas of interest within this field include application of remote sensing to geologic and geomorphic assessments; geo-archeological investigations; applied and numerical geomorphic analysis; computer applications in geotechnical engineering; 3-D visualization systems; uses of geographic information systems; geo hydrology in military and civil applications; including water quality and supply issues; geologic mapping; geologic applications of mathematical techniques and geo statistics; groundwater monitoring, including well installation and design; geologic application of groundwater models; integration of geological and geophysical subsurface exploration techniques; land-loss studies; remedial measures at groundwater contamination sites; seismic hazard characterization and evaluation; subsurface exploration methods (drilling and sampling techniques); test site selection; conceptual and geologic and hydro geologic models.

• H. Excavation, Structural Demolition, and Obstacle Creation (GSL-8)

  Current criteria for improved demolitions call for significantly reduced manning levels and preparation times to accomplish assigned missions. Cost effectiveness, versatility, and safety are also of great importance. Current efforts involve technologies for the standoff creation and reduction of all types of battlefield obstacles, and the excavation of fighting positions. A prime consideration is the development of more efficient means for the application of various types of energetic materials to targets of interest. In addition, modern materials and design principles used in typical target structures must be incorporated into future plans and guidelines for demolitions. Typical missions of interest are road cratering, anti-tank ditching, bridge and tunnel demolition, and the breaching of walls, bunkers, levees, and dams.

• I. Ammunition Storage Safety (GSL-9)

  The military services must store large amounts of munitions, both for war reserves and for training purposes. New conceptual designs for components or systems for storage are needed to reduce the likelihood of an accidental detonation of stored munitions, limit the propagation of air blast and fragments, or mitigate the safety hazards produced by an accidental detonation. In addition, test data and simulation techniques are needed to aid in the definition of the safety hazards from such detonations, and the mechanics of blast propagation among munition stores. Obsolete munitions are often disposed of by deliberate, controlled detonation. Research is needed on new methods for safe, efficient, and environmentally acceptable methods for deactivation of a wide variety of munition types.

• J. Physical Simulation of Munition Phenomenology (GSL-10)

  The mechanical effects induced by munition detonations are physically simulated using a variety of energy sources. Simulations are performed at full- and small (1/2 to 1/10) scale. The mechanical effects from conventional energetic materials are normally performed at small scale. These studies could benefit from improved (better fidelity, less expensive) simulators and simulation techniques. They could also enhance the development of test methodology for micro-scale (1/100 to 1/10) testing including centrifuge testing. Micro-scale test methodology includes the miniature high- fidelity energy sources, miniature sensors, advanced optical techniques, high-fidelity construction techniques for miniature structures, and theoretical developments in the scaling of material behavior.

• K. Geophysical Phenomenology - Multi-Modal Geophysical Phenomenology, Modeling, Data Processing, and Data Management (GSL-11)

  The objectives include detecting, classifying, and locating airborne and ground military targets and buried objects using geophysical methods for homeland defense and homeland security applications. Also included are invasive and non-invasive approaches for measuring and quantifying the geophysical/geologic signatures of diverse geo-environments. This can include the development of new and/or improved analytical and numerical models, rapid data- processing techniques, and new subsurface imaging techniques that include active and passive sensor modalities in a variety of rural and urban terrains.

  Of particular interest is the broadband propagation of energy including, but not limited to seismic/acoustic/infrasonic/electromagnetic/ thermal/chemical, under variable conditions using a variety of sensing platforms (fixed, mobile, airborne, space). The development of new tactics, techniques, and procedures for the employment of novel sensing methods as well as the development and/or verification of empirical testing and evaluation techniques is also desirable. Data management and multi-mode integration techniques and platforms are also of interest.

• L. Laboratory Tests and Constitutive Model Development for Geologic Materials (GSL-12)

  This research requires the formulation of mathematical constitutive models to simulate the mechanical behavior of geological and structural materials and incorporation of models into application-oriented prediction/analysis techniques. Also of interest are the development of dynamic test equipment and techniques and the experimental evaluation of geological and structural material response to high-pressure transient loadings.

• M. Projectile Penetration (GSL-13)

  Theoretical and experimental studies of projectile stresses and trajectories due to impact and penetration into geologic and man-made targets and development of design criteria for shield systems include development of equipment and diagnostic techniques to examine the response of targets to low- and high-velocity impact of penetrators, rods, etc.

• N. Computational Structural Mechanics for DOD Applications (GSL-14)

  The efficient use of scalable computers will require fundamentally new concepts in computational mechanics algorithms. Research includes mathematical formulations and development of scalable computational mechanics algorithms in the areas of structural response, penetration, contact impact, structure-medium interaction, multi-scale, multi-physics, and interdisciplinary flow-thermal-structural interactions. This research area also includes development of computational models for new materials and composite construction (consisting of concrete, composite, and/or geologic materials), as well as the behavior and control of structures composed of such composite construction for military applications.

• O. Concrete Materials (GSL-15)

  Research in this area includes improving the performance of concrete materials and systems. Performance could include very high tensile or compressive strength, high ductility, high fracture toughness, low shrinkage, rapid hardening, very low permeability, resistance to abrasion and erosion durability, chemical resistance, shock-attenuating properties, ultra-low density, thermal insulation properties, workability, and other unique attributes. This includes improvements in the materials typically used in a concrete mixture such as aggregate, cement, supplementary cementitious materials, and chemical admixtures. Aggregates could include waste and/or manmade materials such as fly ash (traditional, blended, or reclaimed), silica fume, ground granulated blast-furnace slag, recycled concrete, lightweight aggregates other potentially low cost and/or green materials. Micro- and Nanoscale aggregates, inclusions, pozzolans, cements and reinforcements such as microspheres, nanosilicates, microfibers and low-cost nanotubes or nanofibers would also be included in this research area. Chemical admixtures such as water reducers, set retarders, set accelerators, air-entraining admixtures, and foaming and defoaming agents that lend unique properties would also be considered in this research area. Since reinforcement is a critical element to the ductility and durability of concrete materials, advanced reinforcement materials that enhance these properties fall under this research area. Additionally, this topic area would include research involving nontraditional cement binders including polymer- impregnated concrete, polymer or resin concrete, polymer Portland-cement concrete and geopolymer concretes.

• P. Concrete Properties and Analysis (GSL-16)

  Research in this area if focused on the development of new nondestructive and destructive test methods and analysis techniques to better characterize the properties and performance of concretes and the constituents that they are composed of at scales ranging from the nano-level to the macro-level. There are a vast number of topics in testing and analysis that could be included in this area as related to the physical and chemical properties of aggregates, cements, pozzolans, admixtures, fibers, and their interaction during the mixing, placing, curing, and service phases of a concrete. This could include but is not limited to: 1. Developing test methods and analysis techniques to better quantify material properties at aggregate-paste and fiber-paste transition zones.

  2. Developing tools, test methods and analysis techniques to non-destructively define the spatial distribution of components in a concrete specimen.

  3. Developing better assessment tools and criteria for predicting durability and longevity of concrete and grout.

  4. Developing better methods to define and classify chemical admixtures by chemical composition and mechanism of performance.

  5. Developing innovative systems to construct concrete materials and structures more economically.

  6. Developing theoretical, computational, and experimental methods for effectively characterizing stress, strain, progressive damage, and fracture of engineering materials subjected to static and dynamic loads.

• Q. Maintenance, Repair, and Rehabilitation of Concrete (GSL-17)

  Forensic analyses such as assessment of remaining life, maintenance and minor remedial measures, repair and rehabilitation, and surveillance and monitoring are topics of interest. Structures of interest include concrete locks and dams and appurtenant concrete and steel structures (outlet works, retaining walls, gates, piles, bulkheads, tunnels, intakes, etc.), other horizontal and vertical concrete infrastructure, and metals and polymer systems related to those concrete components.

• R. Other Areas of Materials Research (GSL-18)

  Research is needed in the development, properties, and performance of a range of materials for military and civil applications. Needed materials research for concrete applications includes such materials as: curing compounds, coatings, and overlays; polymers or other agents for improving bond between old and new concrete; water stop materials for use in hydraulic structures, and methods for characterizing and testing such materials; grouts for injection underground in very fine fracture systems or porous media; organic and inorganic composites that are used in construction; and grout materials and technologies for waste-disposal and containment such as for both commercial and defense-related low-level and high-level radioactive wastes.

  Other materials research needs include the development, testing, and prototyping of metals, composites, or other novel materials exhibiting advanced mechanical, thermal, rheological, chemical, electrical, and multi-functional properties, and performances. Research is performed on energy absorbing materials for impact, ballistic and blast resistance; hierarchical, multi- layered, and functionally graded material systems; multi-scale reinforcement for macro performance; self-sensing and self-healing materials; and materials demonstrating advancements in durability, high strength-to-weight, fatigue resistance, and ease of application.

• S. Bridge Research (GSL-19)

  Research is conducted in support of the Army’s Dams and Transportation Infrastructure Program, specifically the Bridge Safety and Waterfront Facilities subcomponents. Research covers design, construction, maintenance, repair and inspection procedures of Army bridges and waterfront facilities worldwide as well as other engineering functions as they relate to transportation structures. This involves the formulation of engineering criteria for the design, construction, evaluation, maintenance, and rehabilitation of permanent and expedient bridge and port facilities. Research areas of interest include improved inspection procedures, material characterization and evaluation, nondestructive testing, rapid repair, scour, unknown material properties, unknown foundations, traffic safety, underwater inspection, fracture critical and fatigue evaluations, load capacity, load testing, and load ratings.

• T. Structures Research (Civil Works) (GSL-20)

  Research is conducted in assessing the performance of critical structures to extreme loads, such as those resulting from seismic, terrorist attack, and storm events, as well as the effects of flow-induced vibrations. Efforts include assessing sensitivity of structural design and analysis procedures, vulnerability of structures, and critical design parameters to develop appropriate load-resistance factors. Techniques for retrofit, including use of new and innovative materials, of structures to resist extreme loads is of interest. Also, a better understanding of long-term behavior and deterioration of civil structures is needed, including factors such as material interactions, thermal stresses, and any issues affecting design of new structures and operation and maintenance of existing structures.

  Nonlinear and linear system identification research includes vibration testing, data acquisition, data processing, and analysis techniques for determining linear and nonlinear dynamic and static response properties of structures and structural systems subjected to earthquakes, blast effects from mining (or other) operations, other transient random, harmonic dynamic loads, and static or pseudo static loads.

• U. Structures Research (Military) (GSL-21)

  1. Research is needed on the response of aboveground and shallow-buried structures subjected to military dynamic loads; specifically, the prediction of the load and response to failure of aboveground and shallow-buried structures. This effort will involve the following research:

  a. Development of techniques to simulate military dynamic loads on aboveground and mounded structures.

  b. Development of design procedures for components in semihardened and protected facilities.

  c. Analysis of structural loading and damage resulting from internal or external detonations.

  d. Development of fast-running models for PC based applications to predict the response of structures, both hardened and unhardened, to single and multiple explosive detonations.

  2. Research on deeply based structures and hardened existing systems involving the following:

  a. Development of comprehensive structural design for deeply buried and surface-buried structures subjected to air blast-induced and direct-induced ground shock from surface and shallow earth-penetrating high-energy sources.

  b. Formulation of computer models for SSI and pre- and post-test analysis of structural response to include correlation and comparison with experimental data.

  3. Research on surveillance and intrusion detection sensors involves the constraints of the environment on sensor systems used to detect intruders and placed along the perimeter of high-value military installations. Improved methods for rapid and accurate measurement of predetermined influential environmental parameters must be developed. Analytical techniques relating to specific sensing phenomenology’s and target/nontarget-generated signatures and signature wave interactions to variations in environmental characteristics are required. Of particular interest is the integration of multiple sensor systems (both detection-type and environmental/background monitoring transducers) that use various sensing phenomena for enhanced target detection and classification and increase nuisance and background signature rejection. Research studies are required in the determination of automated techniques for monitoring sensor system response and sensitivity to provide optimum and consistent performance as a function of time varying changes of influential environmental characteristics.

  4. The Corps of Engineers is involved with research on the design of military facilities for protection from high-energy sources. These efforts include the following research:

  a. Prediction of the response of structural elements common to conventional or expedient construction to military loads.

  b. Methods of retrofitting conventional buildings to harden them against nearby military high-energy sources.

  c. Development of innovative design of structural components, such as windows and doors, subject to high-energy sources.

  d. Development of analytical methods for predicting the effects of forced entry devices on structural components.

  e. Development of innovative designs using low-density materials for expedient protection of troops and equipment from the effects of military high- energy sources.

  f. Development of microprocessor-based software/hardware and supporting documentation to aid in the assessment of structural survivability to the effects of conventional and advanced weapons systems. The software will address the integration of databases, weapons effects calculations, and operational factors associated with engineer survivability missions.

  g. Development of a procedure to ensure robust codes, user-friendly interfaces, and supporting documentation for use in the testing and development of microprocessor-based survivability and structural assessment software/hardware.

  5. Composite Materials for Force Protection-Research in this area includes developing, characterizing, modeling, and testing of layered composite materials for protection against air blast and penetration/fragmentation. These materials are intended for use in lightweight expedient protective systems to protect against improvised explosive devices and conventional weapons such as small arms, standoff weapons, fragmenting weapons, and shape charges. It is envisioned that panels of these materials could be incorporated into protective structure designs to increase survivability of personnel or to protect mission-critical assets. Performance measures include such attributes as build time, low mass, cost, penetration resistance, ductility, and environmental durability. Additionally, this topic area includes methods to develop appropriate material anisotropic and or non-homogeneous material models for incorporation into advanced computational models such as Abaqus, LS-DYNA, and EPIC. Protocols for evaluation and performance testing of composite materials subjected to energetic, high-strain rate events are desired.

  6. Worldwide Construction Practices- This research includes capturing typical construction practices and construction material properties worldwide. Information of interest is material properties of structural components, building types and construction techniques, building footprints, construction timeframe/era of buildings, and location of the building (country, world region, urban terrain zone).

• V. Multispectral Camouflage Research (GSL-22)

  This research area involves all aspects of fixed-facility survivability incorporating signature management and other technical effects. Fixed facilities include stationary and relocatable high-value targets. The general goal is to directly and indirectly increase the survivability of U.S. and Allied facilities and improve the U.S. and allied counterintelligence, Surveillance, and Reconnaissance (counter-ISR) capability against adversaries. Multispectral refers to those areas of the electromagnetic spectrum used by the United States and potential adversaries in reconnaissance and surveillance and in attack platform target acquisition and detection. Major objectives include: quantifying or otherwise evaluating counter-ISR technology effectiveness; investigating materials and techniques for signature modification; developing technical effects and physical countermeasures, procedures, and applications; developing computer-based analytical procedures for simulating scenes; developing instrumentation for and conducting target/background signature measurements; assessing the United States and threat operations and sensor capabilities with both currently fielded and new design reconnaissance and surveillance and attack platform sensors and systems; developing applications for intelligence information for military missions; providing guidance to field commanders and information for the RDT&E community; and studies of the interaction of camouflage technology with other operational factors, particularly in determining operational supportability, costs and manpower, interoperability, and joint interoperability requirements.

• W. Advanced Maneuver Technologies (GSL-23)

  This research addresses ground vehicle maneuver in urban environments which poses many new operational and tactical challenges for the Army and Joint Forces. While many improvements have been made in protecting ground vehicles in the last decade, these improvements come with a cost, namely limited situational awareness due to reduced visibility and limited maneuverability in tight spaces because of larger vehicle size. Both of these constraints seriously reduce the mobility of ground vehicles in urban environments. To address these constraints, research is needed to develop technologies to identify nearby dynamic hazards for ground vehicles in urban environments and provide early warning to ground vehicle operators or autonomous driving systems. Specifically, this research will address methods and procedures to develop advanced technologies that will be used for detecting dynamic hazards in urban environments such as traffic flow rates and congestion, pedestrians, buried threats, constricted roads, and other obstacles or anomalous objects in real-time. In addition, further research is needed to develop technologies that will deliver the information in a consolidated or data excerpt manner and report the locations of interest and concern to the driver and or operator. The performance of emerging technologies in sensors and data processing to provide better situational awareness in near real-time to ground vehicle operators maneuvering in dynamic urban terrain is also of interest.

• X. Railroad Technology (GSL-24)

  Research in this area is conducted in support of the Corps mission to design, construct, and operate railroad systems worldwide. This research includes railroad design, construction, inspection, evaluation, maintenance, and rehabilitation. Research areas of interest include advanced and composite materials, rapid repair, non-destructive evaluation, geotextile use in construction, in-situ additive manufacturing of components, soil stabilization, GIS, and remote assessment.

Environmental Sensing

• Overview

  Current research is in the acquisition of information by remote sensor systems, the impact of the environment on imaging and other sensor systems, and advanced signal processing. Sensors using electromagnetic, seismic, and acoustic energy forms are of interest. In addition, work is conducted to determine terrain and other environmental effects on high- technology sensor systems. Sensor systems include optical and infrared millimeter wave (active and passive). Briefly described below are specific research areas.

• A. Sensing (EL-1)

  The EL has an ongoing program to develop and demonstrate advanced technologies that support the Army’s requirements for improved detection and discrimination of unexploded ordnance (UXO), depleted uranium (DU) munitions, radiological threats, and deployment platforms. Additional research work is needed for subsurface (land-based) and underwater (proud and buried) UXO sensing, data analysis, display, and platform navigation/positioning. Special areas of interest include novel sensing concepts for the detection and relocation of buried objects (DU, metallic, and nonmetallic targets) using magnetic, electromagnetic induction, ground penetrating radar, seismic/acoustic, chemical, and/or radiological methods or a combination thereof. Fundamental measurements and models that define/predict the performance of these sensing methodologies in varying environmental conditions for UXO, DU and radiological targets are also of interest. Research is also needed to develop advanced data analysis techniques that can significantly reduce the number of false positives arising from natural anomalies and man-made sources.

• B. Environmental and Military Sensing (EL-2)

  1. Research in this area includes basic and applied research to develop environmental sensing, characterization, and monitoring capabilities necessary to quantify environmental site conditions and trends at local and regional scales. In the military area, research is conducted on basic signature research, to better understand target and environmental background signature characteristics.

  2. Specific areas of required research include:

  a. Development, integration, and application of remote sensing technologies and the use of these data in geospatial models to characterize site conditions over large areas.

  b. Development of innovative data fusion approaches, particularly the combined use of hyper spectral and bathymetric and/or topographic LIDAR data for the extraction of environmental information.

  c. Research to identify, model, and mitigate the effects of the environment on novel sensing techniques that address environmental and military requirements.

  d. Development of ground-based and airborne remote sensing approaches, and associated modeling, for unexploded ordnance detection, minefield detection, military targets and vehicles, and smart weapons development.

  e. Rapid collection, analysis, and visualization of sensor data for environmental quality and military applications.

• C. Environmental, Sensing, Characterization, and Modeling (EL-3)

  There is growing need to utilize and develop artificial intelligence (AI) and machine learning (ML) technologies for enhanced characterization of forested environments. Novel technologies should leverage remotely sensed and high fidelity in-situ data to improve understanding of complex forest conditions. Numerous benefits for military defense, environmental stewardship, forest resource monitoring and evaluation, and military readiness exist from identifying, quantifying, visualizing, and understanding forest data. Research is needed to capitalize on recent developments in AI-based big data analytics to characterize forests and forest-dwelling species and habitats data to better understand vegetated ecosystems that is traditionally obtained through in situ sampling. Research is needed to capitalize on recent developments in AI based big data analytics to characterize forests and other ecosystems.

  Specific areas of required research include:

  a. Developing novel forest modeling frameworks that utilize remote-sensing and in-situ field data to inform and validate forest characterization—to include vertical stratification.

  b. Quantifying forest characteristics and associated forest-dwelling fauna—to include threatened and endangered species. Provide specialized expertise in the application and deployment of advanced environmental sensors to detect and monitor rare and sensitive species—particularly focused in tropical forested habitats.

  c. Demonstrated experience deploying, managing, and analyzing data from remotely deployed autonomous environmental sensor platforms, including paired acoustic/visual monitoring systems such as Autonomous Recording Units (ARUs), omnidirectional microphones, trail cameras, and related technologies to document rare and sensitive species presence, behavior, and responses to anthropogenic noise disturbances and military training activities.

  d. Tailoring sensor arrays to rapidly detect, evaluate, and quantify both acoustic and visual data in Pacific Island forested ecosystems.

• D. Environmental Instrumentation (EL-4)

  1. Research and development in this area includes basic and applied research and technology demonstrations that support rapid measurement of biological and chemical hazards of the environment.

  2. Specific areas of required research include:

  a. The integration and interoperability of environmental instrumentation with future and existing military robotic systems: this includes unmanned aerial systems, ground robotics, autonomous submersibles, and robotic surface watercraft.

  b. Provide new applications that support faster processing on small low-power hardware to triage environmental measurements to immediately identify biological and chemical hazards.

  c. Techniques that support biomimicry in robotic systems and the differentiation of biotic from abiotic systems. Instruments that are low-power, small, and compact to assess the biological and chemical characteristics of water, soil, and air, in surface and subterranean environments.

  d. Research into sensing of aerosols and/or plumes from either ground or airborne platforms.

  e. Research into novel uses of unmanned aerial systems for environmental characterization and change detection - including fusion of active and passive modalities.

Contaminated Site Characterization, Assessment & Remediation

• Overview

  An extensive research and development program is being conducted by the Department of Defense to assist in the cleanup of contamination at military installations. The EL is developing technologies for characterizing, monitoring, and applying physical, chemical, and biological treatment of toxic and hazardous waste in contaminated surface and ground waters and soils. The EL is also developing, evaluating, and verifying numerical models and guidance for solid waste disposal systems.

• A. Innovative Technology for Environmental Sensors and Tools. (EL-5)

  The EL has an ongoing research program to develop advanced technologies for environmental sensing, characterization, and monitoring in order to quantify environmental conditions at sites of interest. The program is actively developing field-based tools and sensors to conduct rapid site characterization/screening for environmental contaminants. Additional research is needed in the areas of novel sensing technologies for detection of chemical and biological contaminants allowing for rapid field-based data acquisition. Also, research is needed to develop technologies and platforms allowing for rapid data analysis/interpretation/reporting. Fundamental measurements and models that define/predict the performance of new sensing methods in soil, water and air are also of interest.

• B. Innovative Technologies for Treating Contaminated, Sediment, Soil, Surface Water, Ground Water, and Hazardous Waste (EL-6)

  Presently, EL is continuing to conduct research, develop technologies and apply strategies to treat complex organic- and metal-contaminated hazardous liquids, off-gases, soils, sludges, sediments, and residuals from past disposal practices. Research is divided into two major categories: technologies for treating contaminated soils and sediments, and innovative technologies for treating contaminated surface and ground waters. Areas of R&D include: (1) physical and chemical technologies to destroy/detoxify or reduce the quantity and/or toxicity of the contaminated materials, (2) biological processes and methods to detoxify/destroy hazardous waste constituents, (3) techniques for in situ treatment of groundwater aquifers, (4) laboratory design criteria for and field implementation of piloting equipment for promising technologies, (5) computer-based techniques to assess operational performance of various treatment processes/systems and (6) improved analytical chemistry techniques and methodology to assess treatment technologies.

• C. Design, Evaluation, Verification and Modeling of Solid and Hazardous Wastes and Contaminated Sediments (EL-7)

  Efforts are continuing to develop water balance and leachate models for solid waste disposal systems and dredged material disposal facilities. Additional work is needed to model innovative designs, nonsoil surface materials, cobbled surfaces, preferential flow through heterogeneous waste materials and other layers, and effects of complex mixtures of vegetation including trees. Similarly, additional work is needed to verify the existing models.

Sediment Geochemistry and Biological Effects

• Overview

  Potential adverse environmental impacts of disposal of contaminated sediments must be assessed prior to permitting operations. This includes the determination of the impacts that contaminated dredged materials exert on the environment prior to dredging.

• A. Environmental Risk Assessment (EL-8)

  Current research on the fate and effects of environmental contaminants occurs under the general paradigm of Environmental Risk Assessment. Specific studies fall into one or more of the following areas:

  1. Hazard Identification. This is the process of showing causality (i.e., a chemical or complex mixture can cause some adverse effect). If this causality can be demonstrated, the chemical is referred to as a "hazard." If there is no causal link, risk need not be quantified. Important target receptors are also identified by this stage (for example, humans, endangered species, and ecologically or economically important species). Research is conducted to develop the technology for hazard identification and the establishment of causality.

  2. Effects Assessment. While Hazard Identification decides if a chemical or complex mixture is toxic; Effects Assessment establishes the relationship of the toxicant dose and associated biological response. This is accomplished via experimental research in which surrogate species are exposed to gradients (spatial, concentration, etc.) of the hazard in question, and biological effects are monitored. Biologically important endpoints measured include survival, growth, reproduction, and population-level parameters. These endpoints must be accompanied by technically sound interpretive guidance. Results are expressed in dose- response or exposure-response relationships. Research is conducted to develop the necessary experimental/statistical designs, technically sound tests (for example, chronic sub lethal sediment bioassays) and appropriate extrapolations (for example, high dose to low environmentally realistic exposures, and surrogate test species to receptor of interest). Analysis of the uncertainty associated with these effects assessments is also conducted.

  3. Exposure Assessment. In Exposure Assessment, the magnitude, frequency, and duration of contaminant exposure relative to the target receptor(s) are determined. This research is model-intensive, with both descriptive and quantitative models being used to evaluate pathways and routes. A pathway exists if the hazard travels between the initial source of contamination and the ultimate biological receptor. An exposure route is pathway that the chemical contacts the receptor (for example, ingestion, inhalation, dermal absorption, bioaccumulation, trophic transfer). Analysis of the uncertainty associated with these exposure assessments is also conducted.

  4. Risk Characterization, Management, Communication, and Analysis. Outputs from the Effects Assessment and Exposure Assessments are joined in Risk Characterization to yield an estimate of risk. Research is conducted to determine the best ways to characterize risk both numerically and descriptively. Also, uncertainty analysis is undertaken to identify the qualitative and quantitative important sources of uncertainty. Techniques employed include error propagation, probability distributions, sensitivity analysis, Monte Carlo simulation and others. Once environmental risk has been quantified, management action may be required.

  5. Research is conducted to develop management alternatives, which range from no action to extensive (and expensive) remediation. Results of the Environmental Risk Assessment are weighed and balanced with other factors such as applicable laws and regulations, engineering feasibility, potential benefits, costs, economic impacts, and the socio-political decision environment.

  Risk Communication is a dialogue that occurs at two levels: between the risk assessor and the risk manager, and between the risk manager and the public. Research is conducted to identify optimal procedures for communicating environmental risks, including an appreciation for the limits and uncertainties of the numerical results. Risk Analysis is a broad, inclusive term encompassing the processes of Risk Assessment, Risk Management, and Risk Communication as well as any field verification or monitoring activities. Field verification is a study or studies carried out to determine the accuracy of laboratory observations and predictions. Field monitoring (in the context of Risk Assessment) is undertaken to ensure that steps taken to manage the chemical risks were successful. Field research studies are carried out for both verification and monitoring purposes.

  6. Engineering With Nature® (EWN®) Research Supporting Innovative Field Sampling Practices, Natural Infrastructure (NI) Construction/Deployment and Related Technologies. Conduct a broad array of EWN research and development that may include, but is not limited to: research pertaining to placement of scientific instruments and/or pursuit of novel experiments that advance field-based sampling and laboratory practices for the purpose of measuring and archiving the performance of natural infrastructure (NI); conduct research and/or test innovative instrumentation that records/monitors natural and engineering processes resulting from the placement of NI and/or hybrid infrastructure; conduct research and test new technologies that result in accelerated construction/placement of natural and nature based features and/or improved placement strategies for dredged sediment used to construct EWN projects.

  7. Technology Transfer Development for Engineering With Nature® (EWN®) Research Areas. Research, develop and analyze technology transfer concepts; analyze target audiences for technical information; test innovative methods of transferring EWN research results and technology to supplement conventional technology transfer. Included may be such items as interactive internet and PC technology applied to training and general information transfer; technology applications of electronic media using the Internet; and innovative public information systems/products. Audiences include Corps of Engineers and the Department of Defense; Congress and other Federal, State, and local agencies; port and transportation authorities; universities; environmentalists and other public interest groups; and the general public.

• B. Sediment Water Interactions (EL-9)

  Sediment/Soil Water Properties. Current research encompasses a wide range of investigations designed to increase understanding of sediment-water interactions. Emphasis is on conduct of investigations for determining the impacts that sediment/soil properties have on sorption and transformation of explosives and release of semi-volatile contaminants to the atmosphere. Factors responsible for sorption and transformation of explosives include redox potential, pH, and the geochemical characteristics of the soil or sediment. Factors affecting the release of semi volatile contaminants from soil or sediment to the atmosphere include relative humidity, wind speed, contaminant concentration, moisture content, porosity, and organic carbon content. Research is also conducted on colloidal system contaminant transport, accelerated sediment oxidation, and the role of solution chemistry in contaminant partitioning between sediment and water.

  Diverse research activities focused on characterizing microorganisms and microbial communities in natural and engineered environments relevant to contaminant transformations, biogeochemical cycling, host-microbiome-contaminant interactions, bio- enabled materials, synthetic biology, and environmental biological threats are currently underway.

  1. Biodegradation of Contaminants. Studies in the biodegradation area emphasize destruction of organic contaminants for remediation purposes. Emphasis is on (1) bioinformatics of microbial community diversity and activities in various ecosystems; (2) delineating biodegradation pathways, enzymes, and genes; (3) determining intermediate and final end- products; (4) assessing the role of environmental and genetic factors regulating the pathways utilized and the rate and extent of destruction of the parent compound; (5) determining the survival and activity of microorganisms added to ecosystems, and biotreatment systems; and (6) enhancing biodegradation to obtain the maximum destruction of organic contaminants within a soil, sediment, or treatment system.

  2. Microbial Sensing. Novel microbial, cellular, molecular and/or genomic approaches are sought and developed for the rapid functional and DNA-based identification, detection, and monitoring of microorganisms in various environmental matrices including soils, sediments, and surface waters. Novel ecological approaches to detect, monitor and predict prokaryotic/eukaryotic microbes are sought that combine physiology, molecular tools, biochemistry, modeling, and remote sensing for the management of high biomass events and environmental toxins.

  3. Biomaterials and Composite Structures. Novel biological materials and/or techniques are sought to manipulate bioprocesses and biomineralization pathways as additives to aggregate and composite products. These products will support advancements in material structural properties that support civil works and military operations.

  4. Insect and plant field collections, insect husbandry, plant maintenance with greenhouse access is sought for various microbiome projects. Needs will be seasonal and very specific to limited insect or plant systems as dictated by internal projects.

  5. Soil, Sediment and Environmental Chemistry. Research interests broadly center on deciphering environmental processes that shape the emergent chemical, physical and biological properties of soils and sediments in natural and built environments. Studies aim to bridge the gap between fundamental science and practical engineering solutions to enhance understanding of environmental processes, improve infrastructure resilience, and promote sustainable practices in soil and sediment management.

  a. Geochemistry of Soils and Sediments. Topics of interest include understanding i) the cycling of nutrients, metal(loid)s, and radionuclides in soils and sediments, ii) the impact of dynamic chemical conditions on soil physical properties, and iii) complex interactions between chemical reactions and dynamic fluid flow (reactive transport). Of particular interest are soil systems impacted by seawater inundation, wildfire, and other natural and anthropogenic disturbances, which alter the productivity, erodibility and trafficability of soils, and soil characteristics that influence military operations and natural disasters. Studies employ the use of novel field measurements, laboratory experiments, and advanced methods of soil analysis, such as synchrotron-based X-ray absorption spectroscopy, -X-ray diffraction, and X-ray fluorescence microprobe analysis. Molecular to field-scale processes occurring in soils and sediments are modeled using computational tools such as geochemical and reactive transport modeling.

  b. Soils and Sediments in the Built Environment. Research broadly focuses on the function and characteristics of soil and sediment within built environments, including dynamic urban coastal zones. In the built environment, soils and sediments are altered by human activities and/or derived from human-transported materials. Anthropogenic impacts on soil may be intentional (e.g., engineered for a specific purpose) or unintentional (e.g., accidental release of waste). Our research aims to decipher both intentional and unintentional consequences of anthropogenic activities on the health and function of soils and sediments. Focus area includes (1) standardizing approaches to soil health assessment (2) methods to enhance soil functions in nature-based features such as carbon sequestration and water retention, and (3) fate of legacy contaminants such as lead.

• C. Techniques for Contaminated Dredged Material Disposal and Treatment (EL-10)

  1. Development/implementation of innovative technologies to reduce or eliminate contamination present in surface sediment and/or dredged materials. Research to include 1) technologies for cost effective in situ treatment of surface sediments to reduce bioavailability/toxicity; 2) ex situ treatment technologies to reduce contamination and facilitate expanded opportunities for beneficial use of treated material.

  2. Development or enhancement of computer models to be included in the Automated Dredging and Disposal Alternatives Modeling System (ADDAMS) to evaluate the environmental impacts of dredged material disposal. Evaluations include water quality impacts of initial release in open water, effluent discharge, runoff and leachate, benthic impacts, plant and animal uptake, and volatilization.

  3. Development and/or application of new or improved environmental chemistry methodologies to assess contaminant concentrations of dredged material and other complex matrices (e.g., elutriates, bioaccumulation tissues, etc.) focusing on specific compounds or classes, cost effectiveness, quality assurance, lower detection limits, and removal/reduction of challenging matrix interferences.

• D. EMERGING CONTAMINANTS IN THE ENVIRONMENT (EL-11)

  1. Presently, EL is continuing to conduct research, develop technologies and apply strategies to address emerging contaminants (ECs) in the environment. Research falls into for 5 broad categories:

  a. Detection and Measurement:

  b. Development and application of technologies for the detection and measurement of ECs in environmental media at environmentally relevant concentrations.

  c. Application of innovative technologies to discern source of EC contamination.

  d. Screening level methodologies to facilitate near real time detection and measurement of ECs in the field.

  e. Development of forensic methodologies and computational approaches for detection, measurement, prediction of EC precursors and/or degradation products in environmental media.

  2. Exposure Assessment:

  Development and application of technologies for measuring/predicting the movement and fate of ECs in the environment.

  3. Effects Assessment:

  Development and/or application of technologies for establishing the effects of ECs on important ecological and human health receptors/endpoints.

  4. Risk Characterization/Management:

  a. Development and/or application of innovative technologies for characterizing risk of ECs in environmental media. Development and/or application of decision-making tools to support EC related risk management decision-making.

  b. Development and/or application of innovative technologies to remove, concentrate, and/or destroy ECs in environmental media.

  c. Development and/or application of innovative technologies to assist in identification of safer alternatives.

Environmental and Water Quality Modeling

• Overview

  The Corps of Engineers is involved in research and development related to water quality and contaminant fate/transport modeling for surface water, watersheds, and the subsurface, or groundwater. This encompasses a wide range of environmental issues, such as water quality and ecosystem linkages, contaminant transport and fate, eutrophication, effects of land use/management on watershed runoff quality, total maximum daily loads (TMDLs), and ecological and human health risk assessment as related to contaminants in the environment. Research may include model development and field and laboratory investigations to improve model descriptions and to provide required data for model validation.

• A. Numerical Water Quality and Contaminant Modeling (EL-12)

  This area of work is oriented toward development and application of water quality and contaminant fate/transport models for surface water and the subsurface, or groundwater. Surface water modeling includes watersheds and receiving waters, e.g., riverine, reservoir, wetland, estuarine, and coastal water bodies. Groundwater modeling includes modeling both the unsaturated and saturated zones, as well as multi-component flow and transport. Models are utilized for conventional water quality (e.g., nitrogen, phosphorus, carbon, dissolved oxygen, etc.) and contaminants, i.e., toxic substances, such as organic chemicals, trace metals, radionuclides, explosives, and other military unique compounds. Emphasis includes the following: formulation of appropriated physical, chemical, and biological algorithms; improvement of mathematical and numerical methods; collection and assemblage of data for model evaluation; conduct of field and laboratory process investigations designed to develop/improve model descriptions, dynamic linkage of water quality and biological models, including biomass-based, individual-based, and population- based biological models; integration of contaminant exposure models with biological effects data or models to quantify risk; incorporation of uncertainty analysis into modeling; linkage of physical/chemical models with biological population models; linkage of cross- domain models for system wide modeling; development of routines/linkages to include the effects on water quality of watershed landscape features (e.g., buffer zones) and vegetation management; development of a risk assessment modeling system; and development of software to provide graphical user interfaces and modeling environments to enhance model utility and ease of application.

• B. Complex Adaptive Systems (EL-13)

  The central goal of this effort is to identify the rules and feedback processes that govern how interactions between modular components in natural system shape important holistic properties, like the global resiliency to disturbances, and, invariably, the fate of the individual components themselves. These tasks are central to basic research efforts in Complex Adaptive Systems (CAS); an area that impacts a wide range of critical needs in both military and civil works (e.g., immune system responses, decision-making, social feedbacks, and ecosystem management). Current research focuses on ecological systems in which the use of different species and study systems is encouraged to provide diverse and novel solutions to understanding, predicting, or improving the resiliency of complex systems. Recent case studies range from a contaminant’s (e.g., altered water quality, noise, chemical) impacts on individual development and performance, the social roots of information cascades in social vertebrates (spanning from fish and humans), to overall ecosystem functioning based on infrastructure design, overharvesting, or mismanagement. This topic area is inherently interdisciplinary and emphasizes team efforts in the combination of analytical, numerical, and laboratory experiments to test competing hypotheses.

• C. Water Quality and Behavior Modeling (EL-14)

  This research topic focuses on developing early warning indicators to demonstrate how changes in water quality can affect critical ecological processes, thereby raising the subsequent risks imposed on animal populations. We focus on demonstrating when environmental quality is not merely a potential hazard, but how it elicits a functional (e.g., physiological) change during early exposure stages that can impact future performance and, invariably, population survival. Anthropogenic disturbances would include sediment plumes, temperature spikes, or contaminants. Animals typically display stable and, generally, predictable physiological and behavioral patterns in non-stressful conditions.

  However, sub- lethal (including chronic) or acute environmental changes can drastically alter behavior and activity, remain undetected, and invariably introduce unacceptable levels of error in model predictions. Current methodologies range from simple bioassays to more complex physiological consequences at the individual level, to long-term costs/benefits at higher ecological levels (i.e., habitat use, populations, and communities). Hypothesis testing based on a combination of laboratory and modeling is encouraged, along with field data when possible. Findings from these efforts play an important role in both civil works and military activities.

Environmental Impact Prediction, Assessment and Management

• Overview

  This research program addresses environmental impact prediction, assessment, and remediation and is intended to provide Corps, Army, and other field operating elements with techniques and methodologies for environmental assessments and EIS preparation, guidance on selecting appropriate planning, design, construction, and operation alternatives, and implementation of the planning function pursuant to NEPA and other legislation and guidance. Specific objectives include:

  A. Developing, verifying, and demonstrating practical prediction and assessment techniques including applying and refining habitat-based evaluation methods, evaluating mitigation measures, developing streamlined frameworks for environmental monitoring, applying ecosystem simulation principles to environmental analysis, and estimating future habitat quality.

  B. Documenting and quantifying environmental effects associated with various types of Corps, Army, and other activities. Research has included the effects of aquatic habitat modification on anadromous fishes, the effects of selective clearing and snagging on in stream habitat, and t h e benefits of channel modification for aquatic habitat in reservoir tail waters and local flood control channels.

  C. Developing and demonstrating design, construction, and management alternatives that will minimize adverse effects and protect natural and cultural resources. Research has included techniques for managing wildlife habitats, preserving archeological sites, and stabilizing eroding shorelines.

  D. Developing, validating, and demonstrating novel systems biology-, computational biology- or bioinformatics-based approaches to understanding and quantifying toxicological impacts of environmental contaminants in environmentally relevant organisms.

• A. Biotechnical Shore Stabilization (EL-15)

  Biotechnical (sometimes called bioengineering) shore stabilization is the use of a combination of live vegetation and structural materials (for example, breakwaters, geotextiles, erosion control fabrics/mats, building materials) for erosion control of shores. Shores of particular interest are those of streams, lakes, or dredged material deposits and subject to erosion from waves, surface runoff, and wind. Research is needed to determine the causes and amounts of erosion and to identify and assess cost-effective biotechnical erosion control methods. Studies may include, but are not limited to, identifying, developing, and cultivating appropriate flood- tolerant plants and varieties or cultivars and cost-effective installation procedures of biotechnical techniques.

• B. Freshwater Fishery Investigations (EL-16)

  Primary areas of research are predicting environmental impacts of navigation and flood control projects on fishes, freshwater mussels, and other aquatic fauna; benefits of restoring aquatic habitat including environmental flows; conservation of endangered fish and mussel species; evaluating freshwater and coastal wetland fish communities; management of invasive species movement and colonization including Asian Carp; and fishery management in vegetated waterbodies. New and innovative approaches to determine physiological, behavioral, population and community level responses of fishes to habitat variables are of interest, along with technological advancements in sampling and multivariate data analysis capabilities. Demographic and landscape habitat models are anticipated products of this research.

• C. Freshwater Macro invertebrate Investigations (EL-17)

  Research focuses on assessment of aquatic and terrestrial invertebrate communities, with emphasis on insects and mussels. Studies include stream and river biotic assessments, terrestrial and aquatic insect surveys, assessment of threatened and endangered invertebrate populations, feeding ecology of fishes, and evaluation of stream and river food webs and energetics. Assessments of environmental effects of USACE activities, including stream and river impoundments and structural changes, are also performed using naturally occurring macroinvertebrate and mussel communities as indicators of current and past ecological shifts. Restoration and management recommendations are also made through the analysis of these invertebrate communities in both freshwater and terrestrial ecosystems. Technical and analytical advancements, including sampling and data analysis are of interest.

• D. Mitigation (EL-18)

  An avoidance, minimization, and/or compensation process is required for impacts from water resources projects on ecological resources (fish, wildlife, habitat, or installation activities). Planning and implementing mitigation are a complex process, and new ideas that contribute to success of mitigation are invited. Subjects such as Best Management Practices for avoiding or minimizing impacts, planning for mitigation based on impact analysis, incremental analysis to justify mitigation, mitigation banking, future predictions, and mitigation for indirect or cumulative impacts are included.

• E. In Stream Flow Requirements for Aquatic Biota (EL-19)

  Research focuses on development and application of fish habitat assessment methods. Currently, the most widely used system, the Physical Habitat Simulation System (PHABSIM), is used to assess the effects of reservoir operations on downstream fish habitat. Research is needed to better quantify the relationships for fish preference and flow conditions, as well as habitat requirements for aquatic invertebrates. When appropriate, laboratory-based studies can support field-based modelling efforts. Verification studies of these models will be required as development continues. Assessment methods must be able to evaluate the impacts of a variety of reservoir operations such as base load or peaking hydropower releases and at multiple scales from single project to basin – wide studies.

• F. Behavioral and Structural Fish Barriers (EL-20)

  Entrainment of fish at Corps hydropower projects may result in passage of fish through turbines with attendant death or injury from impact with runner blades, pressure changes, or shear forces. Evaluations of a number of behaviorally based technologies and structural barrier designs conducted under laboratory and field conditions have yielded results that are generally inconsistent. Consequently, there currently exist no consistent guidelines for selection of appropriate technology for site-specific applications at Corps dams. Research is required to relate effectiveness of different technologies to size and species of fish, dam design, operations, season, and other site-specific conditions. The information produced by this research will be used to develop specifications and guidelines for fish protection technologies at Corps dams to reduce entrainment and mortality. This effort may involve literature synthesis, laboratory research, design and fabrication of prototype systems, or field studies as well as simulation analysis of fish movement/passage patterns.

• G. Fish Guidance and Bypass Systems (EL-21)

  CE water resource activities may result in blockage of historical fish migration routes through waterways. These blockages, with associated fragmentation of habitats, may have severe impacts on anadromous and catadromous fish populations. A variety of bypass system technologies are available to guide fish around dams. However, many of these systems operate at reduced efficiencies because they damage fish, fish are unable to locate entrances to the systems, or because fish become disoriented and "fall back" after an initial successful passage. Research is required to better understand the hydraulic and behavioral characteristics of fish bypass systems, including the use of behavioral technologies to guide fishes towards these systems and to successfully orient them within the system.

• H. Coastal Ecology (EL-22)

  Research topics in coastal ecology include multidisciplinary investigations of the environmental impacts of engineering activities in the coastal zone, such as dredging, dredged material disposal, and construction of coastal structures (e.g., jetties, breakwaters, groins, seawalls, marinas). Emphasis is placed on improved technologies for assessment, protection, and management of fish and shellfish resources and their habitats. Of particular relevance are proposals dealing with endangered species (e.g., sea turtles, marine mammals), beneficial uses of dredged material and habitat restoration in the coastal zone (e.g., marsh, oyster reef or mudflat creation), and application of population dynamics and ecological models for impact prediction and assessment at population/community/ecosystem/watershed levels. Other areas of interest include effects of beach nourishment and use of offshore borrows areas, seasonal restrictions on dredging and disposal operations, artificial reef technologies, and cumulative impact determination and mitigation techniques.

  Other focus areas include:

  a. Effects of beach nourishment on benthic communities and surf-zone (near- shore) fishes,

  b. Active and passive fisheries acoustics to assess fish migratory patterns, spawning habitat, fish density and spatial distribution patterns near dredging operations and placement sites.

  c. Essential Fish Habitat (EFH) protection from increases in turbidities and suspended sediments.

  d. Fish entrainment

  e. Behavioral changes to marine organisms (e.g., migratory blockage of migratory fishes due to the presence of the dredge, particularly in narrow or constricted waterways).

  f. Underwater noise impacts to aquatic species due to dredging and disposal operations.

  g. Ecosystem restoration (e.g., filling offshore/near-shore borrow areas to natural bathymetry).

  h. Artificial reef creation using dredged rock and other suitable material to enhance fisheries and shell fisheries resources.

  i. Thin-layer placement, re-contouring natural bathymetries. Increased costs associated due to compliance with environmental windows/seasonal restrictions imposed on dredging and disposal operations, and cumulative impact determination and mitigation techniques.

• I. Techniques for Designing, Operating and Managing Dredged Material Disposal Facilities and Beneficial Use Projects (EL-23)

  1. Refinement and verification of techniques for designing, operating, and managing dredged material disposal areas.

  2. Development of a computerized economic database for costs associated with dredging sediments; disposing of dredged material; and constructing, rehabilitating, and operating and managing dredged material disposal areas.

  3. Development and refinement of computer models for dredged material management and beneficial use to be included in the ADDAMS.

• J. Systems Biology, Computational Biology, and Bioinformatics for Environmental Impact Assessment (EL-24)

  A wide spectrum of research in systems toxicology, biological networks, synthetic biology, predictive toxicology, genomics, bioinformatic data mining of next-generation sequencing data, adverse outcome pathway development, toxicological modes of action discovery, herbicide resistance mechanisms, structural biology, chemoinformatics, and molecular modeling is currently underway. Proposed research in mechanistic/predictive toxicology, structural biology, bioinformatics, or computational biology would complement current research areas.

  1. Novel genomics, epigenetics and synthetic biology approaches are sought and developed to assess biochemical, physiological, or other toxicological (adverse) effects on the biota at molecular, cellular, tissue/organ, individual, population, community, or ecosystems levels.

  2. Novel in silico modeling and data mining approaches that are based on computational biology, biophysical or bioinformatics principles and techniques are sought and developed to systematically analyze and interpret big data generated using cutting-edge and high- dimensional biotechnologies such as next-generation DNA sequencing, hybridization-based microarray, proteomics, and metabolomics technologies. Novel mathematical approaches and analysis methodologies are also sought to interpret or describe data generated using novel experimental protocols, and which may account for internal forces, energy and information flows that regulate biological, biophysical, or bioenvironmental processes.

  3. Tools for assessing environmental impacts of synthetic biology. This work involves identifying synthetic biology technologies and understand their current state of use, development, technology readiness, as well as their potential environmental impact. This includes hazard identification, effects assessment, fate, transport, and transferability of various technologies. Moreover, the work entails quantifying environmental impacts of synthetic biological technologies through experimental and modeling approaches. This includes establishing screening mechanisms for genetic and physiological traits for synthetically derived systems, microcosm experiments with tractable organisms to assess potential for spread/transfer of synthetic constructs.

Environmental Criteria for Stream Channel Alteration Projects

• Overview

  The Corps of Engineers is involved in the alteration of stream channels for flood damage reduction, navigation, channel stabilization, and ecosystem restoration, as well as alterations performed by others as part of the Clean Water Act. Modifications to channels include removal of snags and vegetation, channel alignment (straightening), channel enlargement, construction of levees, stream bank protection, and grade control. The Corps is also involved in regulating and furnishing technical assistance to States in regard to other types of channel alterations such as gravel mining. Work at the US Army Engineer Research and Development Center’s Environmental Laboratory (EL) and elsewhere has generated environmental design criteria for stream channel alterations to improve the net effect of these projects. Examples of environmental design features include low-flow channels, combinations of structure and vegetation, management of cutoff bend ways and other backwater areas, and recreational trails.

• A. Riparian and In Stream Habitat Restoration (EL-25)

  Current research includes formulating guidelines for stream restoration and environmental enhancement of flood control and aquatic ecosystem restoration projects. Among the general issues addressed are, in-stream and riparian habitat assessment; benefits of habitat improvement, structures, and techniques; impacts of vegetation on flow conveyance and/or sustainability, channel stability, and sediment transport; construction practices; and monitoring and maintenance. Proposals are invited in these general areas and related efforts. In addition, specific needs include the following: (1) Techniques to quantify habitat and other environmental benefits of restoration efforts, as well as quantification of adverse impacts to the aquatic environment, (2) Algorithms that account for momentum losses at vegetated floodplain/channel interfaces, (3) Data supporting evaluations of the hydraulic impacts of in-stream structures, (4) Development and refinement of related computerized databases and models, and (5) Calculating impacts to and identifying vulnerabilities of riparian systems.

• B. Assessing Benefits of Channel Modifications (EL-26)

  Dams and local flood control structures may degrade aquatic habitat conditions in tail waters and streams. In some cases, habitat degradation can be eliminated, stabilized, or reversed through channel modification for aquatic habitat (i.e., construction of low-cost, low head weirs to create pools) with minimal changes in dam operation or flood channel design. However, there are no widely accepted methods available to incrementally relate in stream aquatic habitat value, channel modifications, and in stream flows to allow trade-off analyses among cost, design, and habitat benefits. It is desirable to modify existing in stream flow methods or develop new methods that will allow incremental assessment of habitat values, alternative flows, and different channel designs. This work may involve data collection, analysis, interpretation, and software development.

More topics in progress (see solicitation for all topics).

Are there any additional benefits I would receive?

Beyond the direct funding, ERDC awards provide meaningful strategic advantages:

Government Validation and Technical Credibility:
Selection by ERDC signals strong alignment with U.S. Army and national infrastructure priorities, which can materially strengthen your credibility with customers, primes, and investors.

Non-Dilutive Technology Maturation:
Companies can advance core technology without equity dilution, preserving ownership while increasing enterprise value.

Long-Term Government Relationship Building:
ERDC BAAs are often a gateway into follow-on DoD contracts, reimbursable work, and sole-source opportunities.

Increased Visibility Across DoD and Civil Works:
Successful projects frequently expand beyond a single lab, creating exposure across USACE, DoD, and federal infrastructure stakeholders.

What is the timeline to apply and when would I receive funding?

This BAA is continuously open until January 1, 2027, and all submissions initially enter the process as pre-proposals. Pre-proposals may be submitted at any time through the ERDCWERX portal and are limited to five pages, plus a one-page executive summary.

ERDC conducts a preliminary technical review of pre-proposals as they are received. Offerors can expect a response within 60 days of submission, either encouraging submission of a full proposal or advising that the pre-proposal was not favorably reviewed.

If a pre-proposal receives a favorable review, ERDC will issue a formal invitation from the Contracting Office to submit a full proposal. Full proposals then undergo scientific peer review, cost evaluation, and funding availability assessment.

There is no fixed award cycle or batch deadline. Awards may be made at any time following successful evaluation and are subject to availability of funds.

Where does this funding come from?

Funding is provided by the U.S. Army Corps of Engineers (USACE) through its Engineer Research and Development Center (ERDC) and supported DoD research programs.

Who is eligible to apply?

Eligibility is unrestricted, meaning any qualified U.S. or international entity may apply, subject to statutory and regulatory requirements. This includes:

• For-profit companies

• Startups and small businesses

• Universities and nonprofit research organizations

What companies and projects are likely to win?

ERDC evaluates proposals based on:

• Clear alignment with ERDC mission and stated research areas

• Strong scientific or technical merit

• Demonstrated capability of the proposing team

• Practical relevance to military or civil works challenges

• Realistic scope and cost relative to expected outcomes

Are there any restrictions I should know about?

• ERDC may limit awards based on funding availability in specific technical areas

• Some projects may be subject to export control, security, or publication restrictions

• Proposals must clearly identify whether research is considered “fundamental”

• Full proposals must be submitted only through designated laboratory channels, not directly to technical staff

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive pre-proposal under this BAA will likely take 20–40 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 for the Pre-Proposal Submission.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

Parkinson’s Disease Therapeutics Pipeline Program (MJFF)

Below is a brief summary. Please check the full RFA before applying (link in resources section).

Executive Summary:

The Parkinson’s Disease Therapeutics Pipeline Program is a rolling funding program run by the Michael J. Fox Foundation (MJFF) that provides $250,000 to over $2 million in nondilutive funding to industry and industry-academia teams advancing Parkinson’s disease therapeutics. Funding supports pre-clinical and early clinical development of pharmacological, biological, and non-pharmacological interventions with clear potential to slow, stop, or delay disease progression or meaningfully reduce symptom burden. Companies can submit pre-proposals at any time, with reviews typically completed within three weeks, and invited full proposals reviewed on a quarterly cycle.

How much funding would I receive?

Award amounts typically range from $250,000 for smaller, targeted projects to upwards of $2 million for larger, multi-stage pre-clinical or clinical development programs. Final award size is determined in consultation with MJFF based on project scope, stage of development, novelty, and unmet patient need.

What could I use the funding for?

MJFF prioritizes pre-clinical and clinical programs that may slow, stop, or prevent disease progression, efforts that address moderate-to-advanced motor or non-motor symptoms of Parkinson’s not well-managed by current treatments such as advanced gait disturbances (e.g., balance issues linked to falls, freezing) and cognitive changes. Activities within scope of this program include:

• Pre-Clinical: Identifying, validating and/or developing novel pharmacological and non- pharmacological interventions through pre-clinical development from early screening topre-clinical characterization and testing.

• Clinical: Progressing promising interventions with strong preclinical packages into/through initial clinical assessment exploring pharmacokinetics and pharmacodynamics, safety/tolerability, or early proof of biology and/or clinical efficacy.For novel targets, MJFF is particularly interested in de-risking programs by supporting early proof of concept in patients to gain insight into the therapeutic potential, including exploration of biomarker-based or clinical endpoint-based efficacy.

Any intervention may be considered based on clear patient need, rationale and strong mechanism-of-action understanding. Interventions may be pharmacological (small molecules), biological (biologic, gene therapy) or non-pharmacological including surgical approaches, technology-enabled therapeutics and neuromodulation approaches. Competitive non- pharmacologic proposals will have compelling, existing data from human studies with strong potential for clinical adoption. Applicants may also propose testing of repurposed or repositioned therapies but should propose clear and robust biomarker-enabled testing strategies.

Are there any additional benefits I would receive?

Beyond direct funding, MJFF awards offer meaningful strategic advantages:

• Strong Scientific and Patient-Centered Validation: Selection by MJFF signals rigorous scientific merit and strong alignment with patient-driven therapeutic priorities in Parkinson’s disease.

• De-Risking for Follow-On Capital: MJFF explicitly positions this program to de-risk therapeutic programs and catalyze follow-on investment from venture capital, strategic partners, and other funders.

• Access to MJFF’s Ecosystem: Awardees gain access to MJFF’s extensive network of clinicians, researchers, industry partners, patient advisors, and proprietary research tools, datasets, and biosample repositories.

• Enhanced Exit and Commercialization Potential: Government- and foundation-validated programs often command higher valuations during licensing, acquisition, or later-stage financing due to reduced technical and clinical risk.

What is the timeline to apply and when would I receive funding?

Pre-proposals may be submitted at any time and are typically reviewed within three weeks. If invited, full proposals are submitted during one of five annual review cycles. Funding decisions are communicated within three months of full proposal submission.

Upcoming full proposal deadlines include:

• February 22, 2026 → Funding decision May 2026

• April 23, 2026 → Funding decision July 2026

• June 25, 2026 → Funding decision September 2026

Where does this funding come from?

Funding is provided directly by the Michael J. Fox Foundation for Parkinson’s Research, a nonprofit organization dedicated to accelerating cures and better treatments for Parkinson’s disease through aggressively funded translational research.

Who is eligible to apply?

Eligibility is limited to:

• Industry applicants (biotechnology, pharmaceutical, medical device, or other for-profit companies), or

• Academic teams partnered with an industry collaborator capable of commercial development.

Both U.S. and non-U.S. entities are eligible. The for-profit entity is expected to serve as the primary grantee and commercialization lead.

What companies and projects are likely to win?

Successful applications typically demonstrate:

• A strong biological rationale for the therapeutic target, supported by genetic or in vitro/in vivo validation data.

• A clearly differentiated therapeutic approach believed to be superior to existing or pipeline therapies.

• Robust translational biomarker strategies to measure target engagement and mechanism of action.

• Clear preclinical-to-clinical translation potential with a realistic commercialization pathway.

• For clinical programs, a patient-centered development plan incorporating patient input.

Are there any restrictions I should know about?

MJFF will not fund:

• Large-scale target discovery efforts (e.g., genomic or transcriptomic screening).

• Target validation using only tool compounds with no path to drug development.

• Reformulation of commercially available drugs via new routes of administration.

• Studies evaluating dietary supplements.

MJFF does not intend to serve as the sole funder and expects applicants to pursue complementary funding sources.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive pre-proposal for this opportunity will likely take 20–40 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Fractional support is $300 per hour, with most pre-proposal projects requiring 10-20 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See Request for Applications Here.

Defense Sciences Office (DSO) Office-wide BAA – DARPA

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

DARPA’s Defense Sciences Office (DSO) is soliciting proposals under its Office-wide Broad Agency Announcement (BAA) to fund revolutionary basic or applied research that enables breakthrough advances in science, devices, or systems for national security applications. Proposals are accepted on a rolling basis through June 2, 2026, and may be submitted as executive summaries, abstracts, or full proposals. This BAA is designed to capture novel, high-risk, high-reward ideas not already addressed by existing DARPA programs.

How much funding would I receive?

DARPA anticipates making multiple awards, but no fixed award size or funding range is specified in the BAA. Award amounts, duration, and structure are determined based on the proposed technical scope, cost realism, and selected award instrument. An accelerated award option is available for select proposals not exceeding $2,000,000, with awards made within approximately 30 days of selection.

What could I use the funding for?

Funding may be used to pursue innovative basic or applied research concepts that enable revolutionary (not evolutionary) advances aligned with DARPA’s mission. Proposals may address, but are not limited to, the following DSO technical thrust areas:

• Materials, Manufacturing, and Structures - Breaking the tension between performance and efficiency for critical parts, production processes, energetics, superconductors, and propulsion

• Sensing, Measuring, and Affecting - Developing and leveraging new science to overcome existing barriers limiting the performance and/or practicality of sensing, measurement, and control, to achieve orders of-magnitude improvement in operational capabilities.

• Math, Computation, and Processing - Enabling quantum, reimagining classical, and developing entirely new forms of computing for enhanced efficiency and new capabilities. Solutions may range from new approaches to hardware (implementation) to representation and computation.

• Complex, Dynamic, and Intelligent Systems - Creating new scientific capabilities for classes of systems that evolve and adapt and for which traditional reductionist, data-driven, and statistical methods fail. Systems of interest include, but are not limited to, foundations of intelligence, human-AI ecosystems, homeostatic mechanisms, and global systems.

Proposals focused primarily on incremental improvements or manufacturing scale-up are explicitly excluded.

Are there any additional benefits I would receive?

Beyond direct funding, selection under a DARPA DSO BAA provides substantial indirect value:

• DARPA Validation and Credibility: Being selected signals strong technical merit and alignment with DARPA’s mission to create or prevent technological surprise.

• Increased Visibility: Awardees gain visibility within the national security R&D ecosystem and among DARPA program managers.

• Access to DARPA Engagement Pathways: Participation can lead to future invitations to targeted DARPA programs, Disruption Opportunities (DOs), or Advanced Research Concepts (ARCs).

• Nondilutive De-Risking: Advancing frontier technology with nondilutive capital can materially improve company valuation and future exit outcomes.

What is the timeline to apply and when would I receive funding?

1. Review Process: Rolling through June 2, 2026

2. Accelerated Award Option: Awards made within ~30 days of selection for qualifying proposals

Where does this funding come from?

Funding is provided by the Defense Advanced Research Projects Agency (DARPA) within the U.S. Department of Defense, through the Defense Sciences Office (DSO).

Who is eligible to apply?

1. U.S. and non-U.S. organizations may apply

2. Small businesses, startups, universities, and large firms are eligible

3. FFRDCs, UARCs, and Government Entities (including National Labs) are not eligible

4. Non-U.S. participants must comply with export control, security, and nondisclosure requirements

What companies and projects are likely to win?

DARPA evaluates proposals based on the following criteria:

• Scientific and technical merit of a novel, feasible, and well-reasoned approach

• Relevance and contribution to DARPA’s mission and national security impact

• Clear articulation of technical risk and credible mitigation strategies

• Strong alignment between scope, cost, and schedule realism

• Ability to enable revolutionary—not incremental—advances

Are there any restrictions I should know about?

• Incremental or evolutionary improvements are not of interest

• Manufacturing scale-up is explicitly excluded

• Some projects may involve Controlled Unclassified Information (CUI) and require compliance with NIST SP 800-171

• Projects involving human subjects or animal research must follow DARPA approval procedures

• DARPA retains discretion to determine whether work is fundamental or non-fundamental research

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $5,000 for the Abstract Submission.

Fractional support is $300 per hour, with most DARPA proposal projects requiring 80–100 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

Generative Optogenetics - DARPA BTO

Executive Summary:

DARPA’s Biological Technologies Office is awarding $1.7M–$1.99M Phase 1 awards to teams developing optically controlled, template-free DNA or RNA synthesis in living cells under the Generative Optogenetics (GO) program. The program uses a staged process beginning with 5-page abstracts due January 16, 2026, followed by invitation-only oral proposals.

How much funding would I receive?

If selected, you would receive a fixed-price Phase 1 award of $1.7M for Research Objective 1 (RO1) or $1.99M if addressing both RO1 and the optional Research Objective 2 (RO2). DARPA anticipates multiple Phase 2 awards for teams that successfully pass the Phase 1 Concept Design Review at month 9.

What could I use the funding for?

The DARPA GO program aims to develop a protein complex, referred to here as a nucleic acid compiler (NAC), that can be expressed within living cells to allow an end user to program genetic instructions into those cells, template-free, using nothing but light to transfer the genetic information to the cells (Figure 1). The central challenge of developing the NAC involves integrating protein domains / subunits for precise optical responsiveness (i.e., optogenetic domains), substrate binding, and enzymatic activity into a functional complex of proteins (i.e., a holoenzyme). While many of these domains have precedence as either engineered or naturally occurring proteins, the challenge lies in developing the interoperability and seamless integration of these domains into a functional holoenzyme, the NAC. Advances in computational design, which allow for accurate prediction of protein structures and binding interactions, are essential for optimizing substrate binding sites, allosteric interactions, and domain integration. These computational tools are crucial for designing the NAC to respond rapidly and predictably to optical signals, enabling the synthesis of long, accurate nucleic acid sequences that can precisely alter cellular function as intended. Moreover, expression of the NAC itself must not be deleterious to host cell function or viability.

To develop the NAC, the GO program consists of two Research Objectives (ROs):

• Research Objective 1 (RO1): De Novo Synthesis

  All GO performers MUST address RO1, which focuses on developing the core capability of the NAC for template-free DNA or RNA synthesis, where optical inputs precisely dictate the sequence of the nucleic acid produced by the NAC in a living cell. A NAC can be designed using a variety of architectures, ranging from extremes of a single, monolithic protein comprised of multiple domains to multi-unit complex (Figure 2). To accomplish this, performers will need to solve three critical challenges: achieving multiplexed optogenetic control, ensuring stability and the precise polymerization of the NAC-nucleic acid sequences, and successfully integrating the molecular components into the NAC.

  1.3.2.1. Multiplexed Optogenetics

  Achieving distinct multiplexed optical programming of the NAC presents a significant challenge, as it requires precise engineering of multiple protein domains capable of responding to distinct wavelengths of light. Currently optogenetic systems have been demonstrated to support up to three distinguishable wavelengths (red, green, and blue) within a cell, but expanding this capability is essential for enabling the NAC to incorporate nucleotides with high precision. This expansion may involve optimizing existing optogenetic domains or developing new ones with improved photophysical properties, such as enhanced spectral separation, faster on/off kinetics, and reduced phototoxicity. By leveraging photons as massless information carriers, these optogenetic domains must facilitate precise molecular motion and interaction, ensuring accurate nucleotide incorporation and enzymatic activity. Computational protein design tools and directed evolution approaches offer potential strategies to overcome these limitations, enabling the multiplexed optical control required for the NAC to function effectively.

  1.3.2.2. Stable and Precise Polymerization

  The NAC must achieve precise polymerization, including initiating synthesis, maintaining processivity to stabilize elongating nucleic acid sequences, and efficiently releasing the synthesized strand to meet program metrics for length and accuracy. The NAC design may need to include strategies to address the challenge of selectively binding the correct nucleotide substrate at the correct time from the mixture of these substrates that exists within the cellular environment. Overcoming this challenge will be necessary for the NAC to achieve desired sequence accuracy metrics for the GO program. Additionally, the stability of the complex formed between the NAC and the nucleic acid sequence it is synthesizing must be sufficient to avoid unwanted dissociations that will result in truncated sequences. Similarly, NACs that synthesize single-stranded nucleic acids will need to overcome issues associated with secondary structures (e.g., hairpin loops) in the DNA/RNA molecule that could interfere with continued synthesis. Achieving stable NAC-based nucleic acid synthesis may necessitate designs that incorporate accessory subunits/domains to improve processivity by holding on to the newly synthesized strand and/or single-stranded binding proteins/domains that hinder the formation of problematic secondary structure in DNA/RNA molecules. Finally, the performers will need to resolve the challenge of releasing synthesized sequences, which may involve strategies such as natural termination signals or engineering inducible cleavage mechanisms.

  1.3.2.3. Integration of Molecular Components

  A fully functional NAC must integrate optogenetic, substrate binding, catalytic, and other domains into a cohesive holoenzyme capable of precise and predictable operation. This integration presents significant challenges, as the domains must interact seamlessly to ensure accurate nucleotide incorporation and overall system functionality. For example, optogenetic domains may need to regulate substrate binding to ensure that nucleotide incorporation into the DNA or RNA sequence aligns precisely with the optical illumination pattern. Similarly, designs involving protein subunit binding must coordinate these interactions with substrate binding domains to maintain synchronization and fidelity. Addressing these challenges may involve strategies such as identifying domains that interact effectively to control the NAC, ensuring synchronous activation and deactivation of multiple NACs within a living cell, and optimizing domain interfaces for efficient communication. Potential approaches include leveraging computational tools to map allosteric pathways, modeling molecular motion to predict domain interactions, and employing high-throughput empirical methods to refine and validate integration strategies.

• Research Objective 2 (RO2): Error Mitigation

  OPTIONAL, GO performers may elect to address RO2 in addition to RO1. Note that GO performers shall not pursue RO2 without addressing RO1. RO2 addresses the challenge of achieving high-fidelity synthesis in NACs by incorporating mechanisms to detect and filter out sequence errors. Some applications of GO technology will necessitate NACs capable of synthesizing longer sequences, and it is anticipated that increasing the length of the sequence will increase the likelihood it contains errors. To this end, RO2 aims to investigate the tradeoffs involved in designing a NAC with enhanced error detection capabilities to meet stricter error tolerance requirements, including how these design choices impact overall NAC performance. There are several potential approaches to address RO2 (Figure 3), an example includes developing doublestranded synthesis methods that incorporate components such as mismatch-binding proteins (e.g., MutS homologs). These proteins can either flag errors for downstream correction or be engineered to degrade faulty sequences, ensuring that only high-fidelity nucleic acid strands are retained. Other strategies may include utilizing base editors to identify nucleotide incorporation errors or synthesizing palindromic sequences that fold onto themselves to increase error detection. RO2 provides an opportunity to explore innovative solutions to error mitigation while considering the tradeoffs in performance, complexity, and scalability inherent to these approaches.

Are there any additional benefits I would receive?

Beyond the direct award, companies benefit from:

DARPA Validation & Technical Credibility
Selection by DARPA’s Biological Technologies Office (BTO) signals exceptional technical rigor and alignment with DARPA’s high-risk, high-reward biotechnology priorities. This validation materially strengthens credibility with strategic partners, investors, and future government customers.

Non-Dilutive Advancement of Breakthrough Biotechnology
GO awards enable teams to mature foundational, high-risk biological technologies using non-dilutive capital. Companies can advance technically ambitious platforms without sacrificing equity, increasing both technical readiness and enterprise value.

Access to DARPA Program Leadership & Expert Networks
Awardees engage directly with DARPA program managers, technical reviewers, and advisory working groups throughout the program. This access provides rare insight into government priorities, technical expectations, and future transition considerations.

Commercialization Support & Structured Market Exposure
GO performers receive guidance from an Independent Commercialization and Consulting Group (ICCG) and participate in structured commercialization workshops and pitch events. These activities help teams refine business hypotheses, market positioning, and transition strategies alongside experienced investors and operators.

Enhanced Visibility Across the Biotechnology Ecosystem
Participation in a DARPA flagship biology program elevates company visibility across the defense, academic, and commercial biotech ecosystems—positioning awardees as leaders in next-generation genetic and optogenetic technologies.

Stronger Long-Term Exit & Transition Potential
By maturing core technology under DARPA sponsorship and demonstrating government-backed technical progress, companies strengthen their positioning for follow-on funding, strategic partnerships, and long-term acquisition or licensing opportunities.

What is the timeline to apply and when would I receive funding?

The process begins with a 5-page abstract due January 16, 2026.. Selected teams are invited to present an in-person Oral Proposal Package. Phase 1 awards follow oral presentations, subject to funding availability. Phase 1 runs 12 months, with a major down-selection at month 9. Phase 2, if awarded, runs an additional 30 months

Where does this funding come from?

Funding is provided by the Defense Advanced Research Projects Agency (DARPA) within the Department of Defense, through DARPA’s Biological Technologies Office (BTO), using Other Transaction (OT) for Prototype authority.

Who is eligible to apply?

Eligible applicants include U.S. and non-U.S. companies, startups, universities, nonprofits, and research institutions, including nontraditional defense contractors and small businesses. Federally Funded Research and Development Centers (FFRDCs) and government entities may apply with additional eligibility documentation. All performers must be able to accept an OT agreement and comply with export control and CUI requirements.

What companies and projects are likely to win?

Competitive teams will demonstrate deep expertise in protein engineering, optogenetics, enzymatic nucleic acid synthesis, and computational biology, with a credible plan to integrate these into a functioning system in living cells. DARPA emphasizes technically bold, high-risk approaches that directly address program metrics rather than incremental biology research.

Are there any restrictions I should know about?

Yes. The program excludes human and animal research, embryonic stem cells, bioprospecting for new natural proteins, substantial hardware development, in vitro assembly workflows, and systems that operate outside the central dogma. Phase 2 work involves Controlled Unclassified Information (CUI), requiring NIST 800-171–compliant systems and DARPA security coordination.

How long will it take me to prepare an application?

Most teams should expect 4–6 weeks to prepare a competitive abstract, including technical framing, team formation, and compliance review. Invited teams will need additional time to prepare a detailed Oral Proposal Package, cost models, and milestone plans under DARPA’s OT structure

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

$4,000 for Abstract Submission.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

Army Medical Operational Capabilities for 2040 BAA

Executive Summary:

The MED CDID Broad Agency Announcement (BAA) invites industry and other performers to propose innovative medical concepts and technologies that support tactical Army medical units in the 2040 Future Operational Environment. The program is open through December 31, 2030, using a multi-step process: submission of a Vulcan Scout Card, followed—if selected for further interest—by a white paper and then a full technical and cost proposal. Companies should plan their internal timelines to first shape a high-impact Scout Card aligned to MED CDID’s three imperatives: clearing the battlefield, maximizing return to duty, and overcoming contested logistics.

How much funding would I receive?

The MED CDID BAA does not specify individual award ceilings or a total program funding limit. Instead, offerors must propose a Rough Order of Magnitude (ROM) total cost (including any fee) that is consistent with the scope of work, period of performance, and any dollar ranges specified in the announcement or follow-on calls. Common costs range from $500K to $5M.

What could I use the funding for?

Proposals should address at least one problem associated with the following aspects of the future operational environment (FOE):

a. Enemy action (through fires, maneuver, electronic warfare, etc.) will inhibit evacuation and medical resupply operations. Slow, reduced, or ineffective evacuation or medical resupply delays the Soldier’s treatment at the proper medical treatment facility. When evacuation slows, the consumption of medical treatment items increases, thus compounding the resupply problem. The cumulative effects of inadequate evacuation and medical resupply will reduce the return to duty rate and increase the number of preventable deaths.

b. The proliferation of drones, sensors, and other advanced technologies has made the modern battlefield more transparent than ever before. This transparency, coupled with long range precision and massed fires, requires Army forces to be distributed across a wider area and to displace frequently. Enemy precision and massed fires will result in more frequent mass casualty incidents, which will likely occur in support areas rather than near the front lines. Future medical forces must therefore be highly mobile to conduct survivability moves, to support widely distributed units, and to respond quickly to the point of need with both medical personnel and supplies (Class VIII).

c. The future battlefield will likely have a broad range of man-made and naturally occurring chemical and biological threats. These threats may be varied and difficult to detect and prevent, making early warning systems crucial. Toxic industrial chemicals and toxic industrial materials in urban areas pose additional threats. Directed energy and other new weapons may cause novel wound patterns that require new training and treatments.

d. When operating in urban areas, challenges include moving through routes blocked by rubble, craters, and other obstacles. Medical units must plan to extract patients from collapsed buildings, interaction with civil medical infrastructure, and potentially large numbers of injured civilians and enemy prisoners.

e. An increasingly transparent and lethal battlefield with chem-bio threats and new weapons systems will create continuous physiological and psychological stressors. These stressors will lead to a decline in the cognitive, physical, and emotional aspects of Soldier performance, and thus a decline in unit combat effectiveness. Army medical units must expand capacity to build and restore individual resiliency, to reduce disease non-battle injury (DNBI) losses, and increase return to duty (RTD).

AREAS OF INTEREST

The Army is looking for solutions in the following categories. Please note that these categories are not comprehensive, but rather to provide context. Categories may be created or removed as time progresses:

• Clear the Battlefield

  Future wars will produce dramatically higher casualty numbers that will stress patient evacuation systems and restrict freedom of maneuver. Minimizing preventable death requires a multi-modal medical evacuation (MEDEVAC) system with advanced enroute care from the point of injury (POI) to the appropriate medical treatment facility at echelon. This MEDEVAC system must be mobile, survivable, and sustainable. It will leverage manned as well as autonomous and semi-autonomous platforms, integrate with casualty evacuation (CASEVAC) capabilities, and be synchronized to maximize efficiency.

  a. Autonomous / semi-autonomous platforms. Manned evacuation platforms areexpected to be insufficient for future combat operations with peer adversaries or in non-permissive environments. The Army's Robotics and Autonomous System (RAS) Strategy leverages systems to increase reach, capacity, and protection in high-risk areas. Unmanned aerial systems (UAS) and unmanned ground vehicles (UGVs) can be staged with support units to provide delivery of critical medical supplies when evacuation is not possible (i.e., prolonged care). A versatile unmanned system (UMS) with casualty evacuation capability would serve as a valuable tool for medical missions.

  b. CASEVAC. CASEVAC complements MEDEVAC by providing additional evacuation capacity when the number of casualties (workload) or mandated reaction time exceeds the capabilities or capacity of MEDEVAC assets. Casualty evacuation is often the first step in moving patients from the point of injury to the appropriate medical facility. Self-aid and buddy-aid are critical. Effective operational planning and a C2 system that integrates non-standard platforms maximizes the commander’s freedom of action and ensures efficient use of evacuation assets. Augmentation of medical personnel and equipment onboard dedicated CASEVAC platforms will increase survivability.

  c. Multimodal evacuation. Multimodal evacuation capabilities meet FOE challenges by using multiple modes of transportation (e.g. boats, buses, trains, etc.) to fulfill evacuation capability and capacity shortfalls. Future evacuation capabilities involve the seamless integration of land, air, and maritime (sea and river) transportation to ensure an efficient and effective evacuation system. Leveraging different modes of transportation optimizes mobility and flexibility, enhances response capabilities, and enables swift evacuation in a variety of operational environments.
  
  d. Prolonged Care. The FOE may not allow evacuation of patients at a time and place of our choosing, due to unavailability of assets or enemy action. Prolonged care is necessary to provide patient care for extended periods when evacuation is not available. Currently, the Prolonged Care Augmentation Detachment (PCAD) is designed to operate forward of definitive care capabilities in support of medical units, such as Battalion Aid Stations (BAS), medical companies, and Forward Resuscitation and Surgical Detachments (FRSD) to manage patients in a prolonged care setting. Further study is needed to determine if this capability can be significantly improved.

  e. Integrated and synchronized C2 of patient movement capabilities. C2 systems facilitate seamless communication and information sharing among healthcare providers, commanders, evacuation elements, and other stakeholders involved in patient movement. These systems enable real-time coordination, synchronization, and decision-making, ensuring efficient and effective allocation of resources for patient movement. An integrated C2 system incorporates AI-enabled real-time data analysis, predictive modeling, and adaptive learning to enable the following: mission requests management, treatment and evacuation capability tracking and two-way communication, intelligent tasking (dispatching), data management, and telemedicine and telehealth technologies to facilitate remote consultations, triage, and medical guidance during patient movement. These solutions enable evacuation mission and system management and enable healthcare providers to remotely assess and manage patients. They also allow optimization of medical personnel, equipment, supplies, and evacuation resources based on patient needs, urgency, and available capacity.

• Maximizing Return to Duty (RTD)

  Maximizing RTD allows for experienced Soldiers to return to the fight as quickly as possible after becoming wounded, injured, or ill. It includes prevention—minimizing disease and nonbattle injury (DNBI).

  a. Holistic resiliency. Commanders in conjunction with their medical staff will maximize preparedness through a holistic approach prior to and during deployment. This will serve to help minimize DNBI and battle injuries (BI). A holistic approach includes cognitive, physical, and emotional well-being, emphasizing proper nutrition, sleep, and social and environmental factors to navigate the rigors of combat operations. Advances in areas such as body-worn sensors, stress inoculation, and medical cognitive enhancements will further increase Soldiers’ capabilities in austere environments while decreasing the likelihood of becoming a casualty. Advanced biomedical engineering can create vaccines and individualized treatments to address emerging health threats before deployment to preserve the force.

  b. Theater Convalescence. In the theater of operations, convalescence capability is essential to maximizing RTD rates. Soldiers who are unlikely to RTD within the prescribed period (theater evacuation policy) will be evacuated out of theater with the first suitable transportation asset. Establishing in-theater convalescence serves to simultaneously decrease the logistical burden on theater transportation assets while decreasing the burden on replacement operations. Rehabilitation support encompasses cognitive and emotional healing as well as physical recovery (e.g., physical therapy with combat and operational stress control). Advanced prosthetics, exoskeletons, and robotic rehabilitation systems can assist Soldiers in regaining mobility and functionality after injury.

  c. Operational Public Health (OPH). OPH is a critical enabler for commanders to maintain maximum strength on the battlefield. OPH minimizes casualties through full spectrum surveillance, monitoring, and testing activities against environmental, biological, and chemical threats. Equipped and trained field sanitation and CBRN elements will establish tailored active and passive protection measures, resulting in more survivable formations. Army medical formations must integrate manned and unmanned air and surface systems to improve detection, diagnostics, and treatment. These formations must share information with all partners through a single, data-centric C2 system empowering both timely operational decisions and timely medical responses.

  d. Healthcare Training and Education. Medical education and training must align with combat demands. This comprehensive approach will encompass all medical specialties, using advanced training methodologies like virtual reality, haptic feedback systems, and AI-driven simulations to develop and maintain skills. These technologies will provide realistic and repeatable opportunities for personnel to practice high-stress and complex scenarios, like trauma triage or prolonged care.

  e. Advanced Diagnostics. In a combat environment, where split-second decisions can mean the difference between life and death, the benefits of advanced diagnostics are immeasurable. By incorporating cutting-edge technologies such as precision medicine, nanomedicine, robotics, telemedicine, and gene editing technology, Soldiers can experience optimized health and improved combat performance. Additionally, advanced diagnostics enable early detection of internal injuries, such as internal bleeding or organ damage, which may not be immediately evident. Swift identification of these hidden injuries allows medical personnel to intervene promptly and prevent further harm. Moreover, advanced diagnostics aid in identifying infectious diseases or exposure to hazardous agents (e.g., CBRN), thereby preventing outbreaks. Ultimately, the integration of advanced diagnostics in combat empowers medical teams to deliver timely and accurate care, leading to improved outcomes for wounded, injured, or ill Soldiers and enhanced operational efficiency.
  
  f. Advanced Therapeutic Technology (ATT). ATT will play a critical role in supporting commanders and Army Medicine. In austere and contested environments, ATT will enhance Army Medicine's ability to rapidly triage and assess injuries, leveraging portable diagnostic devices and advanced imaging systems to determine the severity of injuries and provide timely treatment. The ability of ATT to track Soldiers' exposure to hazardous conditions, such as chemical agents or extreme temperatures, will also be crucial in protecting personnel from emerging threats.

  g. Advanced Treatment Modalities (ATMs). The integration of ATMs will revolutionize the way combat commanders operate in future operational environments. With the advent of cutting-edge technologies such as robotic surgery and portable diagnostic equipment, commanders will be empowered to make informed decisions that prioritize the health and safety of their troops. ATMs such as bioengineered skin substitutes and negative pressure wound therapy will be particularly critical in managing complex battlefield injuries, promoting faster wound healing, reducing infection risk, and enhancing long-term recovery. The combination of these advanced medical capabilities and technologies, including artificial intelligence, machine learning, and data analytics, will enable rapid and effective treatment of wounded personnel, reduce the risk of mortality and morbidity, and facilitate their swift return to duty.

• Overcoming Contested Logistics

  Future supply lines will likely be disrupted, congested, and under constant threat. Predicted high casualty rates in future warfare requires Army medical forces to have predictable and reliable delivery of Class VIII at the point of need (PON). This will enable clearing the battlefield and maximizing RTD while facilitating expanded maneuver and survivable formations. In the FOE, the threat will likely target sustainment nodes from the homeland (industrial base) to the operational area, cutting off access to sustainment capabilities and resources. Compounding this problem is the demand to support widely distributed friendly forces.

  a. Advanced Manufacturing. Advanced manufacturing can revolutionize logistics by enabling the production of essential supplies at or near the PON. This includes the production of Class VIII A/B medical supplies through synthetic biology and biomedical manufacturing.

  b. Predictive medical logistics (MEDLOG). This capability uses advanced analysis to predict where and when medical supplies will be needed. It allows for the optimization of Class VIII supplies, which include medical materiel and equipment, across all echelons. By analyzing expected casualty rates and injury mechanisms, predictive MEDLOG enables planning and allocation of resources. Integration with partners and allies will additionally enhance this capability by using standardized equipment, supplies, and data-sharing protocols, ensuring that medical logistics systems work seamlessly across different military forces. At higher echelons, persistent assessment of the supply chain (from rare earth metals and active pharmaceutical ingredients to industrial-based capacity) must be conducted through the lens of risk to mission and risk to force.

  c. Multimodal resupply. Multimodal resupply combines air, land, and maritime transportation with manned and unmanned systems to enhance resupply capabilities and reduce reliance on a single mode of transport. Air transport provides speed and agility for time-sensitive items, while land transport offers flexibility in various terrains. Maritime transport (both sea and river, surface and subsurface) handles larger quantities over longer distances. Manned systems provide adaptability, while unmanned and autonomous systems offer speed, precision, and reduced risk. This multimodal approach optimizes logistics operations, ensures timely supply delivery, and overcomes challenges in contested environments.

  d. Distributed supply nodes. These nodes are strategically positioned throughout the operational area to ensure effective resupply. This approach offers several advantages, including reduced vulnerability to disruptions, resupply redundancy, and enhanced operational coordination. By having multiple supply nodes, military forces can mitigate disruptions in one area by relying on alternative nodes (to include those of partners and allies). Supplies can be sourced from the nearest available node, reducing transportation time and costs, and ensuring critical supplies reach the PON in a timely manner. Additionally, strategically positioned supply nodes enable better coordination and synchronization of logistics activities, optimizing resource distribution, and enhancing overall operational effectiveness while reducing strain on logistics capabilities. Robots and autonomous platforms specifically designed to operate in these supply nodes allow for additional flexibility.

  e. Autonomous and semi-autonomous resupply systems. Autonomous and semi- autonomous resupply systems enhance logistics capabilities by reducing reliance on human intervention in contested logistics. These systems leverage advanced technologies to automate and streamline the resupply process, resulting in increased efficiency and flexibility while reducing risk. In addition, these systems can serve to enhance situational awareness by having their sensors gather data from their surroundings.

  f. Tele-maintenance and remote diagnostics. These capabilities will enable medical logisticians to provide guidance and consultation from afar, minimizing the need for physical transportation of personnel and materiel. Advanced diagnostic tools and predictive maintenance algorithms can identify potential equipment failures before they occur, ensuring the highest levels of readiness.

• Cross-cutting Components

  There are functions that support two or more of the three medical imperatives outlined above.

  a. Artificial Intelligence and Machine Learning. By using AI and ML to analyze vast amounts of data, patterns can be detected, outcomes can be more accurately predicted, and sound recommendations can be quickly developed for commanders. This allows medical personnel at all echelons and across all medical functions to act more quickly and decisively, ultimately reducing preventable deaths.

  b. Human-machine teaming. This teaming involves leveraging the unique strengths of both humans and machines to achieve operational goals. Machines, equipped with AI and machine learning, can process, and analyze vast amounts of data at speeds far beyond human capabilities. This allows for real-time analytics of supply chain needs and predictive modeling for medical supply, evacuation, and treatment. The integration of human capabilities with advanced technological systems represents a transformative shift towards more efficient, responsive, and adaptive medical support on the battlefield.

  c. Scalable, highly mobile multifunctional organizations. The FOE demands that medical units at all echelons be as mobile as the maneuver units they support to keep up with the rapid pace of military operations and to better ensure survivability. Medical organizations that are scalable and multifunctional will allow maneuver commanders increased flexibility in rapidly changing situations. In addition, medical units must decrease their signature (physical, electronic, etc.) to avoid enemy detection.

  d. Interoperability with the Combined Joint Force. Interoperability with partners and allies is crucial for achieving success. It ensures that different medical forces can work together seamlessly, share information, and support each other's operations. This capability enhances mission success by leveraging the strengths and resources of multiple Services and nations, fostering mutual trust and cooperation. Moreover, interoperability helps in responding swiftly to global crises, maintaining regional stability, and deterring potential threats through a unified front. Ultimately, it strengthens collective defense and augments the Army's medical capabilities.

  e. Health Engagement. Health engagement plays a significant role in winning in competition and being prepared for crisis and conflict. Through engagement with international health organizations, foreign militaries, and local healthcare systems, Army medical forces can foster collaboration, build trust, and promote a shared understanding of health security threats and responses. This, in turn, enhances interoperability with partners and allies, allowing for more effective coordination and cooperation in response to health crises and other operational challenges. Health engagement also allows for enhancing situational awareness.

  f. Reach back. Reach back is an essential component for enhancing battlefield capability, capacity, and operational readiness. This approach will use advanced telepresence and telemedicine technologies, along with integrated data systems, to conserve a commander's fighting strength. Reach back improves real-time diagnostics and remote treatment, allowing medical personnel real-time remote access to specialized care. Furthermore, in an environment characterized by contested logistics, reach back can provide a lifeline, using virtual platforms to maintain continuity of care and resource allocation.

  g. Operate in a CBRN environment. The best way to deter enemy CBRN use is to demonstrate that Army forces can effectively operate in a CBRN environment. The ability to rapidly assess threats, evacuate and treat patients, and resupply in contaminated areas is crucial to minimize preventable death and maximize RTD. Additionally, continued development of advanced deployable sensors that can observe current and emerging CBRN threats can help decrease those threats.

  h. Medical Modeling and Simulations. Incorporating medical modeling and simulation in both training and in operational settings is crucial. By using advanced modeling techniques, medical professionals can simulate diverse medical scenarios, thereby optimizing treatment plans, forecast the spread of diseases, and evaluate casualties in complex operational environments. These simulations facilitate the development medical resource allocation plans, identifying potential bottlenecks in the treatment and evacuation process, and enhance preparedness in large-scale conflicts. Furthermore, modeling and simulation allows testing of various prevention and intervention strategies, aiding in the identification of the most efficient approaches to minimize casualties and improve overall outcomes.

Are there any additional benefits I would receive?

Beyond the direct award, MED CDID funding offers significant strategic advantages for companies operating in defense, medical technology, logistics, AI/ML, and dual-use innovation:

Government Validation and Credibility:
Being selected by the U.S. Army Medical Capability Development Integration Directorate demonstrates strong technical merit and alignment with Army 2040 operational needs. This validation can accelerate engagement with primes, program offices, integrators, and investors who prioritize government-vetted technologies.

Enhanced Visibility and Notoriety:
Although the BAA does not explicitly promise publicity, MED CDID-aligned innovations often surface in Army medical modernization discussions, technical exchanges, and defense-sector forums—raising your company’s profile across DoD medical, logistics, and capability development communities.

Ecosystem Access and Collaboration Opportunities:
Awardees gain direct interaction with MED CDID, Army Futures Command stakeholders, and operational medical units. These touchpoints can open pathways to experimentation events, requirements discussions, field evaluations, and future contracting opportunities with Army, Joint, and SOF medical acquisition organizations.

Stronger Exit and Acquisition Potential:
Nondilutive DoD funding that advances medical, logistics, or autonomy technologies—combined with Army validation—typically increases a company’s valuation and attractiveness to acquirers in defense, biotech, medtech, autonomy, and advanced manufacturing. Government-backed maturity substantially strengthens both commercial and dual-use exit potential.

What is the timeline to apply and when would I receive funding?

Open period: The announcement is open from its posting date through December 31, 2030, as an open-ended BAA.

• Submission cadence: Vulcan Scout Cards may be submitted at any time during the open period, subject to the process in the BAA. The government may also issue separate, focused calls for follow-on white papers at any time while the BAA is active.

• Multi-step process:

  1. Vulcan Scout Card submission.

  2. If of interest, MED CDID may request a white paper and/or

  3. A formal technical and cost proposal.

The BAA does not specify review cycle timing or when funds would be awarded after a proposal is submitted. Actual award timing will depend on when MED CDID issues a request for proposal, internal evaluations, and contracting timelines.

Where does this funding come from?

This opportunity is issued by the U.S. Army Medical Capability Development Integration Directorate (MED CDID), which is responsible for enabling the Army Health System and developing future medical concepts and requirements for the Army and Joint Force

Who is eligible to apply?

The BAA does not restrict eligibility. Typical BAAs accept proposals from:

• U.S. businesses of any size

• Universities

• Nonprofits

• Federally-funded research and development centers (with limitations)

Foreign entities may be subject to additional restrictions depending on classification and export-control considerations.

What companies and projects are likely to win?

Based on the BAA’s emphasis, competitive projects are likely to:

• Directly address one or more of the three MED CDID imperatives:

  • Clearing the battlefield (evacuation, prolonged care, integrated patient-movement C2).

  • Maximizing return to duty (resiliency, OPH, advanced diagnostics and treatment, training).

  • Overcoming contested logistics (advanced manufacturing, predictive MEDLOG, multimodal resupply).

• Provide innovative, future-oriented solutions for the 2040 operational environment, not just incremental improvements to current practice.

• Show clear relevance to the described FOE challenges (distributed forces, mass casualties, CBRN threats, urban operations, contested logistics).

• Leverage cross-cutting enablers such as AI/ML, human-machine teaming, interoperability with joint and allied forces, and medical modeling and simulation to materially improve outcomes (reduced preventable deaths, higher RTD rates, more resilient logistics).

In short, teams that tightly map their concept to these problem statements and demonstrate operational impact for Corps-and-below medical units are best aligned with the BAA.

Are there any restrictions I should know about?

• Tactical level focus: The BAA is focused on tactical-level (Army Corps and below) medical units, not broader health systems in isolation.

• Targeted white papers: White papers should address only the specific portion of the BAA the offeror intends to accomplish. Submitting a single white paper that tries to cover the entire scope of the BAA is “most likely” to be rejected.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive scout card under this BAA will likely take 20–30 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available to submit a scout card for a flat fee of $2,500.

Fractional support is $300 per hour, with most scout card projects requiring 10-12 hours of work.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on Vulcan

ARPA-H BioStabilization Systems (BoSS)

Executive Summary:

The ARPA-H BioStabilization Systems (BoSS) program provides multi-year support for teams developing ambient-temperature cell stabilization and scalable bioprocessing systems. Performer Solution Summaries are due February 19, 2026.

How much funding would I receive?

ARPA-H anticipates multiple OT awards, with the expectation that Performer teams will be funded through multi-phase development (up to 48 months). While specific award ceilings aren't stated, ARPA-H OT programs typically support multi-million-dollar development efforts and note that several teams may be funded initially with down-selects in later phases.

What could I use the funding for?

The BioStabilization Systems (BoSS) program aims to transform how live cell-based therapies are stabilized, manufactured, and distributed. At its core, BoSS addresses a foundational bottleneck in the delivery of advanced cell and gene therapies (CGTs): the critical dependence on ultra-cold conditions (-80 to -196˚C) for storage and transport. BoSS will yield a bioprocessing system that enables scalable production of thermally stable cells, paving the way for a new era of efficient and resilient manufacturing and distribution of biologics without any need for cold storage. BoSS-developed technologies will also accelerate many other avenues in biotechnology that directly impact healthcare, including bio-surveillance, regenerative medicine, large-scale genetic testing, blood product supply, and wound repair, in addition to improving access to a wide range of existing biotherapeutics.

This ISO is intended to solicit:

1) Performer teams that can pioneer breakthrough cell stabilization technologies and integrate these technologies into a commercially viable system for producing cell therapy products at scale. Strategic partnerships are encouraged to best position technologies for commercialization success, such as assembling multidisciplinary teams that may include experts from academic, industry, regulatory, commercialization, and non-traditional backgrounds.

2) An Independent Verification and Validation (IV&V) partner to reliably provide well-characterized, clinically relevant, government-selected cells to Technical Area Performers. This partner will also assess cell viability and system performance at critical junctures throughout the program.

• Background

  This year approximately 150 million Americans will use at least one thermally unstable biologic, such as a monoclonal antibody, vaccine, or cell therapy. The instability of these medicines necessitates a reliance on cold chain, which jeopardizes product effectiveness, escalates costs, and limits access due to complex, temperature-dependent manufacturing and distribution schemes. Furthermore, costly ultra-cold cryopreservation is the standard approach to extending shelf-life stability for life saving biologics such as CGTs. However, demand for CGTs continues to surge, powered by their transformative impact on healthcare and reflected in rapid market expansion. Globally, there are now >3000 CGTs in the development pipeline, ranging from pre-clinical through pre-registration phases. Innovative solutions that relieve cold chain requirements while preserving shelf-life stability are crucial to meeting this rising demand, as FDA approval and widespread patient access to CGTs rely on maintaining product quality throughout storage and distribution.

  BoSS aims to develop innovative technologies that preserve cells at ambient temperatures, a breakthrough approach we will subsequently refer to as biostabilization. Achieving biostabilization remains a two-fold challenge that has yet to be overcome. The first challenge requires cellular interventions to preserve the integrity and function of vital elements prior to undergoing stabilization, enabling cells to withstand physical changes that would otherwise cause irreversible damage. This could include delivering protectants into cells and/or altering cells in other ways to improve processing and storage resilience. To maintain the clinical utility of cell products, cellular interventions to prepare and deploy biostabilization must be both biocompatible and reversible. The second challenge involves implementing aseptic, cell-friendly handling instrumentation to deploy stabilization techniques across various production scales.
  
  One approach to address the first challenge is to adopt nature’s strategies to accomplish biostabilization. For example, ‘anhydrobiotes’ can tolerate extreme loss of water and persist in a dehydrated state for years (e.g., tardigrades, rotifers, brine shrimp), quickly regaining full function after rehydration. Molecular contributors to this resilience have been elucidated such as amorphous trehalose glass and special classes of intrinsically disordered proteins (IDPs). Recent studies have revealed cell structure re-arrangements and stress-induced formation of molecular condensates that may be essential for surviving the stresses of dry processing. Other discoveries from the genomic to the organismal scale form the natural basis of desiccation tolerance and may be adapted or improved upon for biostabilization. Solutions inspired by chemistry and materials science advances are also encouraged along with approaches that employ biocompatible polymers, scaffolds, multi-organic frameworks, or cell encapsulation to protect and stabilize cells.

  Addressing the second challenge requires development of new processing approaches and potentially new instrumentation that can yield products suitable for ambient storage. Current gold standard methods for batch processing like lyophilization (freeze-drying) are energy-intensive, slow, and challenging to apply to complex biologics. While appropriate for proteins, antibodies, and even some vaccines, lyophilization is a risky and unproven approach for high-value cell products that are widely used in the biopharma industry as starting materials, manufacturing intermediates, host cells, and cell-based therapies. Nascent technologies like microwave-assisted vacuum foam-drying, thin film freeze-drying, and polymerization gelation exhibit potential for processing complex biologics but remain at a low manufacturing readiness level (MRL), i.e., early-stage development and requires significant development to establish full-scale production. Established technologies with high MRL, such as spray-drying, commonly used for food production, offer the advantage of continuous processing and may have potential for adaptation to biologics.
  

  Successful completion of BoSS will yield a bioprocessing system designed as a platform technology for stabilizing cell biologics capable of easy integration into biomanufacturing pipelines. The bioprocessing system will enable scalable production and distribution of thermally stable cells benefiting the biopharmaceutical ecosystem that uses cells as starting materials, manufacturing intermediates, and CGTs. Breakthroughs from BoSS are expected to yield biostabilization innovations including intracellular and extracellular protectants and stabilizers, enabling bioprocessing technologies, and re-animation products. Together, BoSS bioprocessing system and biostabilization technologies will be commercially viable solutions that will establish a new paradigm for biomanufacturing designed to reduce costs and ensure that biological medicines are accessible to patients, including those living in the most remote and resource-limited communities.

• Technical Areas

  BoSS envisions that successful solutions will converge from extremophile biology, biomaterials science, biomanufacturing, pharmaceutical formulation, process engineering, and device development to unlock new bioprocessing and biostabilization solutions, bridging historical silos in biostasis science and advancing biological medicines. Proposals are required to address solutions to both technical areas:
  
  Technical Area 1 (TA1): BioPrep

  Approaches to BioPrep include preparing, protecting, and other methods of intervention to allow cells to endure and recover from biostabilization at room temperature. BioPrep solutions should be reversible interventions that support the suspension of biological activity while ensuring cellular health and integrity upon reanimation. BioPrep solutions may also include the development of re-animation techniques and solutions that rapidly restore biological activities after biostabilization.
  
  Technical Area 2 (TA2): Bioprocessing

  Bioprocessing technologies (e.g., instruments, devices) should enable the deployment of biostabilization concepts at scale. Activities may include the scale-up of an early MRL, cell-friendly processing technology, or the adaptation of scaled systems that can be re-designed to safely and gently handle cells. The proposed solution should mitigate stress on cells while achieving biostabilization with preserved quality and function for extended durations at ambient temperatures.
  
  Proposers must submit proposals to both TAs. A conforming proposal will account for all program requirements outlined in this ISO, both TA-specific and overall program milestones and metrics.

• Program Overview

  Technology commercialization is a critical part of achieving the ARPA-H mission to improve health outcomes for all Americans. To support this goal, progress will be measured by strategic metrics and milestones that must be met to advance through subsequent phases. Technologies will advance across three integrated phases designed to drive both technical advancement and commercial translation:

  •

  Phase 1 focuses on establishing the scientific feasibility of ambient biostabilization. This proof-of-concept stage includes developing innovative cell preparation approaches with enabling instrumentation that, together, are capable of inducing biostabilization as well as re-animation methods to restore function after biostabilization.

  •

  Phase 2 emphasizes integrated capability demonstrations, converging biological and manufacturing innovations into a cohesive bioprocessing system that can produce stabilized cells under simulated commercial conditions.

  •

  Phase 3 advances to scaled solution development and industry transition, preparing the bioprocessing system for market entry through GMP-compliant production, strategic industry partnerships, and validation in real-world use cases.

  Performer teams must meet increasingly stringent technological capability requirements and stabilized cell quality metrics during each phase to demonstrate progress on biostabilization technology development. Performers will choose cells used for end of phase demonstrations from a list of government-selected cell types, which will be identified at the start of the performance period. Sub-phase milestones may be demonstrated on cell types chosen by the Performer, with consideration to the restrictions identified in Table 1. In later stages, end of phase demonstrations will be permitted on cells that are aligned with Phase 3 transition partners. Ideal transitional partners for Performers are organizations equipped with established distribution networks to seamlessly integrate the developed bioprocessing system into their existing biomanufacturing pipelines for cell biologics, accelerating the path from innovation to implementation.

  At the end of the program, biostabilization technologies will demonstrate capability, scalability, and applicability of commercially viable platform technologies that enable room temperature storage and distribution of stabilized cells agnostic of cell type, supporting widespread access to biologic medicines. The ideal bioprocessing system will integrate seamlessly with biomanufacturing and fill-finish systems. Ultimately, partnerships will culminate into early adoption of a new commercially viable bioprocessing system capable of scalable production of stabilized cell products that meet Good Laboratory Practice (GLP) and GMP standards with a path paved for commercialization to support broad industry adoption.

Are there any additional benefits I would receive?

Beyond the primary funding, BoSS awardees gain several indirect strategic advantages:

Government Validation & Credibility
Selection by ARPA-H establishes strong scientific legitimacy and positions your technology as a potential national-level biomanufacturing platform.

Enhanced Visibility & Notoriety
Awardees are featured through ARPA-H communications, Proposers’ Day events, and industry engagement, increasing recognition among biotech investors, health systems, and biopharma manufacturers.

Access to a National Innovation Network
BoSS includes structured engagement with an Independent Verification & Validation (IV&V) partner, FDA interactions, and optional commercialization support—creating opportunities for partnerships, pilot studies, and eventual technology adoption.

Stronger Exit, Growth, and Acquisition Potential
Nondilutive development of platform technologies can significantly improve valuation, especially for companies working in CGT manufacturing, biosurveillance platforms, or enabling bioprocessing technologies. Government validation reduces perceived technical risk for acquirers and later-stage investors.

What is the timeline to apply and when would I receive funding?

Key dates:

• Proposers’ Day: January 29, 2026

• Performer Solution Summary: February 19, 2026

• Performer Pitch: March 26, 2026

• IV&V Solution Summary: April 17, 2026

• IV&V Pitch: May 15, 2026

Where does this funding come from?

Funding is issued through the Advanced Research Projects Agency for Health (ARPA-H), under the Scalable Solutions Office, using Other Transaction (OT) authority for high-risk, high-impact biomedical innovation.

Who is eligible to apply?

Universities, Nonprofits, Small and large commercial businesses, Non-U.S. entities (with restrictions; must not be from foreign entities of concern), Must conduct work in the U.S., FFRDCs and U.S. Government entities cannot participate as Performers.

What companies and projects are likely to win?

See full solicitation for details. Strong candidates include companies with capabilities in:

• Cell & gene therapy engineering

• Bioprocessing & biomanufacturing instrumentation

• Biomaterials, polymers, encapsulation, or intracellular protectants

• Cell preservation technologies (cryopreservation alternatives, desiccation biology)

• Microfluidics, closed-system processing, or continuous manufacturing

• Regulatory-ready biologics or device development expertise

• Advanced analytical platforms (cell viability, potency, functional assays)

Winning projects will propose integrated TA1 + TA2 solutions capable of achieving:

• Room-temperature stability (14 days → 3 months)

• Reanimation <1 hour by Phase 3

• High viability, function, and potency metrics across multiple cell types

Are there any restrictions I should know about?

Key restrictions include:

• No genetic manipulation of cells

• No dangerous gain-of-function research (per EO 14292)

• No demonstrations on RBCs or microbial species

• No slow (>4 hr prep or >1 day processing) methods

• No methods that cannot scale or meet GMP requirements

• No traditional lyophilization

• Teams must maintain SAM.gov registration for Step 2

How long will it take me to prepare an application?

For a first-time applicant, preparing a solution summary under this opportunity will likely take 50-70 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Resources

See the full solicitation here.

DARPA Microsystems Technology Office (MTO) Office-Wide BAA

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

DARPA’s Microsystems Technology Office (MTO) is offering funding for revolutionary research across microelectronics, photonic circuits, quantum systems, biological/organic circuits, advanced manufacturing ecosystems, and dual-use microsystems. Multiple awards are anticipated, with no predefined funding limits. Abstracts are accepted until January 15, 2026, and proposals until March 2, 2026.

How much funding would I receive?

Funding amount is flexible. DARPA anticipates multiple awards, and efforts may span basic research (6.1), applied research (6.2), or advanced technology development (6.3). Proposers can also elect an Accelerated Award Option for awards under $2 million with 30-day award timelines.

What could I use the funding for?

Research areas of current interest to MTO include, but are not limited to, the following topics:

• Quantum circuits

  1. Interconnect technologies for transferring quantum states between qubit platforms

  2. Generalizable improvements for processing chain for all types of quantum sensors

  3. High density low loss mixed signal transfer between room and quantum temperatures

• Biological circuits

  1. High throughput molecular readers for full spectrum sequencing

  2. 3-dimensional bio-templated self-assembly of microsystems

  3. Highly-parallel DNA writing platforms for long DNA writes for genome-scale complexity with low error

• Photonic circuits

  1. Applications for purely photonic circuits not realizable in electronic circuits

  2. Chip scale photonics for ultralow noise microwave sources

  3. Tunable chip scale ultrafast (<10 ps) lasers

  4. Fiber-inspired ultralow loss integrated photonics

• Manufacturing Ecosystem

  1. Litho- and etch-free direct nanoscale semiconductor manufacturing

  2. Low-loss high permeability/permittivity materials

  3. High density cryogenic-to-room-temperature interconnects

  4. Atomically precise, multi-chemistry molecular manufacturing technologies

  5. Energy reclamation from low-grade waste heat

  6. Reconfigurable multiscale manufacturing for onshore manufacturing

• Dual Use by Design

  1. All-weather long distance high bandwidth communications

  2. Commercially relevant tool development challenge problems

  3. Conformal and malleable batteries

  4. Design and assembly of complex microsystems in supply-chain-free environments

  5. Reconfigurable additive manufacturing for multiple classes of materials

  6. Context aware imaging

Are there any additional benefits I would receive?

Beyond direct funding, awardees gain significant strategic advantages:

Government Validation & Credibility
DARPA selection signals elite technical quality and national-security relevance — often accelerating partnerships with primes, OEMs, and investors.

Enhanced Market Visibility
Awards frequently lead to increased visibility through DARPA communications, publications, and industry attention.

Ecosystem Access & Collaboration
Awardees join a national innovation community spanning quantum, photonics, microelectronics, and advanced materials — opening doors to long-term collaborations and follow-on opportunities.

Stronger Exit & Acquisition Potential
Non-dilutive support enables deep tech maturation without equity loss. Companies validated by DARPA historically see improved valuation, stronger commercial traction, and increased acquisition interest.

What is the timeline to apply and when would I receive funding?

Abstract Deadline: January 15, 2026, 1:00 PM ET

Proposal Deadline: March 2, 2026, 1:00 PM ET

DARPA reviews proposals on a rolling basis.

If you select the Accelerated Award Option (<$2M projects), DARPA may issue an award within 30 days of selection notification.

Where does this funding come from?

Funding comes from the Defense Advanced Research Projects Agency (DARPA) under the Microsystems Technology Office (STO).

Who is eligible to apply?

The BAA does not restrict eligibility. Typical DARPA BAAs accept proposals from:

• U.S. businesses of any size

• Universities

• Nonprofits

• Federally-funded research and development centers (with limitations)

Foreign entities may be subject to additional restrictions depending on classification and export-control considerations.

What companies and projects are likely to win?

DARPA will select proposals that score highly on scientific merit, mission relevance, and cost realism.

• High Scientific & Technical Merit: Innovative, feasible, and well-justified approaches with clear deliverables, identified risks and credible mitigations, and a team with the expertise to execute.

• Strong Contribution to DARPA’s Mission: Efforts that meaningfully advance U.S. national security capabilities, show a credible transition path to U.S. defense applications, and include an IP strategy that does not hinder government use.

• Realistic, Well-Substantiated Costs: Budgets that accurately reflect the level of effort, materials, labor, and technical scope—avoiding artificially low estimates and demonstrating efficient use of prior research and existing capabilities.

Are there any restrictions I should know about?

• Research must be revolutionary, not incremental.

• CMMC Level 2 is required for procurement contracts beginning Nov 10, 2025.

• Foreign influence and security review applies to fundamental research teams.

• Classified submissions require coordination with DARPA security.

• Export control and CUI restrictions apply.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $5,000 for the Abstract Submission.

Fractional support is $300 per hour, with most DARPA proposal projects requiring 80–100 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

Autonomous Interventions and Robotics (AIR) – ARPA-H-SOL-26-146

Below is a summary. Please see the official solicitation on sam.gov for details (link in Resources Section).

Executive Summary:

The AIR program will award multiple OT agreements to teams developing autonomous endovascular robotic systems and interventional microbots that can perform key parts of surgical and interventional procedures without direct human control. The program runs for five years (two-year Phase 1 and three-year Phase 2). Companies must submit a Solution Summary by January 26, 2026 and a Full Proposal by March 30, 2026.

How much funding would I receive?

The ISO does not specify a minimum or maximum award amount. ARPA-H states only that it expects to make multiple OT awards under this opportunity; budgets will be driven by the scope, risk, and duration of each proposed 5-year effort (2-year Phase 1 + 3-year Phase 2).

What could I use the funding for?

The Autonomous Interventions and Robotics (AIR) program aims to catalyze the development of autonomous robotic surgery—an intervention during which a robot performs part, or all, of the procedure without direct human input. AIR encompasses two (2) technical areas: Technical Area 1 (TA1)—endovascular robotics, and Technical Area 2 (TA2)—microbots. Technical Area 1 comprises sub-areas TA1-A—endovascular robotic systems and TA1-B—endovascular simulation environment.

• Background

  During an endovascular procedure, the surgeon reviews the pre-operative CT of the patient’s vasculature, makes a small incision in the patient’s skin, then manually navigates guidewires and catheters from the femoral or radial artery up into the patient’s brain, using occasional guidance from intra-operative 2D fluoroscopy images. The surgeon steers the distal tip of the catheter around tortuous anatomy by pushing, pulling, and twisting the catheter at the entry point—a challenging process requiring dexterity, mental mapping, and an understanding of the physical properties of catheters. Often, the surgeon must try multiple types of catheters, restarting the navigation from the beginning and losing precious time in the process. Once the target is reached, additional challenges await. For example, during a mechanical thrombectomy—the removal of a stroke-inducing blood clot from the brain—once the catheter reaches the clot, there is ambiguity around contact and suction; with little tactile feedback beyond translated resistance, the surgeon needs to make a seal and suction the clot. In addition, endovascular surgeons receive high yearly doses of radiation during procedures, increasing their risk of cancer and other sequelae such as cataracts1.

  Thrombectomies are a critical unmet need in the United States and worldwide. Every year, approximately 335,000 Americans experience an ischemic stroke caused by a large vessel occlusion (LVO), a situation in which a major blood vessel in the brain is blocked by a clot. The standard of care is to mechanically remove the clot via thrombectomy; unfortunately, only ~40,000 Americans per year—about 10% of the patients with LVOs—receive thrombectomies2. There are only 311 thrombectomy-capable centers in the United States as of 20223, and they are unevenly distributed, with 50% of Americans living more than one hour away from one. Time to procedure is crucial; every 10-minute delay in revascularization lowers a patient’s disability-free lifetime by ~40 days and increases health care costs by $10,0004. While thrombectomies are currently recommended for patients within six hours from stroke onset, recent clinical studies have shown benefit to 24 hours and beyond5.

  More broadly, other specialized or highly invasive procedures are often the only way to obtain disease diagnostics and treat pathological conditions. These include biopsies of suspicious tissue, ablations of uterine fibroids, and destruction of kidney stones, among numerous others. Overall, surgery remains dangerous: more than one in three patients experience adverse events during surgical care. Furthermore, surgery requires specialist care, which can involve extensive travel and waiting times.

  Automated systems such as microbots (small, mechanical, electronic or hybrid devices) have the potential to dramatically increase access to interventions. However, surgical microrobot research and development is largely at an early stage and mostly devoted to biosensing and microrobot motion; the smaller the entity, the more difficult it is for the entity to propel itself directionally. Implementation of end-to-end clinical solutions is notional at best, except for pill-sized gastro-intestinal (GI) imaging devices, which are specifically excluded from accepted AIR solutions. Autonomous endovascular systems also currently do not exist; although complex robotics elements have been developed in industry and academia, autonomous navigation and control algorithms are still in their infancy.

• Program Goals

  AIR aims to make endovascular procedures available at hospitals everywhere through autonomous robotic systems; it is understood, though, that the transition from the current state of clinical care to this audacious goal is likely to involve multiple practical evolutionary steps. They will likely include: a) clinical trials during which endovascular surgeons present in the room will be ready to take over at any moment from the autonomous endovascular robotic system; b) a first deployment phase, in which local general surgeons and remote endovascular surgeons will oversee the procedure; and ultimately, c) a phase in which only local general surgeons (or other medical professionals) will oversee the operation of thoroughly validated autonomous systems.

  AIR microbots are intended to create a paradigm shift in interventional procedures, transforming these invasive procedures—currently performed in advanced care settings and requiring skilled practitioners—into minimally invasive procedures performed in a general practitioner’s office. Microbots are expected to simplify existing procedures, enable completely new procedures, reduce complications rates and costs, and increase procedure availability.

• Technical Area 1

  Technical Area 1 (TA1) of AIR aims to develop fully autonomous robotic endovascular intervention systems. After a medical professional inserts the catheter system into the femoral or radial artery, the robot will complete an endovascular procedure without human intervention. The system capabilities will be demonstrated in several procedures, including 3D rotational angiogram imaging, vascular embolization, and, most importantly, thrombectomy. Autonomous endovascular systems developed in TA1-A will encompass:

  1) Robotic control systems that can manipulate catheters and guidewires

  2) Navigation algorithms based on pre-operative imaging and real-time sensing

  3) Steerable catheters and guidewires (if required)

  4) Solutions for autonomous clot removal and vascular embolization

  In addition, TA1-B will develop an in silico testing and validation environment for these robots, an activity that will include the collection of fluoroscopic videos of endovascular procedures, CT angiograms, and other imaging modalities as needed for training.

  Note that autonomous blood vessel access is out of scope for the AIR program; a surgeon or surgical technician will obtain vessel access.
  
  Additional details are available in the solicitation.

• Technical Area 2

  Technical Area 2 (TA2) of AIR aims to develop a set of interventional microbots. Performers will specify a target clinical indication and develop microbots that move, sense, and act to diagnose or treat this condition by means of more precise targeting and/or less invasive access. TA2 teams will address:

  a. Microbot locomotion

  b. Anatomy/pathology targeting methods

  c. Miniaturization or externalization of power supplies and computational processing

  d. Autonomous or automated action

  e. Microbot removal or deactivation

  Gastrointestinal/ingestible pill microbots that only image, stimulate, and/or deliver cargo are out of scope for the AIR program.

  Although the technologies for both TAs are developed and validated for a target indication, it is expected that they will serve as platforms for multiple interventions and procedures.
  
  Additional details are available in the solicitation.

Are there any additional benefits I would receive?

Beyond direct funding, AIR awards can provide strategic benefits typical of ARPA-style programs:

• Government technical validation: Being selected by ARPA-H signals that your approach is technically ambitious and nationally relevant in health innovation and surgical autonomy, which can help in discussions with strategics, hospital systems, and investors.

• Positioning for regulatory and ecosystem engagement: AIR is structured with parallel FDA collaboration (for TA1) and explicit regulatory milestones (e.g., simulation frameworks, Q-submissions) that can de-risk later clinical and commercialization steps.

• Access to a high-end performer network: Performers will interact with other top robotics, imaging, and microbotics teams, plus FDA scientific collaborators and ARPA-H program staff—often leading to follow-on partnerships and future solicitations.

• Nondilutive growth capital: Because funding is nondilutive, successful teams can mature high-capex platforms (robotics, microfabrication, imaging) while preserving equity and potentially driving higher valuations and stronger exit options down the line.

What is the timeline to apply and when would I receive funding?

1. Proposer’s Day: December 16, 2025

2. Q&A deadline: January 20, 2026, 5:00 PM ET

3. Solution Summaries due: January 26, 2026, 5:00 PM ET

4. Full Proposals due: March 30, 2026, 5:00 PM ET

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

• Universities and other educational institutions

• Non-profit organizations

• Small businesses

• Other-than-small businesses

What companies and projects are likely to win?

1. Overall Scientific & Technical Merit:
   Companies proposing highly innovative, technically rigorous, and fully executable plans with well-defined milestones, clear risk-mitigation strategies, and IP structures that enable commercialization are most competitive. Winning projects will demonstrate a credible path to achieving AIR’s demanding 5-year technical milestones.

2. Proposer’s Capabilities & Related Experience:
   Teams with deep, directly relevant expertise—including experienced robotics engineers, imaging specialists, microbot developers, and required clinicians (e.g., an endovascular neurosurgeon for TA1-A)—are most likely to win. Prior success delivering complex R&D programs on time and on budget is a major advantage.

3. Assessment of Proposed Cost/Price:
   ARPA-H will favor proposers who submit realistic, well-justified budgets that reflect the true complexity of autonomous surgical robotics or microbot development. Costs must align with the technical plan, leverage past research efficiently, and avoid artificially low budgets or staffing junior personnel simply to reduce cost.

Are there any restrictions I should know about?

• Key restrictions from the ISO include:

  • Scope restrictions

    • TA1 excludes autonomous vascular access and closure; a human must obtain vessel access.

    • GI “pill camera–only” devices and ingestible microbots that only image, stimulate, or deliver cargo are out of scope; GI microbots must at least sense and biopsy, or sense/biopsy/ablate, to qualify.

    • Purely biological, purely chemical, or chem-bio-only delivery concepts (no mechanical/electronic component) are not acceptable microbots. Nanoparticles alone are out of scope.

  • Team composition and application rules

    • TA1-A teams must include at least one endovascular neurosurgeon.

    • A given team may propose to either TA1-A or TA1-B, but not both

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive solutions summary under this BAA will likely take 40–60 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Check the full solicitation here.

DARPA Strategic Technology Office-Wide Broad Agency Announcement (BAA)

Executive Summary:

DARPA’s Strategic Technology Office (STO) BAA is soliciting breakthrough research concepts that create new mission-level capabilities beyond the current state of practice. The agency will fund a limited number of high-risk, high-reward proposals across a broad range of defense and national-security technical domains. Applications are due December 19, 2025.

How much funding would I receive?

DARPA does not publish fixed award amounts for this BAA. STO funds a limited number of proposals, and budgets are determined by the technical approach, the scope of work, and alignment with STO priorities.

What could I use the funding for?

DARPA's STO seeks innovative ideas and disruptive technologies that provide the U.S. military and national security leaders with trusted, disruptive capabilities across all physical domains (Air, Space, Sea, and Land) and across the spectrum of competition. STO programs deliver solutions at speed and scale for today's warfighters while developing the resilient "breakthrough" systems and technologies needed for future battlespaces. STO does not focus on one area of responsibility or phenomenology. Rather, STO programs capture the strategic, logistical, and tactical complexity of today's national security environments. STO is a "systems office" seeking to create new "proof-of-concept" mission systems. Its goals are to develop and demonstrate new capabilities that expand what is technically possible.

Research areas of current interest to STO include, but are not limited to, the following topics:

•  Acoustic communication and sensing

•  Adaptability

•  Advanced computing

•  Additive manufacturing

•  Architecture and advanced systems engineering

•  Artificial intelligence

•  Autonomy and control algorithms

•  "Big data" analytics

•  Combat identification

•  Command and control (C2)

•  Communications and networking, virtual and adaptive

•  Complexity management

•  Critical infrastructure defense

•  Decision aids and C2 technology

•  DevOps and novel software development and integration

•  Directed energy (DE)

•  Distributed autonomy and teaming (machine-machine, human-machine)

•  Economic security

•  Effects chain functions (disaggregated find, fix, finish, target, engage, assess)

•  Electro-optic/infrared sensors

•  Electromagnetic warfare (EW)

•  High-frequency (HF) communications and sensing

•  High voltage electric power systems and architecture

•  Human behavior modeling

•  Human-machine symbiosis

•  Industrial engineering

•  Integration and reliability technologies

•  Interoperability

•  Logistics

•  Modeling and simulation

•  Microwave and millimeter wave communications and sensing

•  Novel kinetic effects

•  Non-kinetic effects (EW, DE, cyber)

•  Optical technologies

•  Photonics

•  Radio technologies (especially software-defined and novel waveforms and processing)

•  Radar and adaptive arrays

•  Resilient systems

•  Robotics

•  Seekers and other expendable sensors and processing

•  Sensors and analytics

•  Signal processing

•  Space sensors, communications, autonomy, and architectures (especially supporting proliferated low earth orbit constellations)

•  Strategy analysis technology

•  Supply chain analytics

•  System of systems

•  Undersea and seabed technology

•  Tactics development technology

•  Testing and data collection

•  Very low earth orbit (VLEO) technology

•  Very low frequency (VLF) technology

Are there any additional benefits I would receive?

Beyond the direct award, DARPA funding offers significant strategic advantages:

Government Validation and Credibility:
Receiving a DARPA award signals exceptional scientific and engineering merit, which accelerates engagement with primes, integrators, strategic partners, and investors.

Enhanced Visibility and Notoriety:
DARPA programs are frequently highlighted in federal communications, technical conferences, and defense media—boosting your company’s profile across the national security sector.

Ecosystem Access and Collaboration Opportunities:
Awardees gain access to DARPA program managers, government labs, test ranges, and a high-level innovation network—opening doors to future contracts and partnerships.

Stronger Exit and Acquisition Potential:
Nondilutive funding that matures breakthrough technology, combined with the DARPA “stamp,” often increases valuation and attractiveness to large defense, aerospace, semiconductor, and AI-focused acquirers.

What is the timeline to apply and when would I receive funding?

Applications are due December 19, 2025.

DARPA does not publish a fixed award timeline.

Where does this funding come from?

Funding comes from the Defense Advanced Research Projects Agency (DARPA) under the Strategic Technology Office (STO), a DoD organization responsible for advanced mission-level systems and emerging technologies.

Who is eligible to apply?

The BAA does not restrict eligibility. Typical DARPA BAAs accept proposals from:

• U.S. businesses of any size

• Universities

• Nonprofits

• Federally-funded research and development centers (with limitations)

Foreign entities may be subject to additional restrictions depending on classification and export-control considerations.

What companies and projects are likely to win?

DARPA will select proposals that score highly on scientific merit, mission relevance, and cost realism.

• High Scientific & Technical Merit: Innovative, feasible, and well-justified approaches with clear deliverables, identified risks and credible mitigations, and a team with the expertise to execute.

• Strong Contribution to DARPA’s Mission: Efforts that meaningfully advance U.S. national security capabilities, show a credible transition path to U.S. defense applications, and include an IP strategy that does not hinder government use.

• Realistic, Well-Substantiated Costs: Budgets that accurately reflect the level of effort, materials, labor, and technical scope—avoiding artificially low estimates and demonstrating efficient use of prior research and existing capabilities.

Are there any restrictions I should know about?

• Proposals must not duplicate existing STO programs or other active STO BAAs.

• Research that yields incremental or “evolutionary” improvements is specifically excluded.

• Offerors are strongly encouraged to review current STO programs and speak with program managers before applying.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $15,000 Project + a 5% Success Fee.

Fractional support is $300 per hour, with most DARPA proposal projects requiring 80–100 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on sam.gov

CIRM CLIN2: Funding Opportunity for Clinical Trials

Executive Summary:

CIRM’s CLIN2 program provides up to $15M to advance interventional Phase 1–3 clinical trials for stem cell–based and genetic therapies addressing serious unmet needs. Applications are accepted quarterly, with 2026 deadlines falling on the last business day of January, April, July, and October at 2:00 PM PST.

How much funding would I receive?

Funding depends on the stage of your clinical trial:

• First-in-Human: Up to $8M (for-profit) / $12M (non-profit)

• Phase 2/Subsequent Phase 1: Up to $15M

• Phase 3/Pivotal: Up to $15M

What could I use the funding for?

The CLIN2 award supports completion of an interventional phase 1, 2 or 3 clinical trial for a stem-cell based or genetic therapeutic candidate and may also fund an associated natural-history comparator or lead-in normal healthy volunteer study. Applicants are encouraged to use accelerating trial designs where appropriate, such as basket trials or adaptive design dose-escalation protocols.

The CLIN2 Program aims to advance clinical candidates that have the potential for transformative patient impact and that address barriers to access and affordability. To support this goal, align with Proposition 14’s mandate, and remain responsive to an evolving scientific and regulatory landscape, funding preferences will be set on an annual basis. These preferences will be guided by portfolio analyses and other strategic considerations in a cyclical manner.

For fiscal year 2025-2026 CLIN2 cycles, the following modalities and project features will be prioritized:

• Pluripotent stem cell-derived therapies

• In vivo genetic therapies

• Therapies using non-viral nucleic acid delivery

• Projects addressing diseases of the brain and CNS

• Applications from California organizations

• Projects progressing from CIRM-funded IND-enabling or earlier phase clinical trial awards

• Projects with Fast Track, RMAT or Breakthrough designations

• Projects proposing pivotal clinical trials (as agreed-to by the FDA)

• Required Activities

  • All clinical operations activities needed to complete the trial according to the proposed timeline

  • Outreach, enrollment, and retention activities to achieve trial enrollment demographics reflecting the target patient population

  • Treatment of patients with the therapeutic candidate (or control) and follow-up visits per the clinical protocol

  • Sharing of any non-clinical as well as clinical data per the CIRM data sharing requirements

  • Establishment and regular convening of a Strategic Planning Committee (SPC) with clinical development expertise to provide forward-looking strategic advice

  • Activities associated with managing, preserving, and sharing data and knowledge from the study

  • Activities associated with access and affordability planning for the therapeutic candidate in the proposed indication

• Allowable Activities

  • Natural history studies needed for baseline or control data for the interventional trial

  • Lead-in studies in normal healthy volunteers for the interventional trial

  • Studies to develop biomarkers, understand mechanisms of action and develop a potency assay

  • Regulatory activities including FDA interactions and requests for designations

  • Non-clinical studies required by the FDA (FDA documentation required)

  • Strategic planning activities

  • Manufacturing activities to supply the current clinical trial, including technology transfer and FDA-approved comparability studies, if needed

• Conditionally Allowable Activity

  Manufacturing for the next phase trial. Funding of that activity will be conditioned on 1) an interim evaluation by CIRM and a panel of independent experts of the clinical trial data to date, and 2) provision of 50% co-funding for this activity, if co-funding is required as specified in “Award Amount and Duration” below

• Unallowable Activities

  • Costs incurred on or before the date of ICOC approval

  • Discovery or translational research

  • Activities already budgeted or paid for under a prior, existing or future CIRM award

  • The costs of activities performed by a separate out-of-state organization that retains intellectual property or independent publication rights in any intellectual property (e.g., invention, technology, data) arising out of the CIRM-funded project

Are there any additional benefits I would receive?

Government Validation and Credibility
CIRM’s rigorous review provides a powerful credibility signal to investors, strategic partners, and clinical collaborators.

Enhanced Visibility and Notoriety
Awardees benefit from increased recognition through CIRM communications and visibility across the state’s stem cell and gene therapy ecosystem.

Access to CIRM’s Specialized Infrastructure

• Alpha Clinics Network for trial acceleration and patient access

• GMP Manufacturing Network for cell and gene therapy manufacturing

• Industry Resource Partners including preferred CROs and CDMOs

Stronger Exit and Valuation Potential
Nondilutive capital allows companies to advance high-value programs without dilution, often increasing valuation and improving partnership or acquisition outcomes.

What is the timeline to apply and when would I receive funding?

Applications Accepted: Quarterly

• 2026 Deadlines: Last business day of January, April, July, October at 2:00 PM PST

• GWG Scientific Review: ~90 days after deadline

• Board Approval: ~60 days after review

• Project Start: Within 60 days of approval

Total time from submission to project kickoff: ~6 months.

Where does this funding come from?

Funding is provided by the California Institute for Regenerative Medicine (CIRM) through Proposition 14, which supports the advancement of stem cell and genetic medicine programs statewide.

Who is eligible to apply?

For-profit or non-profit organizations

1. FDA-cleared IND (or submitted IND for CIRM-funded programs with clearance within 30 days)

2. PI with ≥15% effort

3. Project Manager with ≥50% effort

4. Data Project Manager

5. Applicant must be the IND sponsor

6. At least one California trial site

7. Must begin work within 60 days of board approval

8. Must meet co-funding and solvency requirements

What companies and projects are likely to win?

CIRM scores applications across five scientific merit categories:

1. Value Proposition – Whether the therapy offers meaningful clinical improvement over existing options, addresses unmet need, and is practical for real-world uptake by patients, providers, and payors.

2. Scientific Rationale – Strength of the biological justification, robustness of supporting data, and evidence of disease-modifying activity from relevant models or prior clinical studies.

3. Project Plan & Design – Whether proposed activities efficiently advance development, enable clear go/no-go decisions, support timely enrollment, include appropriate manufacturing plans, and can be delivered within the proposed budget, timeline, and risk-mitigation strategy.

4. Team & Resources – Expertise and coordination of the project team, access to required facilities (including manufacturing), and track record with stem cell or gene therapy programs.

5. Population Impact – Understanding of the affected population and strength of plans for representative outreach, enrollment, and retention.

Are there any restrictions I should know about?

No funding for discovery or early translational research:

1. No pre-approval costs

2. No out-of-state work where the external organization retains IP/publication rights

3. Co-funding required for for-profits (30–50%)

4. Only one CLIN2 application per PI per cycle

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive proposal will likely take 150–250 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for $15000 Initial Fee + a 3% Success Fee.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcement Here.

CIRM DISC5 Awards: Funding Opportunity for Discovery Stage Research

Executive Summary:

CIRM’s DISC5 Awards fund up to $2.5 million per project for small, collaborative teams to run high-risk, exploratory discovery research in stem cell biology, genetic research, and regenerative medicine. Each project must be co-led by a California-based Principal Investigator and Co-Investigator from different labs, with human stem cells or genetic research central to the approach. Applications for the current cycle open November 14, 2025 and are due January 30, 2026 at 2:00 pm PT.

How much funding would I receive?

Each DISC5 award can request up to $2,500,000 in total project costs (including direct, facilities, and indirect costs) for a project lasting up to 3 years. Budgets at or above $900,000 in any single project year require additional justification and may be adjusted during review and negotiation.

What could I use the funding for?

The DISC5 Awards will support exploratory and innovative foundational research led by pairs of interdisciplinary investigators applying a range of technologies and approaches to address fundamental knowledge gaps or bottlenecks in stem cell biology and/or regenerative medicine. Proposals should aim to achieve one or more of the following outcomes:

• Advancing fundamental understanding of human stem and progenitor cells as they pertain to human health and disease.

• Advancing the use of stem cells to interrogate disease mechanisms to uncover biological insights thatcould enable therapeutic target and/or biomarker discovery.

• Gaining mechanistic insights to address key scientific or technical bottlenecks in stem cell, genetherapy, and/or other regenerative medicine approaches.

• Advancing applicability of stem cells, gene therapies, and/or other regenerative medicine approaches to all affected populations.

Proposals focused on validating or optimizing a therapeutic approach or candidate are not aligned with this program’s focus on foundational discovery.

Required Activities: Activities associated with managing, preserving, and sharing data and knowledge from the study

Allowable Activities:

• Any basic research activities that meet the DISC5 objective to address knowledge gaps or bottlenecks in stem cell biology with relevance to human biology and disease, where human stem cells or genetic research is part of the central approach or hypothesis, and that seek to achieve one or more of the outcomes listed in “Scope and Structure.”

• Partnering activities with patient-centered organizations or other project-relevant community groups.

• Travel and accommodation expenditures associated with attendance of CIRM organized meetings and conferences. See additional details in Discovery Program Meetings and Conferences, pg. 13.

• Activities to support outreach or communication of research plans or outcomes with the wider public.

• Engagement activities with trainees supported through CIRM’s EDUC or INFR programs

Unallowable Activities:

• Therapeutic or other commercial development activities including lead optimization, manufacturing, pre-clinical toxicology and pharmacology studies and other activities targeted by CIRM’s PDEV and CLIN programs.

• Costs of activities performed by a separate out-of-state organization that retains intellectual property or independent publication rights in any intellectual property (e.g., invention, technology, data) arising out of the CIRM-funded project.

• Costs incurred on or before the date of ICOC approval.

• Activities already budgeted or paid for under a prior, existing or pending CIRM award or which are already supported by another funder.

Are there any additional benefits I would receive?

Beyond the direct funding, DISC5 awardees benefit from:

Visibility and credibility: CIRM is one of the nation’s most recognized regenerative medicine funders. A DISC5 award strengthens credibility with partners, investors, and follow-on funders.

Positioning for future non-dilutive funding: DISC5 supports early high-risk data generation, enabling teams to later apply for CIRM’s translational and clinical programs or alternative funding sources.

What is the timeline to apply and when would I receive funding?

For the current cycle:

• Application deadline: January 30, 2026 at 2:00 pm PT

• Grants Working Group (GWG) review: ~60–90 days after the deadline

• Board approval and Notice of Award: ~150 days after the deadline

• Project start: Must begin within 90 days of award approval

  Most awardees can expect to start work approximately 6–8 months after the application deadline.

Where does this funding come from?

The DISC5 Awards are funded by the California Institute for Regenerative Medicine (CIRM), a voter-created state agency dedicated to accelerating stem cell, genetic, and regenerative medicine research. DISC5 is part of CIRM’s Discovery Program under its 2024 Strategic Allocation Framework.

Who is eligible to apply?

Eligible organizations:
Must be a California Organization (non-profit or for-profit) as defined by CIRM. More than 50% of W-2 employees must be full-time California residents paying CA income tax. The PI must be located in California. California subsidiaries must retain IP rights from the project.

Eligible teams:
• Exactly one PI and one Co-Investigator (Co-I).
• Both must be employed by California Organizations.
• Each must commit at least 5% effort.
• PI and Co-I must be from different labs.
• The team must include an experienced Data Project Manager.

Project requirements:
• Must include human stem cell and/or genetic research as a central component.
• Any non-human models must be strongly justified and validated with human models when possible.
• Applications must be complete, accurate, and non-duplicative across CIRM programs.

Application limits:
• An individual may serve as PI on only one DISC5 application per cycle.
• An individual may serve on no more than two DISC5 applications total per cycle (as PI or Co-I).
• Co-funding is not required.

What companies and projects are likely to win?

CIRM funds projects that score highly across five criteria:
• Significance: Advance foundational stem cell or regenerative medicine knowledge with broad impact.
• Innovation: Use novel approaches or cross-disciplinary methods.
• Rationale: Present a sound scientific basis and justified experimental models.
• Plan & Design: Offer a clear, feasible research plan with strong team coordination and realistic budgets/timelines.
• Population Impact: Consider genetic, environmental, and community factors to ensure findings apply across diverse California populations

Are there any restrictions I should know about?

Key restrictions include:

• No therapeutic development (manufacturing, lead optimization, preclinical tox/pharm, IND-enabling studies).
• Out-of-state organizations cannot retain IP or publication rights for any CIRM-funded work.
• No costs incurred prior to ICOC approval.
• Applications must be complete, accurate, and not duplicative with other pending CIRM submissions.
• Projects must start within 90 days of award approval.
• Only one no-cost extension (max 6 months) may be requested—and approval is not guaranteed.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive proposal will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for $13000 Initial Fee + a 5% Success Fee.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcement Here.

Making Obstetrics Care Smart (MOCS) – ARPA-H

Executive Summary:

ARPA-H’s Making Obstetrics Care Smart (MOCS) program, run by the Scalable Solutions Office (SSO), is soliciting proposals under ISO ARPA-H-SOL-26-143 to develop new placenta health tests and noninvasive, wireless, AI-backed monitoring tools that can better predict fetal oxygen status and guide intervention during labor and delivery. Pre-proposal discussions are required between December 15–19, 2025, and full proposals are due by 12:00 PM ET on January 21, 2026 via the ARPA-H Solutions Portal.

How much funding would I receive?

Specific funding amounts are not listed so practically, you should assume that budgets must be tailored to the technical scope required to:

• Develop and validate placenta risk-stratification tools, and/or

• Design, build, and test noninvasive, wireless fetal monitoring technologies integrated with AI/ML decision support.

What could I use the funding for?

Based on the stated technical objectives, allowable work is expected to focus on R&D activities according to these guidelines:

The Problem

• The United States has the highest rate of maternal and infant morbidity and mortality of any wealthy country, despite spending more per capita on maternal care.

• This unacceptable status quo is largely the result of a 50-year-old, imprecise tool used during labor and delivery to monitor babies and determine whether they are getting enough oxygen—a tool called the fetal electronic monitor.  

• Without reliable data, confusion prevails and it’s tough to make smart, informed decisions. Women end up having unnecessary cesarean sections and babies are born with low oxygen levels, which sometimes cause lifelong complications.  

• This confusion leads to the dissolution of trust between patients and the medical system, massive lawsuits, and ultimately can cause medical providers to quit obstetrics, exacerbating the healthcare provider shortage.   

The Solution

• The Making Obstetrics Care Smart (MOCS) program aims to address this combination of problems by developing technology to help families and care teams plan for and have safe deliveries.  

• Our goal is ambitious: use advanced diagnostics and smart technology to make births safe. The program seeks to generate tools to predict both chronic and acute fetal status and provide the best recommendations for intervention, giving peace of mind to the care providers, mothers, and families making choices for critical labor and delivery care.

• MOCS will develop better ways to track a baby’s status during labor. First, developing a new test that will assess the health of the placenta to understand which patients are at high risk for complications during labor. Second, designing new types of noninvasive, wireless sensors and AI-backed technology to gain real-time information about a baby’s oxygen levels and make smart decisions during delivery.  

• If successful, MOCS will enable safe deliveries for all, drastically improving the health of women and children.

Are there any additional benefits I would receive?

Beyond direct funding, competitive ARPA-H programs like MOCS typically create several strategic benefits for companies and teams:

• Government validation and credibility
  Being selected by ARPA-H signals strong technical merit and alignment with high-priority national health goals in maternal and infant outcomes. That endorsement can de-risk you in the eyes of hospitals, payers, strategic partners, and investors.

• Visibility in a critical health domain
  MOCS targets one of the most pressing and visible failures in U.S. healthcare: maternal and infant morbidity and mortality tied to inadequate fetal monitoring. Demonstrated progress here can drive significant attention from media, advocacy groups, and professional societies.

• Access to a curated ecosystem
  The program explicitly aims to convene “the best researchers and collaborators in labor and delivery, including healthcare providers, hospitals, payers, attorneys, and families,” creating a structured network of stakeholders that can accelerate pilots, studies, and adoption.

• Non-dilutive capital to mature your product
  ARPA-H support is non-dilutive, enabling you to build and validate high-risk capabilities—advanced diagnostics, sensors, and AI—without giving up equity. That can translate into stronger valuations in later private rounds or at exit.

• Stronger exit and partnership potential
  A validated, government-funded platform for safer labor and delivery can be attractive to medical device manufacturers, hospital system partners, payers, and women’s health platforms looking to expand into perinatal safety and monitoring.

These strategic benefits are not guaranteed, but they are typical of successful participation in high-profile federal health R&D programs.

What is the timeline to apply and when would I receive funding?

From the publicly available materials:

• Proposers’ Day: December 11, 2025 (hybrid; Washington, DC + virtual).

• Required pre-proposal discussions: December 15–19, 2025 (request via ARPA-H Solutions Portal).

• Full Proposal Due: January 21, 2026 at 12:00 PM ET (submitted via ARPA-H Solutions Portal).

The documents provided do not specify:

• Exact dates for selection decisions,

• Award announcement dates, or

• When funds will be obligated or projects will start.

Where does this funding come from?

Funding is provided by the Advanced Research Projects Agency for Health (ARPA-H), specifically through its Scalable Solutions Office (SSO), under ISO ARPA-H-SOL-26-143 for the Making Obstetric Care Smart (MOCS) program.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Official scoring criteria have not been released but typical criteria for ARPA-H opportunities are below (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Attendance at Proposers’ Day is optional.
  It is not required for submission or selection, though ARPA-H notes it may help with teaming.

• Pre-proposal discussions are required.
  Pre-proposal discussions between December 15–19, 2025 must be scheduled via the ARPA-H Solutions Portal and are a required step before full proposal submission.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our support is available for $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

The AFWERX & SpaceWERX Open Topic Small Business Innovation Research (SBIR) Program

Executive Summary:

AFWERX & SpaceWERX’s Open Topic provides SBIR/STTR awards to small businesses to validate feasibility (Phase I) and build prototypes with Air Force or Space Force partners (Phase II or D2P2). Any technology could potentially be funded if it provides real value to the military. Phase I awards are up to $75K/$110K for 3 months; Phase II up to $1.25M/$1.8M; Direct to Phase II up to $1.25M. The next deadlines are estimated to be Q4 of 2025 or Q1 of 2026.

How much funding would I receive?

1. Phase I (Feasibility Study): Up to $75K (SBIR) or $110K (STTR) for a 3-month effort.

2. Phase II (Prototype Development): Up to $1.25M (SBIR) or $1.8M (STTR) for up to 21 months.

3. Direct to Phase II (D2P2): Up to $1.25M (SBIR) for up to 21 months, available to companies that can skip Phase I by providing prior feasibility evidence and a signed Customer Memorandum.

What could I use the funding for?

• Phase I funds a feasibility study and/or customer discovery to identify an Air Force or Space Force end user and customer, culminating in a preliminary and final report.

• Phase II/D2P2 funds R&D to adapt and prototype your dual-use solution with an Air Force or Space Force Technical Point of Contact and the Customer/End User who signed the Customer Memorandum.

See sample projects here.

Are there any additional benefits I would receive?

Beyond the formal funding award, AFWERX/SpaceWERX Open Topic participants gain several strategic advantages:

• Government Validation and Credibility: Selection for an AFWERX or SpaceWERX SBIR/STTR award demonstrates strong technical merit and alignment with Department of the Air Force priorities. This validation builds trust among primes, defense customers, and private investors.

• Enhanced Visibility and Market Recognition: Awardees are often highlighted in AFWERX communications, SpaceWERX showcases, and federal innovation reports—raising profile across defense, aerospace, and venture communities.

• Access to the National Defense Innovation Network: Recipients gain entry into the AFVentures ecosystem, connecting with Air and Space Force end users, program offices, and transition partners to accelerate dual-use commercialization and follow-on contracting opportunities.

• Stronger Commercial and Exit Potential: By advancing technology with nondilutive funding and government-backed validation, companies enhance valuation, de-risk product development, and increase attractiveness for acquisition or follow-on investment

What is the timeline to apply and when would I receive funding?

The next deadlines are expected to be Q4 of 2025 and Q1 of 2026. Funding is generally received 4-5 months after the deadline.

Where does this funding come from?

Awards are made under the Department of the Air Force SBIR/STTR program via AFWERX/AFVentures and the Air Force Research Laboratory.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Proposals are evaluated based on three primary criteria:

• Technical Approach: The soundness, feasibility, and innovation of your proposed solution—how effectively it addresses the problem and advances the state of the art.

• Defense Need: The strength of alignment between your technology and an identified Air Force or Space Force capability gap, as demonstrated through end-user engagement or a signed Customer Memorandum.

• Commercialization Potential: The dual-use viability and market readiness of your solution—its potential to scale in both defense and commercial sectors.

Strong applications clearly articulate all three dimensions, showing technical excellence, a validated Air Force or Space Force use case, and a credible path to commercial success.

Are there any restrictions I should know about?

• Proposal Template Compliance: You must use the required proposal template; any content placed outside designated pages will not be evaluated.

• U.S.-Based R/R&D Requirement: All research and development activities funded under the award must be conducted within the United States.

• ITAR Restrictions: Projects involving ITAR-controlled materials limit the participation of foreign nationals.

• Customer Memorandum Requirement: A signed Customer Memorandum is mandatory for all Phase II and Direct to Phase II (D2P2) submissions.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for

• Phase I: $9,000 Flat Fee + a 5% Success Fee.

• Phase II/D2P2: $15,000 Flat Fee + a 5% Success Fee.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Access the AFWERX Website here.

USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development

Executive Summary:

United States Special Operations Command (USSOCOM) is awarding $2,000,000 to $10,000,000 for projects across defined Research Areas of Interest (RAIs) to advance biomedical, human performance, and canine medicine relevant to Special Operations Forces. This BAA is open continuously through 31 July 2028; applicants must first submit a pre-proposal via eBRAP and, if invited, a full application (generally within 60 days of invitation).

How much funding would I receive?

1. Typical project size: $2 Million to $10 Million

2. Program capacity: “Anticipated total costs… will not exceed $20 Million annually” across all awards funded under this BAA.

What could I use the funding for?

A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) to support far-forward early intervention of life-threatening illnesses or injuries within an Irregular Warfare or asymmetric, multi-domain operational environment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. The equipment must be simple to employ, require minimum maintenance, and have low power consumption. Drugs and biologics should optimally not require refrigeration or other special handling. All materiel solutions must be capable of commercialization. Research projects may apply existing scientific and technical knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements. The proposed research must be relevant to active-duty service members, veterans, military beneficiaries, and/or the American public. Relevant research must be responsive to the health care needs of the U.S. Armed Forces, family members of the U. S. Armed Forces, and U.S. Veterans.

Proposals must address a relevant health problem responsive to one of the Research Areas of Interest below (Clinical trials are normally not funded by this BAA):

• Damage Control Resuscitation (DCR)

  SOF medical personnel require capabilities for far-forward medical care to reduce the mortality and morbidity associated with critical wounds and injuries. The proposed research, application, and/or development of medical techniques and materiel (medical devices, drugs, and biologics) for optimal triage and early intervention in critical life-threatening injuries when casualty evacuation is not possible or is delayed. The project areas under DCR to which the USSOCOM will give highest consideration are:

  • Global Treatment Strategies and Next Generation Wound Management:
    The proposed project must research, apply, and/or develop effective treatment strategies that address the following elements: resuscitation, optimal resuscitation fluid(s), uncomplicated shock, noncompressible hemorrhaging, traumatic brain injuries, and austere damage control surgery. These strategies must be optimized for medics in austere, far-forward areas, with minimal logistical or specialty support, who must stabilize and treat patients for extended periods (days, not hours). Projects that research and develop an all-in-one traumatic wound care treatment that can achieve hemostasis, and incorporate analgesia are preferred.

  • Analgesia:
    The proposed project must research, apply, and/or develop novel, safe, efficacious, peripherally, and centrally acting analgesia that provide easy administration in the field, tolerance of extreme environments, and effectiveness at the point of injury for a prolonged period of field care (days, not hours) and does not sensitize the patient to topical analgesia. Maximum analgesia with minimal sedation is preferred.

  • Far Forward Blood, Blood Components, Blood Substitute, & Injectable Hemostatics:
    The proposed project must research novel strategies to increase the ease, efficacy, and safety of blood transfusions (i.e., person to person, pre-hospital blood banking, rolling blood banks, and blood substitutes) forward of normal logistics support; (e.g., evaluating blood for type/cross matching and for the presence and/or reduction of pathogens, leucocytes, and AB antibodies to improve safety of whole blood transfusion at the point of injury). Projects that will be considered also include injectable medications to address the coagulopathy of trauma and novel strategies to improve tissue oxygenation.

  • Austere Surgical Stabilization:
    Future theatres where SOF personnel will operate are likely to be much less medically robust than the past decade of fighting in our current theatres (this can translate to remote civilian areas), and there will be a mismatch between capability and need. Rather than sitting at hardened structures waiting on patients, surgical personnel may be increasingly asked to go to the patient. Research should focus on mobility/portability of medical and surgical equipment, including support equipment such as sterilization, with emphasis on equipment with greater capabilities than currently fielded devices, smaller size and weight, low power demands, and flexibility in power supplies. Additionally, research and development efforts should include telehealth technologies linking forward surgical providers with higher medical authority consultation and effective, relevant, and dynamic surgical training capabilities. Lastly, research into future procedures and devices may also include a human systems approach to define limitations and mitigation strategies of surgical capability in austere environments (i.e., low light, temperature variability, improving surgical access in distributed maritime environment, surgery in flight, etc.) to bridge time to surgery when patient load exceeds surgical capability.

• Prolonged Field Care (PFC)

  SOF medical personnel require capabilities for far-forward medical care to reduce the mortality and morbidity associated with critical wounds, injuries, diseases, and associated sepsis. PFC should focus on novel treatments that support the ability to manage 3-5 patients across the spectrum of illness to multi-system injury for a minimum of 5-7 days. SOF medical personnel require capability to expedite evacuation and increase survivability with limited site of injury support in austere environments including: hyperbaric, mountainous, high-altitude, arctic, and distributed maritime operations.

• Medical Sensors and Devices

  The primary emphasis is to research, apply and/or develop field-sustainable, rapidly deployable medical sensors and/or devices for extended care beyond initial trauma resuscitation, to include austere/forward surgery while operating in areas where casualty evacuation is delayed or unavailable. In addition, proposals that investigate or develop wireless biosensors should demonstrate physiological monitoring capabilities to include, but not limited to, heart rate, blood pressure, pulse oximetry, respiration rate, capnography, core temperature, heart rate variability and compensatory reserve index (CRI). Research and development of devices and sensors should include or plan for the capability to transmit (Bluetooth 4.2) to Android handheld devices and be designed with an open architecture to allow for sensors to be incorporated into a family of sensors that may or may not report to a central handheld device. (NOTE: Ideally, sensor and equipment technologies should be electronically readable, scannable, or transmittable to the Battlefield Assisted Trauma Distributed Observation Kit (BATDOK), an Android-driven, multi-patient, point of injury casualty monitoring capability being fielded by U.S. Air Force (USAF) Pararescuemen and other SOF Medics. Novel devices are required which aid in measuring physiologic decompensation and/or adequacy of treatment/resuscitation in the field environment and/or provide a trigger for a pre-hospital medical intervention (i.e., validation of tissue (muscle) oxygen saturation (StO2), CRI, traumatic brain injury (TBI) measures, etc.

• Portable Lab Assays and Diagnostics

  The proposed project must research, apply and/or develop novel concepts for portable and environmentally stable far forward laboratory assays and diagnostics. Equipment should be extremely portable, ruggedized, use limited or no external power, and any reagents should be self- contained and stable in extreme environmental conditions. Preference will be given to proposals that are field oriented, rugged, low weight/cube space and have little to no refrigeration requirements. Additionally, novel wireless, transmittable or scannable solutions such as patches, scanner/readers or other noninvasive technologies are encouraged.

• Force Health Protection and Environmental Medicine

  SOF personnel must often operate for extended periods of time in austere environments that expose them to extremes in altitude, temperature, humidity, wind, kinetosis, infectious diseases, toxic industrial chemicals, toxic industrial materials, and environmental hazards (including envenomation). In addition, the environment may be compromised due to chemical, biological, and radiological contamination. The primary emphasis of this research area is to research, apply, and develop techniques, therapeutic measures, and materiel (personal protective equipment (PPE), medical devices, drugs, and biologics) to ensure sustained human performance and effectiveness while operating in harsh environmental conditions and/or wearing appropriate PPE.

  • Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Rapid Diagnostics, Treatment, and Prophylaxis:
    The proposed projects must research, apply, and/or develop novel approaches that will diagnose, treat, and protect SOF personnel from exposure to chemical, biological, radiological, nuclear, and high yield explosives in near real time.

  • Occupational and Environmental Health (OEH) Hazards:
    The proposed project must focus on development of novel methods and devices for rapid identification and analysis of exposures to OEH hazards. Research must support the development and analysis of handheld, field hardened, and environmentally stable analytical devices, monitoring devices, dosimetry, assays for rapid on-site identification, and real-time analysis of OEH hazards in air, water, and soil that could pose an acute or chronic health hazard to SOF personnel. Such OEH hazards include toxic industrial chemicals/toxic industrial materials (TICs/TIMs), lead exposures, food and water borne pathogens, toxins, biological agents, and radiological material exposures.

  • Operational Exposure Monitoring:
    The proposed project must seek to develop wireless biosensors for monitoring SOF personnel in extreme environments (i.e., high altitude, whether in-flight or the environment itself, excessive heat or cold, etc.), and potentially hazardous material exposure. Sensors should address physiological measurements and/or chemical, biological and/or radiological hazards. For hazards monitoring, a personal dosimetry device is desired that can detect and alarm based on radiation and chemical presence. The alarming function can be pre-determined to account for known environmental conditions (i.e., natural occurring radiation levels that are below threshold/detrimental health levels) and parts per million (PPM) counts that would trigger an alert. This detection device needs to be able to alarm differently to identify the "type" of hazard(s), and to trigger a back-off and/or donning of additional PPE. Monitoring should be capable of wirelessly communicating via Bluetooth 4.2 to Android handheld devices, tablets, or compatible wrist-mounted displays.

• Brain Health

  Brain Health research efforts include, but are not limited to: determining if repeated low-level blast exposure (rLLBE) causes brain injury or repeated blast brain injury (rBBI), development and validation of fieldable Neurocognitive Assessment Tools (NCATs) and baseline testing, Comprehensive Symptom History (CASH) collection, blast exposure and impact monitoring, determination of safe acceptable limits for blast exposure, development and validation of capabilities to easily identify/diagnose rBBI, methods to prevent, screen for, monitor, and correct neuroendocrine dysfunction. Additionally, Brain Health research efforts include, but are not limited to: methods to prevent TBI from impact and blast such as redesign of helmets, body armor, and munitions, development of pharmaceuticals to prevent and/or treat brain injury, validation of brain injury prevention strategies, and development of return to duty decision support tools.

  • Environmental Exposures Protection:
    Research that develops novel material and/or approaches to protect SOF personnel from the neurological effects of single and repetitive auditory (impulse noise) and non-auditory (overpressure) blast exposures and other environmental factors determined to affect nervous system function.

  • Environmental Exposure Effects:
    Research that determines the neurocognitive, nervous system, and auditory effects from single and repeated low- and high-level blast exposures, impulse noise, and other potential hazardous environmental factors.

  • Biomarkers:
    Research to determine which biomarkers are indicative of rBBI; sequelae from rBBI causing further injury; recovery status; and recovery rate from rBBI. Testing and validating diagnostic biomarkers for rBBI. Proposals should also consider incorporation of validated biomarkers onto existing or future diagnostic platforms. Use of machine learning and/or model development to interpret and report biomarkers that are indicative of rBBI are of interest.

  • Neuropsychological Testing:
    Research to validate neurocognitive assessment tools (NCATs) to determine baseline neurocognitive status, readiness, neurocognitive degradation, sensitivity to various exposures, TBI and recovery status post injury. Proposals to improve the speed, accuracy, specificity, and proximity to injury for the use of NCATs, as well as to compare new technologies and/or modalities (including passive assessment of cognition) to existing NCATs.

  • Olfactory, Oculomotor, Auditory, Vestibular, Cranial Nerve, and Vocal-Acoustic Performance:
    Research and proposals to perform and validate oculomotor, auditory, vestibular, cranial nerve, and vocal acoustic assessments. Research and proposals to assess the effect of nervous system injury to oculomotor, auditory, vestibular, cranial nerve, and vocal-acoustic performance and strategies to restore their performance after injury and prevent injury or further decline.

  • Postural Stability:
    Research to assess the effects of blast exposure on postural stability including the proprioceptive component. Novel treatment strategies, therapies, and therapeutics to prevent and/or correct detriment to postural stability from TBI and neurotrauma caused by blast, impact, and/or other environmental exposures.

  • Neuroendocrine Dysfunction:
    Methods to prevent, screen for, monitor, and correct neuroendocrine dysfunction.

  • Neuroimaging:
    Research into novel imaging and imaging interpretation techniques including, but not limited to computed axial tomography (CAT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, to diagnose brain tissue pathologies including, but not limited to, axonal injury, myelin injury, and interface astroglial scarring without the need for immunohistochemistry, immunofluorescence, or histopathology testing.

  • Analytics:
    Research into analysis including machine learning, natural language processing, and artificial intelligence enabled analysis of data including, but not limited to, NCATs; environmental exposures likely to affect brain health; blast, impact, and noise exposures; auditory, vestibular, and vocal acoustic assessments; postural stability assessments; and neuroimaging.

  • Neuromodulation:
    Research into the use of neuromodulation techniques for treating TBI, neurotrauma, pain, restoring and improving function, improving behavioral health, and cognitive performance.

  • Brain Lymphatics and Glymphatics:
    Research into measuring the fluid dynamics of the brain lymphatic system, diagnosing dysfunction, and validation for tools or techniques to improve brain lymphatic clearance.

  • Pupillometry, Pupillary Response, and Microsaccades:
    Research into field capable pupillary response measurement capture and analysis, with or without the ability to capture Microsaccades to assess central nervous system loading and/or damage.

• Automation of Systematic Reviews and Metanalysis

  Research into Automation of Systematic Reviews and Metanalysis using the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) or a similar method

• Human Performance

  USSOCOM requires SOF personnel to withstand extraordinary physical demands and psychological stress to complete their missions. The optimization of SOF personnel’s ability to perform at very high levels for long durations, in addition to processing information and making critical decisions in a timely manner, while operating in extreme environments, will significantly improve their overall operational effectiveness. This research area explores alternatives and/or new approaches to sustain and optimize SOF human performance both to increase mission capability and to extend the career longevity of SOF personnel.

  • Improved Sleep:
    The proposed project must research, apply and/or develop novel approaches to achieve the restorative effects of sleep. This may include methods to induce, maintain, or improve the quality of sleep throughout the entire night. Additionally, the ability to accelerate the effects of sleep through methods requiring less time (e.g., the effects of sleeping eight hours are realized in four hours’ time) or enabling the SOF personnel to quickly reach and adequately cycle through the stages of sleep where the highest restorative effects occur (i.e., Stage 3/ deep sleep, and Stage 4/rapid eye movement sleep).

  • Optimal Acclimatization Strategies:
    The proposed project must research, apply, and/or develop novel approaches and/or technologies that provide rapid and sustainable human acclimatization in austere environments, to include fatigue countermeasure, extremes in temperature, extremes in altitude, and time-zone change (i.e., circadian acclimatization).

  • Wearables:
    The proposed project must research, apply, and/or develop novel approaches and/or wearable technologies, and/or leverage commercial-off-the-shelf wearable technologies that will monitor physiological measures of human performance to include, but not limited to, caloric expenditure, heart rate/heart rate response, heart rate variability, body fat percentage, sleep hygiene (deep and REM sleep duration) in real-time. Measures should be accurate with low fixed bias, wirelessly communicated via Bluetooth, Near Field Magnetic Induction or Radio Frequency technology in real-time and provide the command the capability to utilize the data for analysis of individuals and/or team performance via the USSOCOM Human Performance Data Management System. The device should be able to be turned on/off and/or have an inactive mode, provide real-time feedback on a display screen, be capable of displaying time, and be adjustable to fit users of different statures. Of parallel interest to address is a proposed project to track sleep, fatigue, and performance degradations through a wearable device that provides quantitative data (rather than qualitative surveys often seen in Fatigue Studies), that in turn will be gathered and amalgamated from entire units, in order to track individual performance, unit performance, mission impacts to performance levels, length of time for acclimatization (if it is ever achieved), and potential risk of mishaps.

  • Diagnostics for Performance Sustainment:
    The proposed project must research, apply, and/or develop minimally invasive diagnostic devices to provide actionable information on nutritional gaps, hormonal response to training, physiological response to performance interventions and recovery, and epigenetic predictors of potential injury.

  • Performance Nutrition:
    The proposed projects must research, apply and/or develop methods to accurately measure nutritional status of SOF personnel. The proposed project should focus on cost effectiveness, accuracy, and end-user compatibility (i.e., user friendly) methods or devices for identifying and optimizing an individual’s nutrient status. Consideration of alternative fuel (energy) sources, dietary supplementation, biomarkers, and nutrient volume/timing are specific areas of interest.

  • Physiological Performance:
    The proposed project must research, apply, and/or develop novel approaches and/or technologies to maximize the physiological performance of SOF personnel in austere and/or training environments, to include increased endurance, enhanced senses, tolerance to environmental extremes, and enhanced overall fitness, to maintain operational posture/ability in high stress scenarios without noticeable augmentation, and without hampering personnel mobility.

  • Cognitive Performance:
    The proposed project must research, apply, and/or develop novel approaches and/or technology that provide greater mental acuity or neuroenhancement (i.e., targeted enhancement and extension of cognitive and affective abilities). Encompasses pharmacological and non-pharmacological methods of improving cognitive, affective, motor functionality and performance, to include neuromodulation.

  • Psychological Performance and Suicide Prevention:
    The proposed project must research, apply, and/or develop novel approaches to the assessment and improvement of behavioral health within the force. Examples include but are not limited to, novel approaches to treatment and rehabilitation from acute and/or chronic post-traumatic stress, depression, and anxiety, improved emotional and nervous system self-regulation, digital/virtual engagement strategies, methods to measure behavioral health performance over time, and improved suicide prevention tools/strategies.

• Canine Medicine and Performance

  SOF personnel rely on canines’ exceptional capabilities as combat multipliers. This research area explores alternatives and/or new approaches to preserve and enhance SOF canine combat performance. SOF medical personnel place a premium on canine-specific approaches that are effective in extreme environments and do not require significant additional logistical support (i.e., maximize use of available SOF Medic materiel). The eight “Canine Medicine and Performance” project areas, to which SOF will give consideration, in priority order, are:

  • Trauma Resuscitation:

    The proposed project must support development of innovative techniques/strategies for canine trauma resuscitation (e.g., hypotensive resuscitation, whole blood/blood component replacement, and non-compressible hemorrhaging), particularly to address ballistic projectile injuries, in diverse/austere environments that lack immediately available medical evacuation or restorative surgical capacity.

    Note: Research should minimize or refrain from utilizing canine specific equipment or devices; this will allow treatment from existing trauma kits fielded by SOF Medics.

  • Non-Traditional Anesthesia Protocols:

    The proposed project must develop novel approaches for routine and emergency/post- traumatic canine field sedation and/or anesthesia in diverse environments and, utilizing pharmaceuticals available to SOF Medics.

  • Canine Performance:

    The proposed project must research, apply, and/or develop novel approaches and/or technologies that address optimization of canine performance through improved physical conditioning programs, reduction of cognitive decline, enhanced nutrition, and genetics research.

  • Sensory Optimization and Protection:

    Research must be oriented toward innovative methods that enhance or conserve SOF canine olfactory, visual, and/or auditory performance during combat operations.

  • Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Canine Decontamination, Treatment, and PPE Against Possible Exposure:

    The proposed projects must research, apply, and/or develop novel approaches that will diagnose, treat, decontaminate, and protect canines from exposure to chemical, biological, radiological, nuclear, and high yield explosives.

  • Environmental Extremes:

    Project proposals must research, apply, and/or develop novel strategies that address acclimatization to acute extremes in temperature, altitude, and/or time zone change (circadian acclimatization), and/or prolonged marine environmental exposure in SOF canines.

  • Brain Health and TBI

    Brain health research efforts include but are not limited to development and validation of NCATs, blast exposure and impact monitoring, determination of safe acceptable limits for blast exposure, validation of neurocognitive baseline testing, capabilities to easily determine mild, moderate, and severe TBI, pharmaceuticals to prevent or treat brain injury, validation of brain injury treatment strategies, and procedures to determine safe return to duty decisions for SOF canines.

  • Pre- and Post-Trauma Training / Behavioral Issues:

    The proposed project must address unique approaches to diagnosing and treating SOF-peculiar training and post-traumatic canine behavioral issues, to optimize pre-purchase selection and post-purchase training strategies across the enterprise and restore performance in canines with behavioral and/or post-trauma issues.

• Medical Sustainment

  SOF medical personnel require sustainment capabilities to support far-forward medical requirements to reduce the patient and supply risk associated with operational medicine. The proposed research, application, and/or development of medical sustainment techniques and materiel must address unique approaches to optimizing supply management and safeguarding equipment requirements. The project areas under “Medical Sustainment” to which the USSOCOM will give highest consideration are:

  • Power and Energy

    Project proposals must research, apply, and/or develop novel strategies that conserve or optimize medical equipment in-field use to reduce sustainment burden in prolonged, austere environments.

  • Austere Medical Logistics Procurement

    SOF personnel, operating in austere environments, may not have the ability to receive conventional resupply efforts. Project proposals must research, apply, and/or develop novel approaches to assist SOF personnel in developing and receiving medical resupplies or repair parts to meet their needs while in the field. These efforts must meet shipping and handling considerations (i.e. temperature control) for a wide range of medical products from batteries to blood. Efforts may include, but are not limited to, fabrication, improvisation, and/or delivery methods from sea, ground, air, or suborbital domains.

  • Equipment Protection

    Research that develops novel material and/or approaches to protect SOF medical equipment from environmental (i.e. CBRNE, freezing temperatures, etc.) and/or adversarial effects (i.e. jamming, electromagnetic pulse weapons, etc.).

  • Supply Monitoring Capability

    Project proposals must research, apply, and/or develop novel approaches to rapidly forecasting and calculating supply requirements based on patient treatment requirements, shelf-life, and storage considerations.

Are there any additional benefits I would receive?

Beyond direct funding, participation under the USSOCOM Biomedical and Human Performance BAA offers significant strategic advantages:

Government Validation and Credibility:
Being selected for funding by USSOCOM demonstrates exceptional technical capability and mission relevance to U.S. Special Operations Forces. This validation enhances your organization’s credibility with DoD program managers, defense primes, and dual-use technology investors seeking field-proven innovation.

Enhanced Market Visibility and Notoriety:
Awardees often gain visibility through federal award announcements, DoD communications, and defense medical research forums—positioning your company as a recognized contributor to national security and elite force readiness.

Ecosystem Access and Collaboration Opportunities:
Projects funded under this BAA operate within the broader military biomedical and human performance ecosystem, connecting recipients with military laboratories, medical R&D commands, and operational units. This access frequently leads to additional collaboration, follow-on funding, and contracting opportunities.

Stronger Exit and Acquisition Potential:
Advancing your technology with nondilutive government support and demonstrating validation in demanding SOF environments can significantly increase company valuation and strategic attractiveness for acquisition or investment by defense, medical, and performance technology leaders.

What is the timeline to apply and when would I receive funding?

• Open period: Continuously open through 31 July 2028.

• Two-step submission: Pre-proposal via eBRAP; if invited, submit the full application (generally within 60 days).

• Review & notice: Applicants should receive disposition within ~180 days of submission; awards may be made any time throughout the year and are contingent on funding and successful negotiations.

• Regulatory lead times: Allow 2–3 months for DoD human-subjects review (OHRO/HRPO) and 1–2 months for animal research review (VRO), as applicable.

Where does this funding come from?

Funding is provided by the Department of Defense (USSOCOM) and administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA); the program leverages CDMRP/eBRAP systems. Any funds received by USSOCOM appropriate to the BAA’s research areas may be used, up to a program total of $20M annually.

Who is eligible to apply?

Organizations only: national/international, for-profit, non-profit, public, and private. FFRDCs are not eligible for direct awards but may team under their sponsoring agreements. Eligible investigators are individuals employed by/affiliated with eligible organizations. No cost sharing is required.

What companies and projects are likely to win?

Winning projects consistently score high on USSOCOM’s evaluation factors, which include:

• Technical Merit and Scientific Rigor: The proposed approach must be well-founded, methodologically sound, and clearly linked to measurable outcomes.

• Innovation and Impact: Reviewers favor projects that introduce novel methods, materials, or technologies capable of significantly improving SOF medical or performance capabilities. Incremental improvements without clear operational relevance tend to score poorly.

• SOF Relevance: Proposals must explicitly tie their work to unique SOF operational needs—such as portability, durability, limited logistics support, or extreme-environment applicability.

• Feasible Study Design and Realistic Execution Plan: Reviewers expect achievable milestones, well-defined deliverables, and credible transition pathways for eventual use by operational forces or integration into DoD systems.

• Qualified Team and Institutional Capability: Teams with demonstrated expertise in biomedical R&D, human performance, or defense health technology—and with access to appropriate facilities and regulatory infrastructure—are prioritized.

• Appropriate and Realistic Budget: Budgets should align with the scope and complexity of work, typically falling between $2 million and $10 million total costs for projects up to five years in duration.

Companies that combine strong technical innovation, credible execution capability, and a direct line of sight to SOF mission impact are most likely to be selected for funding.

Are there any restrictions I should know about?

• Project length: Up to 5 years.

• Pre-proposal required; unsolicited full proposals without invitation are rejected.

• Clinical trials are typically not associated with this BAA.

• Human/animal research approvals required.

• Administrative pitfalls leading to rejection/withdrawal include: missing/over-limit narratives, missing budget, inclusion of URLs in prohibited sections, and inconsistencies between pre-proposal and full application.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive pre-proposal will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the pre-proposal for $7000. Full proposal quoted upon invitation.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcement: HT9425-23-S-SOC1 BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense

NIH STTR RFA-DA-25-047: Seeking Products to Address Social Needs Impacting Substance Use Disorders (SUD)

Executive Summary:

The National Institute on Drug Abuse (NIDA) is awarding up to $2.0 million per project for U.S. small businesses to develop technologies addressing social needs that impact substance use disorders (SUD), excluding alcohol use disorder. Applications are due March 13, 2026. Companies should start preparing at least 16 weeks prior to ensure registration and submission compliance. Partnership with a research organization is required.

How much funding would I receive?

$314,363 for Phase I projects (up to 6 months).

What could I use the funding for?

A variety of products addressing the individual-level factors of health-related social needs (HRSN) should be considered to confront SUD. Additionally, technology, such as telemedicine and mobile health applications, provide an opportunity to address HRSN with the ability to provide tested, accessible, and ongoing solutions for individuals who are the most at-risk for these risk factors that impact SUD. According to the Substance Abuse and Mental Health Services Administratio (SAMHSA), technology has several advantages in addressing SUD including decreased waiting periods, decreased stigma impact and increased privacy. The advantages of technology are also exhibited in its capability to make treatment services more accessible and convenient, which can aid to improve SUD outcomes and reduce disparities.

Regarding this NOFO, a product is any source of value for the end-users and customers. A product can be a physical/tangible device as well as digital services, software as a service, or non-physical/non-tangible products (including but not limited to digital applications, digital platforms, or service models). These and other comparable examples could be considered eligible products. Products can be the result of original scientific research, recycled existing technology for SUD, extension of an observation into SUD area, development of a new business model or distribution/delivery channel that reveals currently unseen value, or the delivery of a product or service to disregarded consumers.

The National Institute on Drug Abuse (NIDA) supports the development of evidence-based SUD care and treatment technology from multiple funding opportunities published elsewhere. The eligible small businesses can submit applications focusing on products that reduce costs, time, and/or increase access in addressing HRSN including, but not limited to, housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide the best feasible and accessible opportunities for the intended end-users to measurably improve their HRSN and SUD. Products of interest that address, but are not limited to, the following HRSN include:

• Access to housing services.

• Soft skills development and/or job training (e.g., in entrepreneurship, literacy, financial literacy, IT skills) for employment.

• Stigma and nurture compassion.

• Family healthy behaviors, social skills, community opportunities, and productive social involvement.

• Social stability (community, tradition, faith, family), self-regulation, and resilience.

• Well-being (mental, physical, spiritual), communal belonging, and positive productivity.

• Social support networks for recovery, engagement with care, and/or access to needed services.

• Successful community reintegration for formerly incarcerated people.

• Social needs service engagement and coordination among justice-involved organizations.

• Employer education to hire, retain, and facilitate treatment for employees seeking help for SUD.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed STTR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

• Next Application Deadlines: March 13, 2026

• Scientific Review: July following submission

• Council Review: October

• Earliest Start Date: December of the same year

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

• Must partner with a nonprofit research institution.

What companies and projects are likely to win?

Projects that demonstrate:

• Measurable improvement in one or more social determinants of health affecting SUD outcomes.

• Use technology (digital, AI-enabled, or connected health tools) to reduce costs, stigma, or access barriers.

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Align with NIDA’s goals to integrate behavioral health and social needs solutions into recovery ecosystems

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must partner with a research institution who performs a minimum of 30% and maximum of 60% of the work.

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for

• Phase I: $9,000 Flat Fee + a 5% Success Fee.

• Phase II: $13,000 Flat Fee + a 5% Success Fee.

• Fast-Track: $13,000 Flat Fee + a 5% Success Fee.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the RFA Here

ARPA-H Scalable Solutions Office (SSO) BAA

Executive Summary:

ARPA-H’s Scalable Solutions Office (SSO) has an open “Mission Office Innovative Solutions Opening (ISO)” to fund revolutionary solutions that expand access, affordability, manufacturing, and distribution of health technologies across the U.S. healthcare system. The ISO accepts Solution Summaries and, if encouraged, full proposals; it anticipates multiple awards made as Other Transactions (OTs). The solicitation is open now and remains open until March 5, 2029.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

This ISO seeks solution summaries and proposals for projects that fall within the general scope of the ARPA-H Scalable Solutions Office (SSO). The SSO seeks to improve health care access and affordability through revolutionary technical innovations that address the challenges of geography, distribution, manufacturing, and data- and information management. Many communities and remote areas in the United States lack access to timely and quality health care, which leads to disparities in health outcomes for those populations. Bottlenecks during the manufacturing processes of products and health technologies also lead to delays and limited availability, preventing effective distribution of health care solutions to areas of need, especially in emergencies.

Funded SSO health innovation projects will improve the readiness of technologies and medical capabilities to be rapidly, broadly, and affordably adopted by patients, providers, and payers throughout the healthcare ecosystem and improve the patient experience. Manufacturing and supply chain focused SSO projects will lower the bar to entry for new developers, accelerate the rate of development, reduce development and product costs, and improve reliability and agility in manufacturing and product distribution.

Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. The following SSO interest areas categorize the ground-breaking solutions we seek to support:

• Health Technologies and Interventions:

  • Approaches to improve affordability and access to health care that are adaptable to various geographic, demographic, economic contexts and can be rapidly and broadly deployed (e.g., drug-repurposing, point-of-care diagnostics, and modular health care infrastructure).

  • Tailored solutions that provide the pediatric population parity with the adult population with respect to access to treatments and other health care interventions, and that adapt to the pediatric patient’s changing physiology and developmental status over the course of years.

  • Transformational approaches to reduce or eliminate health disparities, including leap-ahead technologies that scale novel approaches in human factors, and human-centered design to respond to full diversity of patients in varied geographic settings. Tools to enable expansion of capacities, capabilities, and reach of individual and institutional healthcare providers (e.g., school nurses and schools, walk-in clinics, homesteading care) to address unmet health care access needs and expand availability of critical services.

  • Foundational capabilities to accelerate diagnoses of rare diseases and reduce the cost and increase the availability rare disease treatments wherever patients are, without the need for specialized facilities or healthcare expertise.

  • Novel materials and technologies to not only return autonomy to limited mobility and/or home bound patients.

• Advanced Technologies for Medical Product and Capability Distribution:

  • Methods for standardization, automation, and broad distribution of complex procedures including, but not limited to, histopathology, rare disease diagnosis and treatment, and surgical interventions to ensure access and delivery to all populations.

  • Technical approaches to enhance delivery of effective healthcare solutions, to include dentistry, in rural or low resource settings, including but not limited to "last mile delivery”, at-home monitoring and diagnosis, imaging, drug delivery, telehealth augmentation, and support for remote medical procedures with limited need for specialized training.

  • Technologies to enable the deployment of critical healthcare resources rapidly and securely at scale to the point of need in permissive and non-permissive (i.e., damaged infrastructure, cyberdenied) environments during a public health crisis or natural disaster.

  • Innovative information technology, data and analytic products and technologies to enable ordering, inventory management, situational awareness, allocation planning and demand forecasting of critical healthcare resources during a public health crisis or natural disaster.

• Biomanufacturing Innovations:

  • Innovative manufacturing technologies

    • Approaches that reduce costs; improve access; expedite production timelines; and strengthen domestic competitiveness for biologics, pharmaceuticals, medical devices and personalprotective equipment (PPE). These innovations aim to mitigate supply chain risks through:

      • Novel solutions to minimize the reliance on cold chain management and specialized handling of pharmaceuticals and biologics.

      • Scalable solutions to strengthen biomanufacturing supplychains, resolve bottlenecks, and enable domestic production, such as:

        • Improved production of active pharmaceutical ingredients, process consumables, and other critical materials (e.g., enzymes, cell lines, etc.).

        • Data-driven models to optimize bioprocessing, enhance process control, and bolster supply chain visibility.

        • Development of alternative materials and innovative methods for PPE manufacturing.

        • Improvement of capabilities to sustainably re-shore manufacturing and utilize readily accessible, cost-efficient feedstocks to strengthen the local and national industry bases.

  • Predictable, programable biological production

    • Advanced analytical technologies designed to improve product knowledge, accelerate release, and/or significantly improve analytical figures of merit.

    • Novel sensor systems, process analytical technologies, and associated process models to precisely manage bioproduction management, including:

      • Process control and monitoring systems.

      • Real-time release assays for rapid product validation.

      • Predictive capabilities to inform process development and enable efficient and effective scale-up of manufacturing to industrial scale.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Scalable Solutions Office (SSO) agreement:

• Government Validation and Credibility:
  Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

• Ecosystem Access and Collaboration Opportunities:
  ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

• Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

• Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

• Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

• Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

• Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

ARPA-H Resilient Systems Office (RSO) BAA

Executive Summary:

ARPA-H’s Resilient Systems Office (RSO) is accepting innovative Solution Summaries and full proposals—on a rolling basis—aimed at strengthening the adaptability, reliability, and interoperability of the U.S. health ecosystem. Multiple awards are anticipated under flexible Other Transaction (OT) agreements. The ISO is open now and remains open until March 5, 2029.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

The Resilient Systems Office (RSO), one of ARPA-H’s mission offices, seeks project proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. Submissions should aim for groundbreaking ideas that solve systemic challenges across the health landscape, leveraging cutting-edge technologies that address long-standing gaps in the quality, consistency, personalization, and efficacy of care.

RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. While RSO welcomes “out of the box” ideas to address the above gaps, the mission office encourages proposals that address the following areas:

• Fortifying systems to improve robustness:

  Novel system designs and modular capabilities that extend the shelf-life of systems, ensuring peak performance across a broad range of healthcare environments and use cases. Applications of interest include, but are not limited to, the adaptability and robustness of biological systems; digital platforms for secure and efficient management of information; and socio-technical systems to maintain access to care and critical information.

• Removing barriers to enhance system efficiency and efficacy:

  Approaches that provide paradigm shifts in system dynamics to improve health outcomes. This includes improvements to system interoperability, process, and transparency; foundational capabilities to enable integration of emerging technology solutions; overcoming systemic barriers driven by misaligned incentives; user-centric tools that improve patient care coordination and user experience; and clinical and research solutions to boost efficiency, reduce cognitive load, and accelerate scientific discovery and its application.

• Early detection and interventions to mitigate disruptions to the healthcare ecosystem:

  Agile interventions to reduce the impact of disruptions and enhance readiness to manage and recover from large-scale health events. This spans the entire health system, including supply chains, manufacturing, and logistics.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Resilient Systems Office (RSO) agreement:

• Government Validation and Credibility:
  Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

• Ecosystem Access and Collaboration Opportunities:
  ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

• Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

• Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

• Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

• Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

• Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

ARPA-H Proactive Health Office (PHO) BAA

Executive Summary:

ARPA-H’s Proactive Health Office (PHO) has an open Innovative Solutions Opening (ISO) to fund high-impact R&D that improves health span and health outcomes before disease onset. The ISO accepts Solution Summaries now through March 5, 2029, with multiple awards anticipated under Other Transactions (OTs). Eligible proposers include for-profit companies, non-profits, and academia. Solutions must be novel (not incremental) and align with PHO interests in prevention, early detection, behavior change, and system-level innovations.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

The Proactive Health Office (PHO), one of ARPA-H’s mission offices, is seeking solutions to improve the health spans and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that: 1) the development of novel early detection methods and prophylactic interventions could drastically improve the health of American throughout their lives; 2) population-level improvements in access to and uptake of disease increase prevention- and wellness-promoting behaviors; and 3) system-level innovations are required to deliver proactive health measures effectively.

Specific PHO interest areas include:

• Novel prevention, detection, and prophylactic treatment methods for disease, including:

  i. Prophylactic approaches to prevention of diseases and harmfuldisease outcomes.

  ii. Methods for continuous and widespread sensing of health-state, and early disease indicators that can be deployed at population-scales.

  iii. Novel and scalable methods for early detection of disease and illness that include the use of low/no-cost sensing modalities.

• Population-level approaches to increase the adoption of prevention- and wellness behaviors:

  i. Methods to inform and educate individuals about healthy behaviors, including lifestyle and preventative medical measures.

  ii. Methods that incentivize individuals to adopt and maintain healthy behaviors.

  iii. Novel approaches to increasing individual health spans and independence even in the absence of disease.

  iv. Early indicators of both disease- and pre-disease states, and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness-building methods for individuals.

• System innovation for the delivery of proactive health outcomes:

  i. Novel, robust, and predictive surrogates for long-term health outcomes with associated epidemiological models.

  ii. Valuation models for long-term treatment effects for vaccination, screening, and other public health interventions.

  iii. New funding and delivery models for preventative interventions.

• Other Topics

  High-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the areas of interest listed above.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Proactive Health Office (PHO) agreement:

• Government Validation and Credibility:
  Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

• Ecosystem Access and Collaboration Opportunities:
  ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

• Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

• Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

• Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

• Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

• Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

ARPA-H Health Science Futures (HSF) Mission Office BAA

Executive Summary:

The ARPA-H Health Science Futures (HSF) Mission Office is accepting Solution Summaries and full proposals for revolutionary health R&D under its Innovative Solutions Opening (ISO), ARPA-H-SOL-24-104. Multiple awards are anticipated via Other Transaction (OT) agreements. The ISO remains open through March 5, 2029, and you must submit a short Solution Summary and receive written feedback before a full proposal. Submissions must align with HSF focus areas (e.g., breakthrough technologies, transformative tools, and adaptable platform systems) and are expected to be high-risk, high-impact—incremental or clinical-trial-stage efforts are out of scope.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. The HSF mission office expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. The HSF mission office
supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change. Specifically excluded from consideration are proposals that represent an evolutionary or incremental advance in the current state of the art, or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed toward policy changes; traditional education and training; center coordination, formation, or development; and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The following areas define the ground-breaking research that HSF seeks to support:

• Breakthrough Technologies

  Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions.

  • Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods.

  • Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need.

  • Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems.

  • Novel approaches to definitively diagnose and cure chronic diseases including, but not limited to, diabetes, autoimmune diseases, neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease, ALS, etc.), and cancer.

  • Technologies that expand the precision, scale, and accessibility of brain circuit mapping technologies that enable causative neuropsychiatric links to mental health disorders leading to definitive diagnosis and reliable therapeutic monitoring.

• Transformative Tools

  Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care.

  • Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease.

  • Development of bionic or biohybrid devices that enable direct integration and communication with the body to activate restorative pathways that restore lost senses, physical abilities, immune functions, and other organ functions.

  • Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders.

  • Synthetic biology approaches incorporating novel logic mechanisms, disease targeting and response methods, and robust control strategies to diagnose, and/or cure a multitude of diseases.

  • Imaging or other technologies engineered from discoveries at the forefront of physics and/or chemistry that reduce cost, improve size and/or portability, increase availability, expand capability, improve resolution, reduce exposure to radiation, and accommodate pediatric patient populations.

  • Integrated sensing and therapy delivery devices for addressing chronic health conditions, including mental health conditions or substance use disorders.

• Platform Systems

  Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs.

  • Novel molecular platforms to target and cure diseases, including the modulation of physiological systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes.

  • New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed.

  • Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.

  • Revolutionary omics platforms that enable unprecedented spatial and temporal scales and resolution of physiological and disease mechanisms.

• Other Technologies

  Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the other listed topics.

  Proposals in response to this Innovative Solutions Opening (ISO) are expected to identify innovative approaches to enable revolutionary advances in medicine and healthcare and the science and technologies underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that offer radically new insights to address specific health conditions, including (but not limited to) cancer, cardiovascular, diabetes, infectious and neurological diseases, and pediatric and maternal/fetal health.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Health Science Futures (HSF) agreement:

• Government Validation and Credibility:
  Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

• Ecosystem Access and Collaboration Opportunities:
  ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

• Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

• Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

• Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

• Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

• Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Continuing Enabling, Enhancing, Restoring and Sustaining (CHEERS) Multiple Authority Announcement (MAA)

Executive Summary:

The Air Force Research Laboratory’s Human Effectiveness Directorate (AFRL/RH) and the U.S. Air Force School of Aerospace Medicine (USAFSAM) are awarding up to $1 billion in total funding under the CHEERS Multiple Authority Announcement (MAA) to support U.S. companies, universities, and research partners advancing technologies that enhance human performance, resilience, and health in aerospace and defense environments.

White papers are accepted through September 30, 2027, and proposal invitations are issued on a rolling basis. Companies should submit white papers as soon as possible in order to have the highest likelihood of funding.

How much funding would I receive?

Funding is project-dependent and determined by the technical approach propose. Typical awards will range from $300,000 to $5,000,000.

What could I use the funding for?

Funding can used for the full range of R&D activities from basic and applied R&D to prototype and experimental testing. See a list of focus areas below:

• Airman Systems Directorate (RH)

  Activities within the 711HPW are organized into research areas which are categorized based on the technology readiness level (TRL). Product lines focus on advanced technology development and identifying paths for technology transition while the CTC’s and CRA’s focus on basic research through early applied research. Each division further breaks down the research into Lines of Effort (LoE) or Product Area (PA) for each CTC or PL, respectively. Descriptors of PL, CTC and CRA are provided below:

  • Product Line (PL): An organizational construct within the Airman Systems Directorate for engineering and transition of technology to the Department of the Air Force and Department of Defense. A Product Line organizes and manages inter-related technology demonstrations and transition paths for Airman Systems Directorate technologies at late applied and advanced technology development stages. The product line may integrate research and engineering tasks across several CTCs within AFRL.

  • Core Technical Competency (CTC): CTCs represent the technical foundation that is difficult to duplicate and allows AFRL to provide unique technical leadership. They span basic research, applied research, and advanced technology development encompassing the people, information, facilities, equipment, and programs allowing AFRL to solve critical AF and national security problems.

  • Core Research Area (CRA): A subset of the Core Technical Competencies within the Airman Systems Directorate. CRAs represent a focused group of basic and early applied research, focused on investigating revolutionary, higher risk concepts. The CRAs mature new foundational technologies and transition promising research to product lines of the organization.

  Airman Biosciences (RHB)

  • Aerospace & Operational Medicine PL1: Matures and transitions aeromedical knowledge, technology, and materiel solutions in force health protection, human health and performance, and aeromedical evacuation & enroute care in order to enable, sustain, enhance, and restore operational and aeromedical health and human performance for Airmen executing Air Force missions across all operational domains. Objectives focus on generating high performance Airmen and Guardians through medical availability, enhancing joint combatant commander capabilities, and maximizing human capital and strategic resources by aligning resources to strategic and workforce development. The goal is to transition products that address validated AF/AFMS requirements by focusing on stakeholder engagement to ensure clear demand signals and to create and maintain extensive partnership network to ensure rapid execution and flexibility.

    • Air & Space Austere Environment Patient Transport (En Route Care) PA1: Advances combat casualty care in the air through biomedical research into interventional strategies and technologies that mitigate the risks for additional insult due to aeromedical evacuation. Transitions promising Science and Technology (S&T) into knowledge and material products that promote the recovery and return to duty of injured or ill service members, from point of injury back to definitive care. Research within this program includes but is not limited to ground medical operations in agile combat employment, autonomous care of patient movement, and optimization of patient movement.

    • Air & Space Force Health Protection (FHP) PA2: Medical development and biomedical technology investments seek to deliver an improved FHP capability across the full spectrum of operations with research that prevents injury/ illness through improved identification and control of health risks. Under FHP, subproject areas include Occupational Hazard Exposure (Includes Flight Hazards and Integrated Risk), Targeted Risk Identification, Mitigation and Treatment (Formerly Pathogen ID and Novel Therapeutics and includes Big Data), FHP Technologies Development and Assessment (Assay and disease detection), and Health Surveillance, Infection, Injury & Immunity. FHP also includes Innovations and Personalized Medicine. Operational medicine is focused on in garrison care – our next most critical issue post OIF/OEF – and how to care for the whole patient and consideration of comorbidities in treatment of wounded warriors and dependents.

  • Biotechnology for Performance, Research, and Demonstration PL2: Develops and delivers capabilities to enhance human performance in near-peer conflict. Objectives focus on modular systems that integrate with warfighting platforms and maintaining and enhancing end-user engagement to ensure relevance and realism all while working in close sync with DoD and external partners to deliver high value solutions. The goal is to build momentum for Wearable technology, continue to develop and advocate for human assessment & tracking, strategically plan for product usage in austere environments, and expand on current platform products to develop and connect capabilities with operational challenges.

    • Airman Sensing & Assessment PA1: Develop and demonstrate advanced prototype products that integrate physiological, cognitive, behavioral, and environmental sensing capabilities with validated analytics, assessments, and intervention capabilities to sustain and enhance air and space operator performance.

    • Human Performance Augmentation & Development PA2: Develop and deliver capabilities to enhance human performance in near-peer conflict by focusing on modular systems that integrate with warfighting platforms. Working in close sync with DoD and external partners to deliver high value solutions to maintain and enhance end-user engagement to ensure relevance and realism.

    • Air & Space Physiology, Medicine, and Human Performance (HP) PA3: Enables, sustains, and optimizes performance of Airmen through elevation and alleviation of health effects associated with AF operational missions. Addresses operational environments such as the mitigation of stress in AF personnel, to include aircrew, care providers, aircraft maintainers, intelligence, surveillance and cyber operators, as well as remote piloted aircraft operators. Research within this project includes but is not limited to airman performance and readiness, advancing air and space medicine, and medical operator performance digital engineering. Advanced technology development to enable, sustain, and optimize cognitive, behavior and physiologic performance in highpriority career fields for the United States Air Force (USAF) and in multidomain operations. The sub-project areas include cognitive and physiologic performance under operational and environmental stressors, detection and improvement of physiological performance, and safety via sensor systems and targeted conditioning, which includes training techniques for optimal performance. This project also develops and demonstrates technologies which ingest health status monitoring data to provide scalable situational awareness of individual, unit, and group medical readiness in support of command and control and develops strategies to mitigate performance limitations through physical, pharmacological/non-pharmacological, or behavioral medical interventions and/or technological augmentation.

  • Medical and Operational Biosciences CTC1: Develops, validates, and enhances medical and operational biosciences and emergent biotechnologies for transition into advanced development products in the Air and Space operational environment to lead to a highly resilient and medically ready force. These products can sense, assess, sustain, and segment warfighter physiological-cognitive performance in multi-domain operations. Deliverables will be enhancing and researching new technologies and concepts to sustain, augment, and restore the multi-domain Airman & Guardian Health and Performance. Customers, end-users, and stakeholders include the DHP and DAF 6.3 programs and product lines: Human Performance/Medical Readiness, Force Health Protection, and En Route Care as some of the primary users.

    • Biotechnology for Health and Performance CRA1: The Biotechnology for Health and Performance CRA utilizes multivariant, systems biology approaches to provide advanced science and technology solutions to understand the warfighter’s biologic state and the underlying mechanism of responses with the goal of enabling, enhancing, and sustaining the human's ability to dominate air, space and cyberspace.

    • Applied Cognitive Neurosciences CRA2: Develops and validates technologies in cognitive neuroscience and physical performance to sustain, augment, and recover operator performance and determine medical attributes/metrics for optimal career field alignment.

    • Health and Performance Sensing and Assessment CRA3: Develops sensing technologies in a variety of form factors to identify, validate and monitor human signatures related to Airmen's and Guardians’ health, exposures and physical/cognitive performance in their associated environments. The research from this CRA will develop sensing solutions optimized for real-time, noninvasive and autonomous sensing and assessing capabilities to enhance and protect Airmen and Guardians in a variety of operational environments.

    • Biomedical Impact of Air and Space CRA4: Conducts research investigating Airman and Guardian performance degradation resulting from exposure to air and space environments and seek understanding the fundamental mechanisms driving environmental and operational risks. Develop technologies to mitigate or eliminate the root physiologic causes of these degradations and to ultimately optimize Airman and Guardian performance resulting in the capability to fly faster, higher, and longer than our adversaries.

  Bioeffects (RHD)

  • Bioeffects PL: Creates and demonstrates developmental technology & tools to generate products/applications. These products provide optimized design requirements for weapon systems & personal protection device developers, risk and collateral hazard assessments for directed energy systems, and analysis libraries for the representation of humans as part of model-based systems engineering approaches and within engineering-level models of system performance, informing overall system performance impacts and adding fidelity to concepts in wargames. Approaches include the integration of components in engagement and mission-level simulation tools within USAF and DoD software architectures, and model-based systems engineering artifacts to enable future integration and technology transition. Key technologies include directed energy bioeffects systems characterization and risk assessment, directed energy bioeffects components of modeling and simulation tools, and human representation in digital engineering.

  • Bioeffects CTC1: The Bioeffects CTC will conduct research to enable the maximum safe exploitation of the electromagnetic spectrum for nation defense by protecting personnel & communities and assessing weapons applications. CTC research will focus on characterizing fundamental bioeffects, optimizing the safety/effectiveness of directed Energy systems, developing/assessing dosimetry tools, modeling & simulation of products/applications, protecting device development and providing science-based information to national & international safety standards.

    • Directed Energy Bioeffects Modeling, Simulation, & Analysis CRA1: The directed energy bioeffects modeling, simulation, & analysis core research area emphasizes research that focuses on new modeling, simulation, and analysis techniques which represent and optimize concepts of directed energy systems employment from the bioeffect standpoint, develops capabilities for studies and means of measuring of effectiveness and suitability for directed energy systems to include direct, scalable, and collateral effects. Research areas include highperformance/ high-fidelity multi-physics simulations, advanced electromagnetic dosimetry models, mechanistic theories & models of injury, thermal/thermoregulatory response models, physics-to-physiology color vision theory, component models of human response to directed energy, statistical approaches for risk assessment, near-real-time numerical approaches and surrogating complexity through machine learning.

      • Directed Energy Bioeffects Modeling Simulation & Analysis LOE1: Develop and mature physics & engineering-level models for directed energy dosimetry & the resulting biological effects; create algorithms encapsulating empirical datasets & physics-level models of directed energy dose response; supports directed energy modernization campaign and enables the Directed Energy Weapons Review and Approval (DEWRAP) process.

      • Directed Energy Bioeffects Dosimetry LOE3: Develop novel dosimetry to better understand directed energy interactions and injury to inform software approaches enabling simulation of dynamic scenarios; supports directed energy modernization.

    • Directed Energy Bioeffects & Mechanisms CRA2: The directed energy bioeffects & mechanisms CRA provides fundamental knowledge of mechanisms of interaction of directed energy with molecules, cells, tissues, and organs in support of military directed energy systems and enables future weapon systems with scalable, disruptive, and ultra-precise effects. Research areas include: discovery science for understanding mechanisms, neurobiological & behavioral response to directed energy, hardening of biological targets to directed energy, mechanistic response of human vision to directed energy, epigenetic response to directed energy exposure, membrane and ion channel response to rapid onset exposures, supra-threshold response – severity of effects, and human factors in technologies for protection.

      • Research in Directed Energy Multi-Interaction Systems LOE2: Develop and deliver an integrated modeling environment and studies to address critical national defense interests & prevent technological surprises. Study radio frequency, combined or synergistic responses, and their interaction with biology.

      • Directed Energy Hazard & Protection Assessment LOE4: Feedback & expertise for DoD to optimize safety/performance trades for directed energy systems; evaluation of dose-response of directed energy exposures to achieve specific endpoint; understand human vision response to optical radiation and related protective devices; elucidate margin of effectiveness and safety to meet DoD mission success. Assure no technology surprise.

      • Directed Energy Weapon Effects LOE5: Feedback & expertise for DoD to optimize safety/performance trades for directed energy systems & provide scientific basis for risk criteria definitions; Allows directed energy weapon modernization & enables review and approval processes for weapons systems.

  Warfighter Interactions & Readiness (RHW)

  • Airman-Machine Integration PL1: Delivers advanced, situationally-adaptive and scalable interface technologies and decision aiding tools. S&T is focused on ABMS compliant, intuitive user interfaces, and intelligent aided decision support to provide rapid, accurate battlefield awareness, maximized distributed human-machine team performance and decision superiority. Operator-centric interfaces increase human combat capabilities while managing human cognitive workload in complex, degraded environments. Key technologies include human-autonomy collaboration and trust in autonomy, development of successful distributed, heterogeneous teams with metrics of team performance, exploitation of human perception and enhancement of operational communication. These efforts address the critical needs for ABMS and JADC2 with optimal human-machine teams ready to operate.

  • Readiness PL2: Develops and extends technologies and tools for improving the cognitive effectiveness, performance and proficiency of airmen in current and potential future operational mission contexts. Aims to deliver operationally relevant, unobtrusive, integrated metrics, software, & hardware to assess proficiency & readiness in real-time. Develops methodologies to create models & algorithms for performance prediction, training support, & automated instruction. Key technologies include the ability to support multi-capable airmen resilience and mission performance in austere deployed contexts and develop standards for sharable scenario content, data, models, & metrics.

  • Analytics PL3: Identifies & matures software that streamlines workflow & enables cognition at the scale of war, enabling airmen effectiveness in the air, space, & cyberspace domains for effective C2ISR in Multi-Domain Operations. Develops analytic tools that optimize human cognition with the power of machine computation, thereby enabling consumers to better visualize, interpret, and act on information. Aims to deliver software that is open-architecture, modular, networked, and distributed; able to leverage statistics, machine learning, and artificial intelligence; and focuses on speed, accuracy, insight, and action.

  • Warfighter Interfaces and Teaming CTC1: The Warfighter Interfaces and Teaming CTC will conduct research to enable robust decision superiority across our Air and Space Forces by dynamically optimizing the integration of Warfighter cognition with increasingly complex and intelligent machines/systems, creating maximally effective and resilient warfighting teams. CTC research will focus on discovering, developing, evaluating, and transitioning advanced adaptive warfighter interface technology, mission-optimized distributed team performance enhancements, communication management processes, and context-tailored intelligent decision aids/analytics in order to achieve and maintain decision superiority in uncertain environments against peer threats.

    • Distributed Teaming and Communication CRA1: The Distributed Teaming & Communication CRA emphasizes research that explores the rapid formation, real-time assessment, and dynamically optimized performance of distributed heterogeneous teams of warfighters as well as human-machine teams in order to enable rapid, agile & robust mission operations. Research areas will include: methods to enable the rapid formation of mission-effective heterogeneous teams, dynamic monitoring / assessment of team performance via optimal assemblage of novel and existing metrics, adaptive tactics for recovery from real or predicted team performance degradations, and novel distributed communication & collaboration tools, technologies and management methods that are responsive to variable network environments.

      • Dynamic Team Performance Assessment LOE1: Enable the rapid formation, real-time assessment, and dynamically optimized performance of distributed heterogeneous teams of warfighters as well as human-machine teams in order to enable rapid, agile & robust mission operations. Research areas include methods to support the rapid formation of mission-effective heterogeneous teams, dynamic monitoring of team performance via optimal assemblage of novel and existing metrics, and real-time contextual aids from team communication.

      • Team Optimization and Recovery LOE2: Design, develop, and evaluate team optimization and recovery technologies to enhance communication, coordination, and improve decision making among distributed teams. Research areas include interfaces to support joint tasking and team shared awareness (SA) across multiple domains as well as conversational AI technologies to enable high bandwidth natural communications.

    • Human Machine Interactions CRA2: The Human-Machine Interactions CRA emphasizes research to identify principles of human interaction with highly complex systems, including advanced automation & increasingly intelligent AI enabled machines. The goal of this research is to achieve and sustain decision superiority across complex & uncertain mission environments. Research areas include identifying, characterizing and overcoming key challenges to warfighter interactions with complex and intelligent systems such as situationally-adaptive interface design and usability, knowledge representation across sensory modalities, system observability & transparency, directability, joint cognitive decision making, and maintaining calibrated trust across changing conditions.

      • Rapid Joint-Cognitive Awareness LOE1: To develop human-centric interfaces and interaction strategies for improved AI/automation transparency, closed-loop adaptive systems that are responsive to warfighter state, and advanced techniques for effectively visualizing large, complex data sets.

      • HMI-enabled Decision Superiority LOE2: To develop capabilities for continuous planning for C2, next generation interfaces for complex intelligent platforms, and interfaces tailored for emerging Cognitive Warfare (CogWar) concepts.

  • Human Learning and Cognition (HLC) CTC2: The Human Learning and Cognition CTC enables more lethal Air and Space Forces through research on human multisensory perception, learning, information processing, and action. The research seeks to maximize mission effectiveness by (1) Establishing a persistent, global training and test ecosystem that creates the foundation for personalized, proficiency-based readiness for multi-capable Airmen and Guardians in joint all-domain operations, (2) Creating capabilities that allow teams of humans and machines to adapt and learn together in real time in training and operational settings, & (3) Advancing considerations of human performance in system development and operational planning with digital models of perception, cognition, & action.

    • Digital Model of Cognition CRA1: The Digital Models of Cognition Core Research Area emphasizes research to identify computational and mathematical mechanisms to represent human perception, information processing, and behavior, including the integration of models that reflect the role of internal and external factors that modulate performance efficiency and effectiveness. The goal is to develop holistic models that support quantitative understanding and prediction of mission effectiveness across domains and at different levels of abstraction for improved systems engineering, wargaming, and operational planning.

      • Holistic Models for Decision-Making LOE1: Develop models of cognitive systems that support quantitative understanding and prediction of mission effectiveness for decision superiority.

      • Information Mastery in Cognitive Warfare LOE2: Analytic methods, models, and tradecraft that enables operators to improve Information-Related Capability (IRC).

    • Learning and Operational Training CRA2: The Learning and Operational Training Core Research Area emphasizes learning and understanding in the context of evolving technology. This includes research to establish an ecosystem that maximizes mission effectiveness while minimizing costs by matching technologies to learning and performance needs; supporting high resolution human and system measurement and quantitative, proficiency-centric readiness assessment and prediction at the individual and team levels; and exploring how to enable human and machine co-learning to support mutual adaptation and understanding in human-machine teams.

      • Warfighter Learning Technologies LOE1: Research, demonstrate, & transition learning technologies, methods, & infrastructure for personalized, proficiency-based readiness.

      • Co-Learning for Adaptive Human and Machine Teams LOE2: Establish the foundation for interactive learning and collaborative training of humans and AI-enabled machines to enable uniquely effective human-autonomy teams.

• United States Air Force School of Aerospace Medicine (USAFSAM)

  Aerospace Medicine and Physiology

  • Aerospace Physiology: Solutions relating to physiologic assessment of aircrew in high altitude Fighters/Trainers.

    • Assessments of the physiologic response to exposures and stressors from the fighter/trainer environment; can cover any of the following: including effects of fluctuating pressure, high O2, air quality, breathing resistance, thermal burden, dehydration, rest/sleep (physical fatigue), cognitive fatigue, Aircrew Flight Equipment (AFE) integration (how AFE impacts in-flight physiology, and how AFE components interact with each other to impact physiology and aircrew performance), and combined stressors on performance and decision making in ground-based testing and operational environments, including the analysis of potential countermeasures to optimize pilot performance and eliminate sources of risk.

    • Solutions to sustain Aircrew performance in extreme environments.

    • Conduct comprehensive technology assessments of the current military health system simulators that can monitor and track physiologic responses from training student pilots.

    • There is a strong demand for wearables that are cross compatible across multiple systems to collect physiologic data, that are reliable and validated in the operational environment. Offerors are to conduct a comprehensive technology assessment of commercial off the shelf products, including their suitability for use in the operational environment and their validated measurement capabilities, to help aid aircrew and decision makers on what can be flown in the aircraft and what can be accurately collected from those sensors.

    • Musculoskeletal Injury Prevention and Treatment for Aircrew and Maintainers: Neck and back pain is a known occupational hazard for the high-performance aircraft community. The government seeks solutions, including tools to prevent, reduce, screen and diagnose musculoskeletal condition as well as alternative/integrative medicine approaches, for prevention or treatment of musculoskeletal injuries. Proposed solutions shall focus on providing reliable measurements to determine platform-specific neck/back dysfunction and improvements due to embedded care.

    • Gender-specific operational aircrew considerations

    • Assessment, modeling, detection, and/or mitigation Aircrew and Operator fatigue

  • Precision Medicine and Medical Standards: Development of solutions relating to the following areas:

    • Surveillance of conditions, indications, clinical practice guideline adherence, and outcomes to support cost benefit analyses for Air Force population.

    • Genomics for mishap investigations (gene expression, subtracting human and molecular autopsy).

    • Studies providing data to support evidence-based aerospace medicine standards and waivers.

    • Psychological Performance and Mental Health (solutions should relate to at least one of the following areas)

      • Mental health and psychological disorders amongst airmen and potential influence on readiness and retention.

      • Neurocognitive diversity; cognitive testing and correlates with mental health and other outcomes.

      • Assessment of the feasibility of integrating the use of personality data and wearable technology to facilitate adjustment and success during career specific training. Personality assessments and wearables both as tools to facilitate readiness via positive change, wellbeing, and performance by increasing self-awareness.

  Public Health and Preventative Medicine

  • Development, optimization, and validation of pathogen detection methodologies

  • Cancer analysis in the Air Force population

    • Development and evaluation of prototypes that can identify carcinogenic toxins or hazardous materials associated with military flight operations from shipboard or land bases or facilities.

    • Development and evaluation of prototypes that can identify exposures to ionizing radiation and nonionizing radiation from which airmen could have received increased radiation amounts.

    • Establishment of guidelines for carcinogen exposure as it relates to demographics for each airman to include duty stations, duties and aircraft flow.

    • Establishment of guidelines that outline the duties and potential exposures of airmen that are associated with higher incidence of cancer.

    • Development and evaluation of screening tools and/or methods that relate to carcinogen exposure to airmen.

  • Assess methodologies to prevent wound infection.

  • Assess infectious disease conditions in Air Force populations.

  Occupational Medicine and Bioenvironmental Engineering

  • Enhancement of capabilities to detect, measure, and assess occupational and environmental health hazard contaminants and extreme environmental conditions.

    • Assess technologies to enhance capabilities to detect and identify chemical, biological, toxins, radiological, directed energy, poisons and physical hazards on surfaces (including soil and powder), in liquids and in the air in near real-time at the detector's point of operation and notify end user of risk.

    • Assessment of Aviation-Specific Exposures

    • Develop, test and evaluate real-time health threat surveillance and reporting system inclusive of all available health information/databases to identify risks/outbreaks and provide decision support to operational commanders.

  • Evaluation/development of mitigation technology capable of reducing or eliminating occupational and environmental health hazard risks.

  En Route Care/Expeditionary Medicine/Prolonged Field Care: Needs in this area include medical capabilities to support in route care to/from remote, austere settings, and in extreme environments.

  • Training methodologies to improve operational readiness for individuals and teams responsible for delivering basic and advanced en route care capabilities within the aeromedical evacuation system.

  • Technology assessment/development to support the Air Force Surgeon General’s medical modernization priorities with a focus on modernizing outdated technologies and techniques to promote en route care growth/preparation for future peer/near-peer conflicts involving mass casualty care.

  Education and training technologies and methodologies to support efforts to generate, develop, and maintain skillsets across the AOME.

  Applications of data science to analyze medical and operational data and outcomes across the AOME, which may include implementation of AI and machine learning to answer operationally relevant questions.

Are there any additional benefits I would receive?

Beyond direct funding, CHEERS participation offers significant indirect advantages for growth and strategic positioning:

Government Validation and Credibility:
Selection under AFRL’s CHEERS program signals strong technical merit and alignment with Department of the Air Force human performance priorities—an endorsement that enhances your credibility with defense primes, OEMs, and investors.

Enhanced Market Visibility and Notoriety:
Awardees benefit from exposure in federal announcements, AFRL communications, and defense industry press—raising visibility and positioning your company as a trusted innovation partner in the human-performance and aerospace ecosystem.

Ecosystem Access and Collaboration Opportunities:
CHEERS projects operate within a national network that includes top-tier military researchers, AFRL directorates, and medical readiness centers. This access often leads to future R&D partnerships and contracting opportunities.

Stronger Exit and Acquisition Potential:
By advancing your technology with nondilutive support and demonstrating government-backed validation, companies can increase valuation and strengthen their position for acquisition or strategic investment by defense and medical technology leaders.

What is the timeline to apply and when would I receive funding?

• White Paper Deadline: Rolling through September 30, 2027. This means applicants should apply as soon as possible before funds are fully expended.

• Review Period: Technically 180 days for AFRL to review white papers - but it could also be reviewed faster.

• Proposal Invitation: AFRL will invite full proposals only from offerors whose white papers align with Air Force needs.

• Proposal Deadline: Defined in each Request for Proposal (RFP).

• Award Timing: Awards are issued once funds become available; no awards are made until funding is confirmed.

Where does this funding come from?

Funding is issued by the Air Force Research Laboratory (AFRL) under the following authorities:

• Open Period 1: 10 U.S.C. 4001 / FAR 35.016 (Broad Agency Announcement).

• Open Period 2: 10 U.S.C. 4023 (Procurement for Experimental Purposes).

These authorities allow AFRL to fund both research contracts and prototype agreements, depending on project maturity and experimental needs.

Who is eligible to apply?

1. Open to U.S. companies, universities, and research organizations.

2. Foreign participation is allowed subject to export and security controls.

3. Cost sharing is not required.

4. Offerors may submit multiple white papers, provided each represents a distinct technical approach.

What companies and projects are likely to win?

Offer innovative, defense-relevant solutions that measurably enhance warfighter performance, medical readiness, or operational resilience.

1. Demonstrate clear technical feasibility, transition potential, and sound risk mitigation.

2. Show strong alignment with AFRL’s human effectiveness and medical research priorities.

3. Have experienced teams capable of performing under experimental or prototype authorities.

Evaluation criteria (in descending order of importance):

1. Uniqueness and innovation.

2. Understanding of scope and technical approach.

3. Technical soundness and team qualifications.

4. Transition potential.

5. Cost realism and value.

Are there any restrictions I should know about?

• Export Control: Some projects may require U.S. or Canada Joint Certification (DD 2345).

• Human/Animal Subjects & Hazardous Materials: Approval requirements vary by project and will be outlined in each solicitation.

• S&T Protection: AFRL’s Science and Technology protection and OPSEC rules apply.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive white paper + full proposal will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the White Paper for $3000. Full proposal quoted upon invitation.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcements:

• Continuing Human Enabling Enhancing Restoring and Sustaining (Master Announcement)

• CHEERS Open Period 1 - All Technical Areas

• CHEERS Open Period 2 - All Technical Areas